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Abstract
The renin angiotensin aldosterone system is the dominant hormonal
regulatory system controlling sodium balance and therefore blood pres-
sure homeostasis. Abnormal modulation of this system is implicated
in the pathogenesis of hypertension and end organ injury. We have
previously developed the Cyp1a1-Ren2 transgenic rat to model an-
giotensin II (ANG II) dependent hypertension. In this model hyper-
tension causes renal injury, predominantly in the preglomerular vas-
culature. The susceptibility to renal injury has a genetic component.
A consomic/congenic study identified angiotensin converting enzyme
(Ace) as an important modifier.
However, renal injury is unlikely to be influenced by a single gene. In
this thesis it was hypothesised that examination of a renal microar-
ray to compare the relative expression in F344 (susceptible) and Lewis
(relatively protected) strains would reveal further genetic factors me-
diating renal injury susceptibility. Genome wide expression analysis
confirmed that Ace was a key modifier gene. Furthermore, the puriner-
gic receptors P2x7 and P2x4 were identified as additional candidates.
Gene and protein expression of these P2X receptors were both higher
in F344 compared with Lewis. Immunohistochemistry localised P2X7
and P2X4 to the renal vasculature and tubules: the expression pattern
was similar in both strains but became distinct in the renal medulla.
F344, but not Lewis, responded to acute antagonism of P2X7 and
P2X4. F344 showed a significant drop in blood pressure but maintained
renal blood flow, indicative of tonic renal vasoconstriction. When
ANG II was infused into F344 rats, there was a modest increase in
blood pressure and an impairment of the pressure-natriuresis mecha-
nism but no overt injury. Blood oxygenation-level dependent magnetic
resonance imaging of the kidney identified a decrease in renal R2* sig-
nal following P2X7 and P2X4 antagonism in ANG II infused F344
rats. P2X7/4 receptor activation reduces oxygenation and suppresses
pressure-natriuresis. These effects are pro-fibrotic and may underpin
susceptibility to renal injury.
Contents
Glossary viii
List of Figures x
1 INTRODUCTION 1
1.1 The Genetics of Hypertension . . . . . . . . . . . . . . . . . . . . . 1
1.1.1 Monogenic hypertension . . . . . . . . . . . . . . . . . . . . 2
1.1.2 Polygenic hypertension . . . . . . . . . . . . . . . . . . . . . 2
1.1.2.1 Genetic linkage analysis . . . . . . . . . . . . . . . 3
1.1.2.2 Genome wide association studies . . . . . . . . . . 3
1.2 Blood Pressure and the Kidney . . . . . . . . . . . . . . . . . . . . 4
1.2.1 Renal haemodynamics . . . . . . . . . . . . . . . . . . . . . 5
1.2.2 The pressure-natriuresis mechanism . . . . . . . . . . . . . . 8
1.2.3 The pressure-natriuresis mechanism in hypertension . . . . . 9
1.2.4 Renal tubular function and syndromes of innaproriate salt
reabsorption . . . . . . . . . . . . . . . . . . . . . . . . . . . 9
1.2.5 Hypertension and renal transplantation . . . . . . . . . . . . 12
1.3 The Renin Angiotensin System . . . . . . . . . . . . . . . . . . . . 13
1.3.1 Angiotensinogen . . . . . . . . . . . . . . . . . . . . . . . . 15
1.3.2 Renin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15
1.3.3 Angiotensin converting enzymes . . . . . . . . . . . . . . . . 15
1.3.4 Angiotensin II . . . . . . . . . . . . . . . . . . . . . . . . . . 16
1.3.5 The intrarenal renin angiotensin system . . . . . . . . . . . 16
1.4 The Renin Angiotensin System and Hypertension . . . . . . . . . . 17
1.5 The Cyp1a1-Ren2 Transgenic Rat . . . . . . . . . . . . . . . . . . . 18
1.6 Hypothesis & Aims . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
1.6.1 Hypothesis: . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
1.6.2 Aims . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
1.6.3 Summary of outcome: . . . . . . . . . . . . . . . . . . . . . 20
2 IDENTIFYING GENETIC MODIFIERS OF RENAL INJURY 21
2.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21
2.2 Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21
2.2.1 Renal microarray analysis . . . . . . . . . . . . . . . . . . . 21
v
CONTENTS
2.2.2 Enrichment analysis . . . . . . . . . . . . . . . . . . . . . . 22
2.2.3 Protein quantification . . . . . . . . . . . . . . . . . . . . . 23
2.2.4 Statistical analysis . . . . . . . . . . . . . . . . . . . . . . . 23
2.3 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23
2.3.1 Differential gene expression . . . . . . . . . . . . . . . . . . 23
2.3.2 Enrichment analysis . . . . . . . . . . . . . . . . . . . . . . 25
2.3.3 Protein quantification . . . . . . . . . . . . . . . . . . . . . 27
2.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29
3 LOCALISATION AND FUNCTION OF RENAL P2X7 AND
P2X4 RECEPTORS 31
3.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31
3.2 Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31
3.2.1 Renal immunolocalisation . . . . . . . . . . . . . . . . . . . 31
3.2.2 Renal functional studies . . . . . . . . . . . . . . . . . . . . 32
3.2.3 Statistical analysis . . . . . . . . . . . . . . . . . . . . . . . 32
3.3 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34
3.3.1 Renal immunolocalisation of P2X7, P2X4 & P2X1 . . . . . . 34
3.3.2 Renal function . . . . . . . . . . . . . . . . . . . . . . . . . 34
3.3.2.1 F344 and Lewis Strains . . . . . . . . . . . . . . . 34
3.3.2.2 Strain dependent responses to BBG . . . . . . . . . 41
3.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44
4 P2X7 AND P2X4 RECEPTORS IMPAIR PRESSURE NATRI-
URESIS FOLLOWING CHRONIC ANGIOTENSIN II INFU-
SION 47
4.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47
4.2 Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48
4.2.1 Study 1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48
4.2.1.1 Angiotensin II infusion model . . . . . . . . . . . . 48
4.2.1.2 Protein quantification . . . . . . . . . . . . . . . . 48
4.2.1.3 Renal injury . . . . . . . . . . . . . . . . . . . . . 48
4.2.1.4 Renal immunolocalisation . . . . . . . . . . . . . . 49
4.2.2 Statistical analysis . . . . . . . . . . . . . . . . . . . . . . . 49
4.2.3 Study 2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49
4.2.3.1 Angiotensin II infusion model . . . . . . . . . . . . 49
4.2.3.2 Renal functional studies . . . . . . . . . . . . . . . 49
4.2.4 Statistical analysis . . . . . . . . . . . . . . . . . . . . . . . 50
4.3 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 50
4.3.1 Study 1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 50
4.3.1.1 Protein quantification . . . . . . . . . . . . . . . . 50
vi
CONTENTS
4.3.1.2 Renal immunolocalisation of P2X7, P2X4 & P2X1
following angiotensin II infusion . . . . . . . . . . . 52
4.3.1.3 Renal injury . . . . . . . . . . . . . . . . . . . . . 52
4.3.2 Study 2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 58
4.3.3 Renal functional studies . . . . . . . . . . . . . . . . . . . . 58
4.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 62
4.4.1 Pathogenesis of kidney disease . . . . . . . . . . . . . . . . . 62
4.4.2 Renal P2X7 and P2X4 receptors in a pre-fibrotic setting . . 63
5 P2X7 AND P2X4 RECEPTORS IMPAIR RENAL OXYGENA-
TION AND PERFUSION FOLLOWING CHRONIC ANGIOTENSIN
II INFUSION 65
5.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 65
5.2 Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 66
5.2.1 MRI scanning protocol . . . . . . . . . . . . . . . . . . . . . 66
5.2.2 Image analysis pipeline . . . . . . . . . . . . . . . . . . . . . 66
5.2.2.1 Image selection and registration . . . . . . . . . . . 68
5.2.2.2 K-means clustering analysis . . . . . . . . . . . . . 70
5.2.3 Study 1: Validation of renal BOLD MRI clustering analysis 70
5.2.4 Study 2: Effect of P2X7 and P2X4 antagonism on renal
BOLD signal . . . . . . . . . . . . . . . . . . . . . . . . . . 71
5.2.5 Statistical analysis . . . . . . . . . . . . . . . . . . . . . . . 71
5.3 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 72
5.3.1 Study 1: Validation of renal BOLD MRI clustering analysis 72
5.3.2 Study 2: Effect of P2X7 and P2X4 antagonism on renal
BOLD signal . . . . . . . . . . . . . . . . . . . . . . . . . . 76
5.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 81
5.4.1 Clustering analysis of renal BOLD MRI data . . . . . . . . . 81
5.4.2 The effect of P2X7 and P2X4 antagonism on renal oxygenation 83
6 GENERAL DISCUSSION 85
References 89
7 Appendix A: Computational Models of P2X4 and P2X7 143
7.1 Modelling P2X Receptor Electrophysiology . . . . . . . . . . . . . . 143
7.2 Model Code . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 149
8 Appendix B: Peer Reviewed Work 155
8.1 Personal Grants, Awards & Meetings . . . . . . . . . . . . . . . . . 155




ACE2 Angiotensin converting enzyme 2
AGT Angiotensinogen
ANG 1-7 Angiotensin 1-7
ANG 1-9 Angiotensin 1-9
ANG I Angiotensin I
ANG II Angiotensin II
ANG III (2-8) Angiotensin III (a.k.a.
2-8)
ANG IV Angiotensin IV (a.k.a. 3-7)
ANOVA Analysis of variance
AQP1-4 Aquaporins 1-4
ASDN Aldosterone sensitive distal
nephron
AT1 Angiotensin Type I Receptor
AT1a angiotensin receptor type 1a
AT1b angiotensin receptor type 1b
AT2 Angiotensin Type II Receptor
ATP Adenosine-5’-triphosphate
BBG Brilliant Blue G
BOLD Blood oxygenation level-
dependent
bp base pair
CCD Cortical collecting duct
CD68 Cluster of differentiation 68 a.k.a
ED-1
cGP Causally cohesive genotype pheno-
type mapping
CHARGE Cohorts for heart and ageing
research in genomic epidemiology
CKD Chronic Kidney Disease
CRP C-reactive proteins





DBP Diastolic blood pressure






ENaC Epithelial sodium channel
GFR Glomerular filtration rate
GWAS Genome wide association studies
H&E Hematoxylin and eosin









LIMMA Linear models for microarray
data
LOD Logarithm (base 10) of odds
mmHg Millimetres of mercury
MRI Magnetic resonance imaging
NaCl Sodium chloride
NaF Sodium fluoride
NCC Thiazide-sensitive NaCl cotrans-
porter
NHE3 Sodiumhydrogen antiporter 3
NKCC2 Na+−K+−2Cl− cotransporter
NO Nitric oxide
NOS Nitric oxide synthase
PAS periodic acid-Schiff
PBS Phosphate buffered saline
PCT Proximal convoluted tubule
PKD Polycystic kidney disease
pO2 Partial pressure of oxygen
qRT-PCR Quantitative real time poly-
merase chain reaction
QTL Quantitative trait loci
RAS Renin Angiotensin System
RBF Renal blood flow
RIHP Renal interstitial hydrostatic
pressure
RMA Robust multi-array average
RNA Ribonucleic acid
ROI Region(s) of interest
ROMK Renal outer medulla potassium
channel
RVR renal vascular resistance
(mmHg/ml.min−1)
SBP Systolic blood pressure
SEM Standard error of the mean
SNP(s) Single nucleotide polymor-
phism(s)
TAL Thick ascending limb
TGF Tubuloglomerular feedback
Tris tris(hydroxymethyl)aminomethane
TRP Transient receptor potential
WNK lysine deficient protein kinases




1.1 Renal Vascular Architecture . . . . . . . . . . . . . . . . . . . . . . 5
1.2 Renal Autoregulation . . . . . . . . . . . . . . . . . . . . . . . . . . 7
1.3 The Relationship Between Sodium Intake and Blood Pressure . . . 10
1.4 Major Renal Sodium Transporters . . . . . . . . . . . . . . . . . . . 11
1.5 Renin Angiotensin System in Man . . . . . . . . . . . . . . . . . . . 14
1.6 Hypertension in the Cyp1a1-Ren2.F Transgenic Rat . . . . . . . . . 19
2.1 P2X7 and P2X4 Receptor Expression in Whole Kidney Homogenates 28
3.1 Exemplar Surgical Preparation . . . . . . . . . . . . . . . . . . . . 33
3.2 Renal P2X7 Localisation . . . . . . . . . . . . . . . . . . . . . . . . 35
3.3 Renal P2X4 Localisation . . . . . . . . . . . . . . . . . . . . . . . . 36
3.4 Renal P2X1 Localisation . . . . . . . . . . . . . . . . . . . . . . . . 37
3.5 Renal Medullary P2X Localisation . . . . . . . . . . . . . . . . . . 38
3.6 Blood Pressure and Renal Haemodynamics in F344 and Lewis strains 39
3.7 Blood Pressure and Flow Relationships in F344 and Lewis strains . 40
3.8 Effect of BBG on Blood Pressure, Flow and Renal Vascular Resistance 42
3.9 Effect of BBG on F344 and Lewis pressure diuresis . . . . . . . . . 43
4.1 P2X7 and P2X4 Receptor Expression Following Chronic ANG II
Infusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51
4.2 Renal P2X7 Localisation Following Chronic ANG II Infusion . . . 53
4.3 Renal P2X4 Localisation Following Chronic ANG II Infusion . . . 54
4.4 Renal P2X1 Localisation Following Chronic ANG II Infusion . . . 55
4.5 Renal Vascular Injury Following Chronic ANG II Infusion . . . . . 56
4.6 Glomerular Injury Following Chronic ANG II Infusion . . . . . . . 57
4.7 Effect of BBG on Blood Pressure and Renal Blood Flow Following
Chronic ANG II Infusion . . . . . . . . . . . . . . . . . . . . . . . . 59
4.8 Effect of BBG on Pressure-Diuresis Following Chronic ANG II In-
fusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 60
4.9 Effect of BBG on Pressure-Natriuresis Following Chronic ANG II
Infusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61
5.1 Analysis Pipeline of BOLD MRI Data. . . . . . . . . . . . . . . . . 67
5.2 Statistically Detected BOLD MRI Outlier Scans . . . . . . . . . . 69
x
LIST OF FIGURES
5.3 Reproducibility of Baseline BOLD MRI Data. . . . . . . . . . . . . 73
5.4 Control BOLD MRI and Renal Haemodynamic Data. . . . . . . . 74
5.5 Renal BOLD MRI and Haemodynamic Analysis After 3 Day ANG
II infusion. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 75
5.6 Anatomical Heterogeneity of Renal BOLD Signal After 3 Day ANG
II Infusion. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 77
5.7 Renal BOLD MRI After 6 Day ANG II infusion. . . . . . . . . . . 78
5.8 R2* Effect of P2X7 and P2X4 Antagonism . . . . . . . . . . . . . 79
5.9 Histogram of T2* Maps . . . . . . . . . . . . . . . . . . . . . . . . 80
6.1 Working Hypothesis . . . . . . . . . . . . . . . . . . . . . . . . . . 86
7.1 Human P2X7 Receptor Voltage-Current Relationship . . . . . . . . 145
7.2 Human P2X4 Receptor Voltage-Current Relationship . . . . . . . . 146
7.3 Calcium Currents Mediated by P2X7 and P2X4 Receptors . . . . . 147
7.4 Time Dependent Calcium Currents Mediated by P2X7 and P2X4
Receptors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 148
xi
For my parents James and Christine.
1
INTRODUCTION
1.1 The Genetics of Hypertension
Hypertension is defined as systolic blood pressure (SBP) ≥140 mmHg or diastolic
blood pressure (DBP) ≥90 mmHg and affects around one third of the Earth’s
population (250). Hypertension is a major risk factor for future cardiovascular
and kidney diseases (290, 345, 436) and therefore exerts a profound socioeconomic
burden on most societies.
Hypertension has a heritable component. On average, half of blood pressure
variability has been ascribed to inherited genetics (187, 297, 327). Genetic variabil-
ity within families is also important as evidenced by the greater similarity of blood
pressure between monozygotic, compared to dizygotic, twins (124). Furthermore
cardiovascular morbidity confers greater risk for a surviving monozygotic, com-
pared with dizygotic, twin (124, 203).
Hypertension is either essential (primary), whereby the origin of the blood
pressure rise is unknown, or secondary, in cases where a causal mechanism can be
defined. Essential hypertension is almost certainly polygenic and by far the most
prevalent form of hypertension, affecting 90-95% of hypertensive patients (59) who
are typically treated with a drug, or drugs, targeting the renin angiotensin sys-
tem (see section 1.3), calcium channel blockers or diuretics (111, 307). Common
secondary forms hypertension are predominantly caused by sleep apnoea or renal
parenchymal disease (also see Table 1 of (426)). The rarest forms of secondary
hypertension have a strong genetic component (511) and might present an op-
portunity for high specificity pharmacotherapy (111). This is consistent with the
observation that single gene variants with large effects on blood pressure are rare
(see sections 1.1.1 & 1.2.4) whilst multiple genes each with small effects are more
common (see section 1.1.2).
Long term population-wide studies (particularly the Framingham studies (134))
have identified hypertension as a major, modifiable, risk factor for cardiovascular
disease and morbidity. Environmental factors also play a causative role in cardio-
vascular disease (82). Low birth weight confers cardiovascular disease susceptibility
(23) and a number of contributing factors are implicated (8), for example glucocor-
ticoid overexposure (30). Together these studies support the present understand-
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ing that the molecular aetiology of hypertension is complex and key mechanisms
remain elusive.
1.1.1 Monogenic hypertension
Monogenic forms of hypertension are rare, accounting for only a small proportion
of secondary forms of hypertension. These can be described by three convergent
mechanisms (463). First, Liddle’s syndrome (457) and Gordon’s syndrome (68) are
caused by deleterious mutations in salt transporters causing increased renal sodium
reabsorption. Secondly, deficiencies in adrenal steroid synthesis lead to increased
plasma volume, examples of this are congenital adrenal hyperplasia (472), or the
syndrome of apparent mineralocorticoid excess (534). The third major monogenic
mechanism is caused by abhorrently high aldosterone synthesis which perpetuates
volume dependence and decreased renin release as seen in glucocorticoid remedial
aldosteronism (288, 289). For example, somatic mutations in ion channels of the
adrenal gland are associated with aldosterone producing adenomas (14, 32).
Monogenic human hypertension has been recapitulated in animal models (485).
Specifically, gene targeting in rats and mice (148, 220, 489) including cell specific
(382) and inducible (276) mutagenesis techniques have provided deeper mecha-
nistic insights into the renal physiology than would be ethically viable in human
studies (see section 1.2.4). These approaches have validated the concept that im-
paired renal salt homeostasis is found in all monogenic forms of hypertension (181).
Importantly however this does not necessarily equate to causality since causative
genes are often expressed in multiple tissues and major endocrine systems affect
multiple organs.
1.1.2 Polygenic hypertension
Essential hypertension is likely polygenic but genetic mechanisms are not clear-cut.
Broadly speaking, attempts to define critical genetic factors fall into two categories.
Firstly, familial based genetic linkage studies, such as (376), assert that heritable
traits are tractable within related subjects with comparable phenotype. Secondly,
genome wide association studies (GWAS), such as the Wellcome Trust case control
consortium (WTCCC) (532), are designed on the assertion that common genetic
variants cause common complex disease at the population scale. Both approaches
have made important contributions to the study of essential hypertension, and both
have their respective caveats. Linkage analysis identifies rare variants with large
effects on phenotype: GWAS identify multiple variants each with small additive
effects on phenotype (308).
Blood pressure quantitative trait loci (QTL) have been established in animal
models through microsatellite guided selective breeding to produce ever refined
2
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congenic strains (144, 316, 415). Enrichment of these refined QTLs by methods
such as gene network analysis (reviewed (242)) provide a holistic strategy for the
identification of causation (provided all/most causative genes are captured by the
congenic region) in these complex polygenic phenotypes (81, 100).
1.1.2.1 Genetic linkage analysis
Genes located in close proximity to each other on the chromosome are said to be
genetically linked as they tend to segregate into the same chromatid during meiosis
(25, 321, 338). Genetic linkage analysis utilises this property to study inherited
diseases (for examples see section 1.2.4).
Pedigree studies are, however, limited in their applicability to populations. One
of the earliest major studies which tried to address this was the Framingham cohort
which began in 1948 with the aim of identifying population wide cardiovascular risk
factors (93, 94, 238). Framingham cohort studies have produced far-reaching, even
policy forming, insights: cigarette smoking (93), lipoprotein profile in men (239),
obesity (204) and arterial fibrillation (539) were all identified by Framingham
studies as risk factors for cardiovascular disease.
1.1.2.2 Genome wide association studies
The most common genetic variations are single point variants or single nucleotide
polymorphisms (SNPs) occurring approximately every 1,000 bp (482). SNPs have
the potential to alter protein function and associations between multiple SNPs and
physiological measures such as blood pressure provide an opportunity to unlock
polygenic mechanisms. There is thus an assertion that multiple SNPs found fre-
quently in hypertensive individuals are informative in identifying mechanisms of
polygenic hypertension.
GWAS requires a priori that common complex disease is caused by common
genetic variants (427). This assertion has provided limited functional insights
since SNPs frequently occur in non-coding regions and such variation cannot be
clearly tied to function (482) and is not absolute: phenotypic consequences of
both common and rare gene variants might be important (149). This presents
a challenge in tying SNPs from genotype to phenotype. Mechanistically, small
variants in renal transporters appear important (224) but many other small effect
variants have also been identified (389). Most of the SNPs identified by GWAS to
date cannot be reconciled mechanistically with known physiological mechanisms
of blood pressure rise (24).
Statistical methods can provide association of genes and their phenotypes. This
lacks causation, and therefore the prediction of acquired phenotypes. Causally
cohesive genotype phenotype mapping (cGP) has been proposed as one method to
3
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bridge this conceptual gap (381, 412). This method argues that the unexplained
variance, also known as the problem of missing heritability (308), found in genetic
association studies might map to the variance found in physiologically measurable
parameters imparting causation in the genetic and phenotypic scales (151, 524).
However, genetic interactions also play a role in explaining some of this unexplained
variance (38, 552).
Causation is important in GWAS interpretation. GWAS have had limited suc-
cess at associating disease causing SNPs to both renal function and hypertension
(112, 385, 388, 497). The gene encoding Tamm-Horsfall glycoprotein (Umod),
the most abundant mammalian urinary protein, being one exception. In terms of
causation the limited success of GWAS in this context can be explained by the
observation that renal function (particularly salt handling) itself is implicated in
the genesis of hypertension whilst hypertension alone cannot explain progression
of kidney disease (as evident from the limited range of antihypertensive therapies
for kidney disease). These concepts are explored in the following sections.
1.2 Blood Pressure and the Kidney
Poiseuille’s law defines the proportionality between changes in luminal pressure
and blood flow. Changes in blood pressure without parallel increases in haemody-
namic flow can be interpreted as increases in vascular resistance. This relationship
shows that blood pressure homoeostasis requires appropriate regulation of total
blood volume or extracellular fluid volume (146). High salt intake increases ex-
tracellular fluid volume: the opposite effect is observed under low sodium intake
(274). A positive linear association exists between 24-hour sodium excretion and
SBP (114, 473). Importantly salt sensitivity of blood pressure is not apparent in all
individuals, yet those susceptible show increased mortality rates even in normoten-
sion (133, 322, 528, 529). Low sodium diet reduces blood pressure in normotensives
and hypertensives (189). Together these data indicate that a population-wide re-
duction in blood pressure (thus reducing cardiovascular risk) might be achieved
by simply reducing salt intake. However, this is vehemently debated (7, 273, 479).
The kidney is the principal regulator of sodium excretion in the body. Guyton
and co-workers used a systems analysis approach to model circulatory regulation
and proposed the kidney as the dominant regulator of cardiac output (172, 173)1.
The evidence presented in the following sections supports the tenet that long
1One criticism of the Guytonian model is the level of detail on dynamic mechanisms mediating
the central control of blood pressure (304). This highlights an important uncertainty and ongoing
debate regarding the key events (and organ(s)) initiating hypertension. That is to say, salt
driven volume expansion is not necessarily the initiating event; changes in sympathetic tone, for
example, might be important (27, 101, 232, 305, 487).
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term blood pressure homoeostasis is regulated by the excretion of sodium through
vascular and tubular interactions within the kidney.
1.2.1 Renal haemodynamics
The renal arterial system supplies oxygen rich blood, approximately 20% of the
cardiac output, through a vast network of arteries and arterioles (269, 352). Since
the work of Bowman (40) the injection of fine inks and resins into the renal circula-
tion has provided great insight into the beautifully complex microstructures of the
kidney (333, 334). Construction of arterial tree network maps is now becoming
possible (118, 368) allowing for microcirculatory mathematical models that are
architecturally considerate (79, 206, 264).
Figure 1.1: Renal Vascular Architecture - Illustration of the renal arterial net-
work leading to the cortical glomeruli (cortical glom) or juxtamedullary glomeruli
(juxtamedullary glom) and the vasa recta. DVR: descending vasa recta, AVR: as-
cending vasa recta, A: artery (red), V: vein (blue)
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The major contributories to the renal circulation consist of renal, segmental,
lobar, interlobar, arcuate, interlobular and glomerular-supplying afferent arterioles
in order of decreasing lumen diameter (Fig.1.1). Not all glomeruli are presumed
structurally, or functionally, equivalent. The two acknowledged types of glomeruli
are shown in Fig1.1. Cortical (or superficial) glomeruli supply tubules which ascend
only to the outer medullary structure (Fig.1.1, as indicated). Glomeruli positioned
at the edge of the renal medulla, known as juxtamedullary glomeruli (Fig.1.1, as
indicated) supply the descending vasa recta of the medulla and supplying tubules
ascending into the deepest sections of the inner medulla. Approximately 10%
of juxtamedullary glomeruli can be bypassed to perfuse the vasa recta directly,
(61, 63, 450). This may occur in response to altered metabolic demands in a
pathophysiological setting (142, 143).
Total renal blood flow (RBF) and glomerular filtration rate (GFR) are au-
toregulated, that is, maintained constant over a physiological blood pressure range
whilst urine flow is not regulated. Typical human values for RBF, GFR and urine
flow for a range of blood pressures are given in Fig.1.2. Autoregulation is medi-
ated by multiple vascular (myogenic response) and tubular feedback mechanisms
(including tubuloglomerular feedback (TGF) and connecting tubule glomerular
feedback (CTGF)).
Arterial resistance is inversely proportional to arterial diameter. Thus the
myogenic tone of the renal vasculature increases with decreasing lumen diame-
ter (13, 335) such that afferent arterioles are thought to be the most functionally
important for renal autoregulation. It is estimated that up to 80% of total autoreg-
ulation occurs in the preglomerular vascular tree (62) protecting the glomeruli as
well as pre- and post-glomerular vasculature from mechanical damage (299, 350).
Myogenic tone is mediated by smooth muscle cell contractility (92, 196, 320) and
regulated differentially in afferent and efferent arterioles which ensures a constant
GFR (58, 298, 357, 428). Mechanistically, vascular smooth muscle purinergic P2X1
receptors (216) and transient receptor potential (TRP) channels (102) have been
identified as important mediators of the myogenic response.
TGF occurs through purinergic signalling between the proximal convoluted
tubule (PCT) and the afferent arteriole (171, 444, 447). Increased PCT sodium
reabsorption decreases sodium chloride (NaCl) concentration sensed by the mac-
ula densa and therefore decreases afferent arteriole resistance (41, 207, 359). Si-
multaneously, efferent arteriole constriction will be increased by renin secretion
(10, 329, 330).
There are likely multiple molecular mechanisms mediating TGF. Increased lu-
minal NaCl is sensed by macula densa cells provoking the release of ATP through
a maxi anion channel (29). ATP activates messangial cell purinergic P2X1 re-
ceptors directly (211, 213, 303). The expression pattern (afferent but not efferent
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Figure 1.2: Renal Autoregulation - Autoregulation is observed in renal blood
flow (RBF) and glomerular filtration rate (GFR) but not urine flow over a physiolog-
ical mean arterial blood pressure range. Tyical values are given for measurements in
dogs. Adapted from the Guyton and Hall Textbook of Medical Physiology, Chapter
26, Figure 26-17.
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arteriole) of P2X1 receptors suggests an important role for this receptor subtype
in afferent arteriole tone (212). Rapid hydrolysis of ATP to adenosine diphosphate
(ADP) also activates P1 receptors (387, 443, 446) which are critical for the TGF
mechanism (480, 491). Together adeonisine receptors increase intracellular Ca++
levels within extraglomerular mesangial cells. Transmission of intracellular Ca++
to the afferent arteriole (to produce constriction) requires gap junction proteins
such as connexin 40 (234, 404, 419). Recently a new tubular feedback mechanism
has been identified, CTGF, which occurs following increased luminal NaCl in the
connecting tubule and mediates prostaglandin and epoxyeicosatrienoic acid release
(418, 420).
Dynamic interactions of the renal autoregulatory mechanisms ensures appropri-
ate luminal flow, and therefore concentration, of luminal NaCl as well as protecting
the kidney from barotrauma (88, 233, 486, 492, 506, 518, 521).
1.2.2 The pressure-natriuresis mechanism
Stable GFR ensures stable sodium filtrate (453, 458). GFR appears impressively
consistent over a wide physiological pressure range, (468). Total RBF is simi-
larly well autoregulated; typical values are given in Fig.1.2. This stability of renal
haemodynamics ensures that filtrate of fluid and sodium does not fluctuate with
perfusion pressure. This does not hold true for urine flow and sodium excretion.
This is the basis of the pressure-natriuresis mechanism as seen in the physiologically
normal renal function curve (Fig.1.3A). Pressure-natriuresis is an interaction be-
tween vascular and tubular components. Mechanistically, increases in renal perfu-
sion generally increase papillary flow and therefore capillary pressure causes an in-
crease in total kidney interstitial hydrostatic pressure (RIHP) (162, 256, 267, 272).
Increased RIHP inhibits total sodium reabsorbption (123, 141, 429). Furthermore
osmotic forces ensure that sodium and water are excreted proportionally.
Micropuncture studies have observed increasing natriuresis in accordance with
increases in renal perfusion (175, 353, 384). During such pressure increases the re-
nal cortex remains well autoregulated but many studies have observed transmission
of pressures directly to the medulla suggesting this is the important region of the
kidney mediating this effect (80, 268, 429, 454). This was originally confounded by
the contrasting evidence from other studies which have found autoregulation of the
renal medulla (76, 87, 476). More recent studies have gone some way to resolving
this apparent contradiction: the circulations of the renal cortex and medulla are
regulated oppositely by a number of factors. For example, the potent vasoactive
peptide endothelin-1 causes constriction in the cortex but dilation in the renal
medulla (168). Unique regulation of the medullary circulation involving multiple
vascular-tubular interaction supports the assertion that this region plays a critical
role in natriuretic responses to changes in renal perfusion pressure (122, 314).
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1.2.3 The pressure-natriuresis mechanism in hypertension
Oedema in congestive cardiac failure patients correlates with reduced renal blood
flow (preceding an increase in venous pressure), implicating kidney function per se
in heart failure pathophysiology (325, 525). Such clinical observations emphasise
the role of deleterious renal sodium and water handling in cardiovascular disease
(436, 453, 458, 490).
All forms of hypertension described to date involve a shift in the pressure-
natriuresis relationship (179). In normal physiology Guyton’s so called ‘infinite
gain’ of the kidney maintains stable blood pressure within a wide range of dietary
salt intakes through appropriate balance of salt excretion and reabsorption. It is
thus assumed that hypertension is characterised by any deviation from this process.
Fig.1.3 demonstrates the normal relationship and its deviation in hypertension.
Normal salt intake confers the standard pressure-natriuresis curve (curve A). A
sustained high salt intake shifts the curve leftward: greater sodium excretion occurs
and physiologically normal blood pressure is maintained (curve B). In hypertensive
individuals pressure-natriuresis is ineffective. That is, blood pressure becomes
sensitive to salt intake by insufficient renal salt handling (curve C).
1.2.4 Renal tubular function and syndromes of innaprori-
ate salt reabsorption
The kidneys filter around ∼24,000 mEq/day of sodium from some ∼180L of wa-
ter, 99% of which is reabsorbed along the nephron. The kidneys show an impres-
sive propensity to retain sodium appropriately for a wide range of salt intakes
(see Fig.1.3) when pressure-natriuresis is intact. Fig.1.4 shows the approximate
percentages of sodium reabsorption in the major nephron segments; 50% at the
proximal convoluted tubule (PCT), 20% at the descending limb (DL) , 20% at
the thick ascending limb (TAL) , 5% in the distal convoluted tubule (DCT) and
around 4% in the cortical collecting duct (CCD).1
The majority of sodium reabsorption is performed by the sodium-hydrogen
antiporter 3 (NHE3) in the PCT (125, 449) (Fig.1.4B). Micropuncture studies
demonstrate that PCT reabsorption is decreased by 75% in NHE3−/− mice (449).
NHE3−/− mice are volume depleted and hypotensive which appears consistent but
compensation of renal salt transporters means that total renal sodium excretion
is actually more efficient. This is in part because of decreased epithelial sodium
1Water homeostasis is mediated by the aquaporin (AQP1-4) family. AQP1 is expressed in
the PCT and TAL (364, 445). AQP2-4 are expressed in the CCD and are involved in vasso-
pressin mediated water reabsorption (363). Rare AQP2 mutations cause a diabetes insipidus like
phenotype (33, 99, 510).
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Figure 1.3: The Relationship Between Sodium Intake and Blood Pressure
- In Man blood pressure rises minimally with sodium intake according to normal
pressure-natriuresis (A). A leftward shift in the curve occurs following sustained
sodium intake, the kidneys excrete a greater proportion of salt to ensure blood
pressure remains stable (B). A rightward shift in the curve describes impairment
of the mechanism, as found in hypertensive individuals (C). Figure adapted from
(170).
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Figure 1.4: Major Renal Sodium Transporters - The percentage of sodium
reabsorbed in each major nephron segment (A). The major salt transporters are
shown for the proximal tubule (B), thick ascending loop of Henle (C), distal convo-
luted tubule (D) and the cortical collecting duct (E). From (343)
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channel (ENaC) activity and RAS activation increasing sodium reabsorption in
the aldosterone sensitive distal nephron (ASDN) (16, 46).
In the loop of Henle (Fig.1.4C) sodium reabsorption is dominated by Na+ −
K+− 2Cl− cotransport (NKCC2) (163). Mice null for either NKCC2 or the renal
outer medulla potassium channel (ROMK) are severely volume depleted (300, 484)
and reflect the phenotype of Bartter’s syndrome sufferers (460).
Gordon’s syndrome (pseudohypoaldosteronism type II) is so named because the
clinical symptoms are equivalent to those found during chronically low aldosterone
(lack of salt wasting and hypokalemia), however aldosterone levels are in fact
chronically elevated (538). Gordon’s syndrome is caused by of a lack of feedback
owing to mutations in with-no-lysine-K (WNK) kinases WNK1 and WNK4 (71,
235, 546) from the thick ascending limb to the CCD (200).
DCT sodium reabsorption is predominantly mediated by the thiazide-sensitive
NaCl cotransporter (NCC) (140). Loss of function mutations in the gene encoding
NCC, Slc12a3, cause Gittleman’s syndrome characterised by hypokalemia (causing
metabolic alkalosis), hypocalciuria and hypomagnesemia (461). NCC−/− mice
have the Gittleman’s syndrome phenotype (449). However, much like the increased
total sodium reabsorption in the nephron of NHE3−/− (16) NCC−/− display only a
mild phenotype indicating a striking redundancy of sodium transport in the kidney
(46).
The fine tuning of sodium reabsorption is mediated by ENaC within the con-
necting tubule and CCD. ENaC consists of α, β and γ subunits all three of which
are regulated by aldosterone (310) describing an important arm of sodium regu-
lation by the RAS. Liddle’s syndrome is caused by mutations in the β subunit of
ENaC (457) preventing ubiquitination by the enzyme NEDD4 (474) resulting in
uncontrolled natriuresis.
The identification of mutations in renal sodium transporters as causative in
several hypertensive syndromes has highlighted both the role of the kidney in
hypertension and the redundancy of sodium transport in the kidney. The effect
of these mutations on blood pressure is not equally proportional to their effect on
total renal sodium flux.
1.2.5 Hypertension and renal transplantation
Some renal transplantation studies have found that host genotype is the predomi-
nant cause of hypertension. For example, renal transplants from Dahl salt sensitive
(normotensive) donors into hypertensives does not alleviate hypertension (73). It
is not yet clear whether severing of renal innervations during the transplant process
plays a critical role (45, 275, 441).
Renal transplant recipients from donors of hypertensive families are susceptible
to developing hypertension (167). Hypertensive individuals receiving kidney trans-
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plants from normotensive donors achieve long term normotension (89). Blood pres-
sure lowering has been observed in multi-treatment resistant hypertensive patients
following bilateral nephrectomy and transplantation from normotensive donors
(266). As such, renal transplantation studies have provided significant insight into
the role of the kidneys in genetically determined hypertension (165, 422).
Kidneys transplanted from young Milan rats (pre-hypertension) into controls
do not cause hypertension whereas hypertensive renal donors instigate hyperten-
sion (130). Dahl salt sensitive rats treated with low salt and co-transplanted
demonstrate the importance of donor over recipient genetics (90, 190, 337, 423).
Spontaneously hypertensive rats maintained chronically normotensive become hy-
pertensive following renal transplantation into normotensive controls. (421). The
case is similar for the stroke-prone spnetaneously hypertensive rat (423). Mech-
anistically, renal transplantation studies have identified renal ANG II receptors
as key mediators of hypertension and detrimental cardiovascular consequences
(74, 85, 86). These data support the notion that renal allograft genotype, over
host genotype, predominate the propensity for hypertension.
Renal transplant studies are also limiting in their interpretation due to immune
activation by cross genome implantation (437, 438) typically requiring immune
suppression. Over-activation of the renin angiotensin system (RAS) plays a direct
role in immune cell activation during inflammation and vascular injury (174, 245,
455) and the use of RAS inhibitors might reduce transplant rejection rates (291,
369, 477). However recent studies suggest that the RAS is neither overly active in
transplant recipients (217) nor does its inhibition improve rejection rates (191).
1.3 The Renin Angiotensin System
The renin angiotensin system (RAS) is the dominant hormonal system regulat-
ing blood pressure and fluid homeostasis (see Fig1.5). Angiotensinogen (AGT) is
cleaved by renin producing angiotensin I (ANG I). This is the rate-limiting step in
RAS activation (12). The ubiquitously distributed angiotensin converting enzyme
(ACE) rapidly converts inert ANG I to the vasoactive peptide ANG II which reg-
ulates blood pressure both directly; due to peripheral vasoconstriction, activation
of the sympathetic nervous system, increased sodium reabsorption and indirectly;
influencing secretion of aldosterone and vasopressin. RAS blockade has proven
integral in the reduction of cardiovascular risk (442). The RAS operates normally
through balancing of feedback loops (192).
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Figure 1.5: Renin Angiotensin System in Man - Adapted from page 866-




1.3 The Renin Angiotensin System
1.3.1 Angiotensinogen
Plasma angiotensinogen is synthesised predominantly in the liver (526) but to a
lesser extent in the peripheral systems potentially moderating local RAS activation
(56). Nonetheless, hepatic angiotensinogen is the major preliminary for renal ANG
II production (313). Angiotensinogen synthesis is also regulated by various steroid
hormones including corticosteroids (265).
1.3.2 Renin
Renin is predominantly synthesised in the juxtaglomerular cells of the kidney (164,
176). Other tissues expressing renin have been identified (164) which release only
the inactive form, prorenin (278). In juxtaglomerular cells amino acid cleavage
from the c-terminus in the endoplasmic reticulum produces prorenin, which on
passing through the golgi apparatus, introduces glycosylation sites for tagging
(106, 451). These tags can be identified for storage in granules to be later secreted.
Renin is also secreted following synthesis in its inactive form constitutively from
juxtaglomerular cells.
Most species studied have a single renin gene. Mice such as C57BL/6 have
a single renin gene (Ren1c) whilst other strains such as 129 have two (Ren1d
and Ren2) (342). Ren1 controls renin expression in the kidney, whilst Ren2 has
relatively lower renal expression but also controls renin expression in the sub-
mandibular gland. Appearance of two renin genes is thought to have occurred by
a gene duplication event (103). Mice with two renin genes have higher circulating
renin activity, higher blood pressure and are salt sensitive compared with single
renin gene controls (456, 522).
Increases in arterial pressure typically inhibit renal renin secretion whilst sym-
pathetic innervations increase secretion following a decrease in blood pressure
(160, 516). Changes in luminal fluid, sensed by the macula densa can also in-
fluence renin secretion levels (64). Specifically it has been shown that adenosine
released by the macula densa, in response to a decrease in tubular sodium chloride
concentrations, signals renin release from the juxtaglomerular cells (405, 447).
1.3.3 Angiotensin converting enzymes
Angiotensin converting enzyme (ACE) cleaves two c-terminal residues of ANG I
to produce the active peptide ANG II (119, 396). ACE is predominantly highly
expressed in the lungs (119). Lower expression levels are also found in other tissues
including the kidney (119), at decreasing levels throughout the nephron (60) where
it is implicated in the regulation of a local intrarenal RAS (see section 1.3.5).
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ACE mediates vasoconstriction through ANG II production and reduces va-
sodilation directly by inactivation of bradykinin (277). Chymases can convert ANG
I to ANG II (395) and several non-renin enzymes can produce ANG II directly
from angiotensinogen (504).
The ACE homologue ACE2 is found in the testis, kidney and heart (104).
ACE2 converts both ANG I to ANG 1-9, which might prevent cardiac hypertrophy
(373). ACE2 protects the lungs from acute dysfunction and injury (208). ACE2
also converts ANG II to ANG 1-7 which exerts a tonic vasodilatory effect following
binding to the Mas receptor (284, 435). In the kidney ANG 1-7 infusion can initiate
natriuresis (182).
1.3.4 Angiotensin II
ANG II is the dominant vasoactive peptide in the RAS. Sodium reabsorption is
regulated by the actions of ANG II in the proximal tubule, (75). The G-protein
coupled angiotensin receptors AT(1-4)mediate the effects of ANG II with distinct
roles (96, 493). The AT1 receptor is dominant in its regulation of physiological
and pathophysiological blood pressure regulation (243). Two types of AT1 recep-
tor exist in the rodent, AT1a and AT1b, having high homology with the human
receptors (20, 53). AT1a receptors in the proximal tubule regulate blood pressure
directly (169). AT2 receptors appear to regulate cell cycle progression (318, 346)
and vasodilation through flow mediated kinin release (244). Furthermore, NHE3 is
down regulated following ANG II infusion (169, 317). In transgenic Cyp1a1-ren2.F
rats (see section 1.5) systemic activation of the mouse renin-2 gene results in ac-
tivation of NCC (11). AT1 receptors in CCD stimulate ENaC (403), additionally
to the effects of aldosterone (306).
Degradation of ANG II can also result in physiological effects. Cleavage of ANG
II by aminopeptidases produce active peptides such as ANG III (2-8) which is the
dominant regulator of vasopressin release by the brain (550)) and ANG IV (3-7),
albeit with much reduced potency in comparison with ANG II (159). Cleavage of
ANG II by endopeptidases produces ANG 1-7 which produces a tonic vasodilation
as described in section 1.3.3. AT3 and AT4 receptors have been also identified
with the AT4 receptor showing higher affinity for ANG IV than ANG II. Their
function appears to mediate sensory and neuromotor regulation (65, 96, 540).
1.3.5 The intrarenal renin angiotensin system
Many tissue and cell populations communicate locally enabling local physiological
regulation. This phenomenon is paracrine signalling and whilst distinct from sys-
temic processes there is often significant endocrine/paracrine overlap. Paracrine
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signalling mediates a number of autoregulatory feedback mechanisms in the kidney
(198, 357, 358, 440, 447).
The RAS is regulated locally in a number of tissues including those of the car-
diovascular system (395). In mice, brain RAS activation regulates systemic blood
pressure (340) by a mechanism dependent on sympathetic stimulation and release
of vasopressin (293, 475). In the kidney the local RAS regulates the pressure-
natriuresis mechanism (356, 360).
Early renal functional studies in dogs indicated functionally important in-
trarenal regulation of ANG II (19, 259). Localisation of angiotensinogen mRNA
to the proximal tubule subsequently provided integral evidence of local regula-
tion (209). This is because angiotensinogen (∼65 kDa) is not easily filtered by
glomeruli (347). Urinary angiotensinogen concentration has been proposed as a
non-invasive method for the of intrarenal RAS (271).
Counterintuitively, elevated circulating plasma ANG II levels cause a dispro-
portionately higher inter-renal concentration of ANG II (270, 354, 355). Internali-
sation of ANG II into tubular endosomes by an AT1 receptor dependent mechanism
might negate otherwise deleterious consequences of inappropriate activation of the
RAS (351, 395).
1.4 The Renin Angiotensin System and Hyper-
tension
As a dominant hormonal system the RAS sets the level of overall pressure-natriuresis.
Inappropriate activation is a major factor of hypertension and thus drugs targeting
the RAS are integral for hypertensive management (72, 221, 431, 537).
The Framingham study identified a blood pressure QTL, albeit with LOD>2,
on chromosome 17 overlapping the ACE locus (286). Polymorphisms in AGT have
been associated with hypertension in Japanese and European cohorts (186, 223).
The cohorts for heart and ageing research in genomic epidemiology (CHARGE)
consortium has confirmed the association between polymorphisms in AGT and
hypertension in >80,000 individuals (228, 231). The MboI of the renin gene as-
sociates with essential hypertension in Japanese (378), Caucasian (237) and Gulf
Arab populations (5, 137). Furthermore renin gene insertion/deletion is associated
with hypertension in the Mongolian population (547). An insertion/deletion poly-
morphism in the ACE gene has been associated with hypertension in a Tunisian
cohort (319). Gene-gene interactions are also important: epistasis has been de-
scribed between pairs of AGT, ACE and AT1 polymorphisms associated with
coronary artery disease (498).
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1.5 The Cyp1a1-Ren2 Transgenic Rat
Animal models can provided tractable genetic and physiological dissection of the
mechanisms leading to renal injury in hypertension (301). In the study of inappro-
priately activated RAS, the mouse Ren2 gene was introduced into the rat genome
on the Sprague Dawley background. Presence of this additional gene results in
severe hypertension by two months of age (344). Furthermore the highest blood
pressure was observed in homozygotes confirming that the absolute magnitude of
synthesised renin set the blood pressure (282). Expression of Ren2 is highest in
the adrenal gland, lowest in the kidneys and lungs and overall circulating renin
levels are much reduced (117, 282). High adrenal transgene activity might suggest
that hypertension in this model is adrenal-dependent (402, 494) but sprionolactone
failed to lowering blood pressure (11, 434).
The spontaneous development of hypertension was controlled through fusion
of Ren2 to Cyp1a1. Since Cyp1a1 is not constitutively expressed, and can be
reversibly induced by dietary administration of various aryl hydrocarbons such as
indole-3-carbinol (I3C), this transgenic rat can provide accurate temporal control
over hypertension (240). Mechanistically, I3C actually binds the aryl hydrocarbon
receptor which can then bind DNA elements in the Cyp1a1 promoter and initiate
expression (222, 400).
The rise in blood pressure in Cyp1a1-Ren2 can be titrated to study the organ
injury associated with slowly developing (78) or malignant hypertension (240). In
the malignant setting (Fig.1.6), vascular injury predominates, with myocycte vac-
uolation preceding confluent myocyte cell death and microalbuminuria (11). The
critical receptor for hypertension appears to be the AT1 receptor since blockade
prevents malignancy (11, 331, 332). Renal injury can be attenuated with spirono-
lactone (11, 383). Following induction RBF is initially preserved, but increased
vascular resistance coincides with the onset of microalbuminuria,(11), which is
indicative of impaired autoregulation and glomerular barotrauma.
Quantitative trait loci (QTL) for cardiovascular mortality have been identified
on chromosomes 10 and 17 (241). The chromosome 10 QTL was subsequently
captured in reciprocal congenic lines and expression of the ACE gene was found
by microarray in a QTL-dependent manner (296). Furthermore histological and
functional studies validated ACE as a key modifier of hypertensive organ injury
(296). Genetic background also plays a role in hypertension, renal injury and
malignancy in the Cyp1a1-Ren2 transgenic rat identified using strains susceptible
(F334 (77)) or relatively resistant (Lewis (26)). Specifically the Lewis background
confers some renoprotection whereas the F344 strain is susceptible (240, 296).
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Figure 1.6: Hypertension in the Cyp1a1-Ren2.F Transgenic Rat - Tele-
metric recordings prior to, and during, I3C administration (shaded area) in the
Cyp1a1-Ren2.F rat. A) locomotor activity; B) Blood pressure; SBP (solid line);
DBP (broken line) and C) heart rate (HR). This figure is reproduced from (11) a
reprint of this paper is included in Appendix B, section 8.2.
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1.6 Hypothesis & Aims
1.6.1 Hypothesis:
Genes differentially expressed in the Cyp1a1-Ren2 transgenic rat in the normoten-
sive state contain candidates contributing to poor renal function and susceptibility
to renal injury in the F344 strain or the relative renoprotection observed on the
Lewis background.
1.6.2 Aims
• Identify candidate modifier genes of renal injury using informative inbred
susceptible (F344) and protected (Lewis) strains. This aim will be achieved
by re-examination of an exon microarray previously published by the Molec-
ular Physiology lab (296)
• Prioritize candidate gene(s) in the normotensive kidney using stratified bioin-
formatic enrichment analysis
• Determine the renal functional consequence of candidate gene(s) activation
in the progression of renal injury in hypertension
1.6.3 Summary of outcome:
Using these approaches two purinergic receptors P2X7 and P2X4 were identified
and validated as candidate genes for renal injury susceptibility Gene and protein
expression of these P2X receptors were both higher in F344 compared with Lewis.
Immunohistochemistry localised P2X7 and P2X4 to the renal vascular endothelium
and tubules: preglomerular expression was similar in both strains but became
distinct in the renal medulla. Vascular P2X4 receptor function has recently been
described (545) whilst little is known about vascular P2X7 receptors.
Renal functional studies examined P2X7 and P2X4 function in vivo indicating
that F344 showed a significant drop in blood pressure but maintained renal blood
flow, indicative of tonic renal vasoconstriction. The Lewis strain did not responded
to BBG. When ANG II was infused into F344 rats, there was a modest increase in
blood pressure and an impairment of the pressure-natriuresis mechanism but no
overt injury. Renal blood oxygenation-level dependent MRI identified a decrease
in renal R2* signal following P2X7 and P2X4 antagonism in ANG II infused F344
rats. These results suggest that P2X7/4 receptor activation exerts tonic con-
striction reducing renal perfusion/oxygenation and therefore pressure-natriuresis.
These effects are pro-fibrotic and may underpin susceptibility to renal injury in
the earliest, and most poorly understood, stages of kidney disease progression.
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IDENTIFYING GENETIC MODIFIERS OF RENAL
INJURY
2.1 Introduction
Genetic background influences susceptibility to renal injury in the Cyp1a1-Ren2
transgenic rat (240). The F344 genetic background is susceptible, whilst transgene
activation on the Lewis background bestows some protection from renal injury
(296). These informative strains have been used to identify QTL for organ injury,
(241), and the development of reciprocal congenic lines validated the gene Ace as
a plausible modifier of renal injury (296). The AT1 receptor antagonist losartan
prevents the blood pressure rise on the F344 background but is only partially
protective against renal vascular injury (11). This suggests that susceptibility to
renal injury in this model is governed by the interplay between multiple pathways.
In the present study genome wide expression analysis is used to identify candidate
genes and pathways with a focus on normotension.
2.2 Methods
2.2.1 Renal microarray analysis
A previously published Affymetrix microarray (296) was re-mined1 to identify dif-
ferentially expressed probe-sets in the kidney of normotensive Cyp1a1-Ren2 trans-
genic rats, i.e. rats in which the Ren2 transgene was silent. The array was per-
formed on four groups of rats (n=4 per group): the two consomic parental strains
(F344, Lewis) and the two reciprocal congenic strains (F344-MOD-Lewis, Lewis-
MOD-F344) containing a 14Mb region of chromosome 10. This congenic region
contained the Ace locus and the congenics were included in the present analysis to
determine whether cis (or trans) regulation occurred. The 16 CEL intensity files
were imported into Bioconductor and arrays normalized by the robust multi-array
average (RMA) method. Microarray analysis was performed in collaboration with
Jon Manning (CVS Bioinformatics).




Differentially expressed genes were imported into the web client online version of
the multi-database enrichment tool Endeavour (3, 4). The following passage is
reproduced from the Endeavour website:
“...identification of key genes involved in health and disease remains a formidable
challenge. We develop novel bioinformatics to prioritize candidate genes under-
lying biological processes or diseases. Currently, our prioritization strategies are
based on how similar a candidate gene is to a profile derived from genes already
known to be involved in the processes. Data from multiple heterogeneous sources
(coding sequence, gene expression, annotation, literature, regulatory information,
etc.) are integrated, or fused, into a global ranking of the candidates. Endeavour
is a software application for the computational prioritization of candidates genes,
based on a set of training genes. It is made up of three stages: training, scoring
and fusion. In the first stage, information about the training genes (genes already
known to play a role in the process under study) are retrieved from numerous data
sources in order to build models. It includes functional annotations, protein-protein
interactions, regulatory information, expression data, sequence based data and lit-
erature mining data. In the second stage, the models are then used to score the
candidate genes and to rank them according to their scores. Lastly, the rankings
per data source are fused into a global ranking using order statistics...”
In the present study a list of 157 ‘training’ genes isolated from the rat genome
database (280) were selected for their association with blood pressure regulation
in the rat and imported into the Endeavour tool. These genes were not tissue
specific and assumed no mutual exclusivity with inflammatory, or other disease,
processes. The Endeavour method then employed multiple database mining us-
ing parallel approaches to enrich the list of differentially regulated genes. These
approaches were: i) published literature text mining; ii) protein-protein interac-
tions in the STRING database; iii) transcriptome analysis from the WalkerEtAl
database; iv) sequence comparison with BLAST; and v) annotations within Gene
Ontology, InterPro, KEGG and Swiss-Prot. Finally, global ranking by Q-statistic
generated a list of genes in order of prioritization for the observed phenotype. This




Kidneys were freshly harvested1 and snap frozen on dry ice followed by storage at
-80C. Whole kidneys were homogenized in ice-cold buffer containing 250mmol/l
sucrose and 10mmol/l triethanolamine. Protease inhibitors (Cocktail set III, Cal-
biochem) and phosphatase/kinase inhibitors (2mmol/l ethylenediaminetetraacetic
acid (EDTA), 50mmol/l sodium fluoride (NaF), 25mmol/l sodium glycerophos-
phate, 5mmol/l pyrophosphate and 1mmol/l sodium orthovanadate) were added
and the pH adjusted to 7.6. Following quantification by Bradford assay, pro-
tein samples were added to Laemlli buffer and resolved by SDS-PAGE, on a
NuPAGE®Tris-Acetate gel (8% Novex®) using a Tris-acetate running buffer
(50mmol/l tricine, 50mmol/l Tris base, 0.1% SDS, pH 8.24) NuPAGE®antioxidant
was added to the upper chamber. For the P2X4 receptor, 12µg of total protein
was loaded; 20µg for P2X7 receptor experiments. Following semi-dry transfer
the membrane was incubated overnight at 4C with the primary antibody P2X4
1:2000 (APR-002, Alomone Labs) and P2X7 1:1000 (APR-004, Alomone Labs). A
goat-antirabbit horseradish peroxidase (HRP) secondary antibody was then added
and the bands visualized by enhanced chemiluminescence (ECL). The autoradio-
gram was scanned and band intensity (corrected for background) was quantified by
densitometry using ImageJ. Values were normalized to the total protein intensity
(Coomassie-Blue) at the appropriate molecular weight.
2.2.4 Statistical analysis
Data are presented as mean ± standard error of the mean (SEM). Statistical anal-
ysis was performed by the linear models for microarray data (LIMMA) to calculate
fold-change and p-value statistics from normalized intensities (for microarray anal-
ysis) or Mann-Whitney U-test (for Western analysis).
2.3 Results
2.3.1 Differential gene expression
After normalization, 67 probe-sets were differentially regulated on the basis of
genetic background: 23 over-expressed and 44 under-expressed (Table 2.1). The
congenic strains (F344-MOD-Lewis, Lewis-MOD-F344) had no effect on expres-
sion profile in the present setting where transgene activation is not expected: all
expression differences were explained by genetic background.
1Explicitly the kidneys harvested for protein quantification were not from the same rats as




Symbol Chr. Fold p-value Symbol Chr. Fold p-value
Rpl30 7 7.6798 0.0226 Olr1668 20 -27.2451 0.0123
Akr1c2 17 7.3466 0.0241 Olr1680 20 -24.6268 0.0162
Spta1 13 5.6906 0.009 RGD1309362 18 -13.1217 0.0162
Akr1b8 4 4.6613 0.0178 Pigzl1 11 -6.7012 0.007
LOC361914 2 3.6785 0.0094 Kif5c 3 -6.6248 0.009
Ace 10 3.54 0.0178 Ces1e 19 -5.7903 0.0094
LOC100359585 8 3.386 0.025 Cyp4v3 16 -5.2337 0.0166
Guca2b 5 2.7994 0.0479 Olr1326 8 -5.1722 0.0336
Ypel4 3 2.7596 0.0253 Acsm5 1 -4.7035 0.0178
Rtp4 11 2.6916 0.0241 Hhip 19 -4.6118 0.0166
Clstn2 8 2.5879 0.0253 Hmgcs2 2 -4.2039 0.0336
P2rx4 12 2.5327 0.0162 Cyp2d5 7 -3.8624 0.0289
Klkb1 16 2.4303 0.009 Rdh2 7 -3.4214 0.0162
Exnef 1 2.4073 0.009 LOC302192 9 -3.3622 0.0256
Pigr 13 2.3473 0.0336 Lcn2 3 -3.097 0.0253
P2rx7 12 2.1586 0.0336 Csmd1 16 -3.019 0.0336
Akr1b7 4 2.1071 0.0336 Slc10a2 16 -2.7769 0.0226
Cd59 3 1.854 0.0256 Rxrg 13 -2.6987 0.0336
Fam149a 16 1.7008 0.0336 Cntnap4 19 -2.6686 0.0192
P4ha2 10 1.6668 0.0336 RT1-CE5 20 -2.6679 0.0336
Arl4d 10 1.5187 0.0336 Erc2 16 -2.5297 0.0253
Igfbp4 10 1.4873 0.0336 Ptprq 7 -2.4522 0.0182
Col15a1 5 1.2734 0.0336 RGD1311723 8 -2.4244 0.0372
Rbp4 1 -2.3816 0.0336
Abcb10 19 -2.2669 0.0256
Sult1b1 14 -2.2336 0.0493
RGD1563120 3 -2.1689 0.045
Mis18a 11 -2.1532 0.0192
Slc35f1 20 -2.1291 0.0372
Tcerg1l 1 -2.0443 0.0253
Acadsb 1 -1.9181 0.0336
Rgs7 13 -1.8925 0.0277
Retsat 4 -1.8721 0.0253
Gas2 1 -1.8114 0.045
Ly75 3 -1.74 0.0442
Slco1a6 4 -1.7194 0.031
Slc26a11 10 -1.6736 0.0317
Pfas 10 -1.6633 0.0178
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Eps8l2 1 -1.6505 0.0336
Dpp6 4 -1.6382 0.0259
RGD1311575 14 -1.5914 0.0491
RGD1564614 13 -1.5199 0.0344
Cdc42ep2 1 -1.4477 0.0372
Synm 1 -1.4011 0.0442
Table 2.1: Genome wide comparison of gene expression between F344 and Lewis
inbred strains listed in order of magnitude of fold change (F344 vs. Lewis, fold
>±1.2, p<0.05).Chr: Chromosome
Ace which was identified previously as a key modifier of renal injury (296) fea-
tured as the sixth most highly expressed gene (fold = +3.54, p<0.05). This serves
to exemplify the notion that that neither fold change or p−value alone capture the
collective knowledge of microarray data. Unbiased microarray enrichment methods
can illuminate important features within the 67 differentially regulated probe-sets
using the collective knowledge of many databases.
2.3.2 Enrichment analysis
Instead of a labour intensive search for functionally important gene(s) in this
dataset the Endeavour analysis, as described in the methods section, was used to
rank the differentially expressed genes enriched against the training genes of blood
pressure regulation. The result for the ten highest globally ranked genes are given
in Table 2.2.
Ace was the highest ranked gene, consistent with our previous QTL and con-
genic studies (296), and was not studied further. The second and third ranked
genes were purinergic receptors P2rx7 and P2rx4, respectively. The expression of









































































































































































































































































































































































































































































































The P2X4 antibody detect a band of ∼60kDa; the P2X7 antibody detect a band
at ∼75kDa. For P2X7 faint bands at ∼165kDa (which appears most distinct in
mitochondria/nuclei subfractions when the ∼75kDa is less distinct and therefore
might relate to receptor localisation or trafficking (194)) and ∼55kDa (which rep-
resent a protease cleavage artefact (515, 533)) were also detected (not shown). No
other bands were detected.
The expression pattern of P2x7 and P2x4 was confirmed by Western analysis:
there was a 7-fold increase in total P2X7 receptor protein (P<0.05; Fig2.1A) and
























































































































































































The method of enrichment analysis presented in this chapter directed focus towards
the P2X7 and P2X4 receptors. P2X7 and P2X4 receptor abundance is higher in
F344 rats , both in the microarray analysis and at the protein level. Adeno-
sine nucleosides and nucleuotides have been identified as important extracellular
messengers (47, 50, 380, 413). In the kidney adenosine and ATP mediate renin
secretion as well as vascular and tubular function (15, 211, 218, 358, 447, 507) and
their function as autocrine/paracrine signalling networks is supported by the rapid
hydrolysis of ATP culminating in a mean plasma half-life <1 sec (341). Purinergic
receptors are divided into P1 and P2 families, (371). Most purinergic receptors
have been identified in the kidney (16, 66, 501, 503, 513). P1 receptors are further
divided into the Go/Gi protein coupled A1 and A3 subtypes (6, 391) and the Gs
protein coupled A2A and A2B subtypes (379, 406). The P2 receptor family are
widely expressed, (52), consisting of eight metabotrophic P2Y(1,2,4,6,11,12,13,14)
receptors (1, 51) and consisting of seven ioinotropic P2XR(1-7) receptors (371).
P2X7 receptors are predominantly associated with inflammatory processes (116)
and are most highly expressed on macrophages (533). Loss of endothelial P2X4
receptors has been associated with vascular dysfunction (543). However the P2X1
receptors are the best described functionally in the kidney, regulating microvascu-
lar tone (216) and potentially TGF (see section 1.2.1).
Comparison of two distinct inbred rat strains without congenic refinement is
arguably one major limitation of this study. Equally, the result that the region of
chromosome 12 encoding P2X7 and P2X4 is functionally interesting now provides
an avenue for such refined breeding strategies. The microarray presented in this
study has been extensively validated by previously (295). Nonetheless a second
limitation of the present study was a re-analysis of raw intensity files comparing
strains only and most of the differential expression presented was not verified by
qRT-PCR, particularly validation was limited to protein abundance of P2X7 and
P2X4.
Enrichment analysis found several other potentially relevant genes for renal
paracrine signalling. The 4th hit was the regulator of G-protein signalling 7 (Rgs7 )
which interacts with polycystin-1 to promote polycystic kidney disease (PKD)
(257). Furthermore P2Y receptors are G-protein coupled and reduced P2X7 ex-
pression reduces cyst formation in PKD (67, 197). The 6th hit was the plasma
kalikrein (Klkb1 ) involved in inflammation and more highly expressed in F344 rats
(336). However these enriched genes scored lower than P2xr7 and P2xr4.
High throughput identification for coding sequences responsible for broad phe-
notypic differences each have caveats. Ribonucleic acid (RNA) sequencing can be
used to identify causative microRNAs and SNPs but statistical methods for quan-
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tifying differential expression in both short and long coding sequences is not yet
standardised (386, 470). Conversely the Affymetrix microarray used in the present
study provides a reliable tool for identifying genome-wide differential expression
in protein encoding genes. Thus identifying P2xr7 and P2xr4 as pertaining to in-
jury susceptibility must be interpreted as a result based on protein coding regions.
Localisation of these receptors within the kidney and the functional consequence
of their activation remains to be determined. This is the subject of chapter 3.
Data presented in this chapter have been published (323). A reprint of this
paper is included in Appendix B, section 8.2.
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LOCALISATION AND FUNCTION OF RENAL P2X7
AND P2X4 RECEPTORS
3.1 Introduction
Multiple subtypes of P2X and P2Y receptors are expressed throughout the kid-
ney and extracellular nucleotides regulate renal tubular, endocrine and vascular
functions (17, 18, 459). Infusion of ATP into the renal artery increases blood flow
(483) and vasodilatation is dependent on production of nitric oxide/prostacyclin
by the endothelium (115). Conversely ATP applied in vitro to the adventitial
surface of the renal microvasculature causes contraction (214) mediated by P2X1
receptors (216) in the vascular smooth muscle (66). In the previous chapter renal
microarray did not detect P2X1 expression in either rat strain. However P2X1 is
the most extensively described vascular P2X receptor (166, 211, 215) hence im-
munolocalisation of P2X1 was therefore performed for comparison with P2X4 and
P2X7 immunolocalisations. Downstream in all nephron segments studied, lumi-
nal increases in ATP activate epithelial P2X receptors in an autocrine/paracrine
manner to regulate local homeostatic processes (459).
The previous Chapter identified P2X7 and P2X4 as candidate genes for re-
nal injury in the F344 strain. The experiments presented in the present chapter
describe the renal immunolocalisation of these receptors and their functional con-
sequence in renal homeostasis measured by pressure-diuresis.
3.2 Methods
3.2.1 Renal immunolocalisation
Kidneys were freshly harvested and immersion fixed in formalin. After 48 hours
kidneys were transferred to 70% ethanol for longer term storage.
Immunohistology was performed by the Shared University Research Facilities
(SuRF) paid service. Primary rabbit polyclonal antibodies against the P2X1
(APR-001, Alomone Labs) as well as P2X4 and P2X7 (as described in chapter
2 section 2.2.3) receptors were selected based on supplier reported validation for
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use in the rat by immunohistochemistry (Alomone website). Each antibody was
optimised in a dilution series (1 : 250, 500, 1000, 2000, 4000, 5000 & 7500) using
control rat kidney, following heat-induced epitope recovery (HIER) with citrate
buffer. The final titers were selected to give minimal background : P2X1 (1: 5000),
P2X4 (1: 7500) and P2X7 (1: 2000). All staining was performed on a Leica Bond
X immunostaining robot using a refined HRP polymer detection system. Following
HIER and blocking in peroxidase, the section was incubated in primary antibody
for 2 hours at room temperature. Following two 5 min washes, sections were ex-
posed to anti-rabbit HRP polymer before being washed. Immunopositive staining
was visualized with 3,3
′
-Diaminobenzidine (DAB; Sigma, UK) and counterstaining
with haematoxylin.
3.2.2 Renal functional studies
Rats were anaesthetised (Thiobutabarbital 120 mg/kg IP) and prepared surgically
for measurement of the pressure-diuresis relationship. The right jugular vein was
cannulated and 0.9% NaCl was infused at a rate of 50µl/min/100g during ab-
dominal surgery (to minimize surgical losses) and then at 33µl/min/100g during
the post-surgical equilibration (60 minutes) and throughout the experimental pro-
tocol. The left femoral artery was cannulated and connected to brass transducer
(MLT844; Capto) connected to a Powerlab (AD Instruments, UK). Blood pressure
was recorded continuously at 1kHz. A midline laparotomy was performed and a
Doppler transit time probe (MA1PRB; Transonic, USA) placed around the left
renal artery. Acoustic gel was used to ensure good sonic coupling. Loose silk ties
were placed around the superior mesenteric and coeliac arteries: these ligatures
were tightened during the experimental procedure to create an acute pressure ramp
of two stages above baseline blood pressure. The bladder was catheterised for urine
collection under mineral oil with flow rate being determined gravimetrically. The
entire procedure was performed under homeostatic temperature control at 37oC. A
typical surgical preparation, with complete isolation of the kidney from perirenal
adipose is given in Fig.3.1A. Stability of the preparation and step-wise increases
in blood pressure following sequential ligation is also shown (Fig.3.1B).
Pressure-diuresis experiments were performed first on a control group of F344
(n=7) and Lewis (n=5) rats and then on a second cohort of F344 (n=5) and Lewis
(n=6) rats receiving an IV infusion (50µg/min/100g) of Brilliant Blue G (BBG,
Sigma, UK).
3.2.3 Statistical analysis
Data are presented as mean ± standard error of the mean (SEM). Statistical
analysis was performed by unpaired t-test unless otherwise stated. Comparisons
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Figure 3.1: Exemplar Surgical Preparation - A) Surgical setup demonstrating
isolation of the left kidney from perirenal fat (held in position by a stereotactic
perspex cup), measurement of renal blood flow by Transonic flow probe placed
around the renal artery and urine collection by bladder catheterisation .B) Typical
blood pressure trace over a ∼1.7 hour period is given. Sequential blood pressure
increases following ligation of respective arterial beds are indicated.
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between groups of the pressure-diuresis relationship were made by linear regression.
3.3 Results
3.3.1 Renal immunolocalisation of P2X7, P2X4 & P2X1
P2X7 localised to the endothelium of the entire preglomerular vasculature (Fig.3.2A-
F). Endothelial staining was qualitatively lower in the large to medium arteries of
Lewis (Fig.3.2A,C). compared to F344 (Fig.3.2B,D). P2X7 positive staining was
also seen in F344 glomeruli (Fig.3.2F) but rarely in vascular myocytes.
Vascular P2X4 immuno-positive endothelial staining was found in the pre-
glomerular vasculature (Fig.3.3A-F). P2X4 receptor staining was also observed in
the renal tubules, particular in the F344 strain (Fig.3.3D). In some places this
staining was punctate and localized to both the nucleus and cytoplasm (Fig.3.3F).
No P2X4 staining was seen in the renal glomerulus (Fig.3.3E,F)
P2X1 receptor expression was limited to the vascular network and not expressed
in the renal tubules (Fig.3.4A-F). P2X1 receptor immunopositive staining was
observed in the smooth muscle layer of all artery types from lobar to afferent
arteriole in both rat strains. P2X1 positive staining appeared qualitatively lower in
the F344 strain, particularly in interlobar arteries (Fig.3.4D) and afferent arterioles
(Fig.3.4F.)
Postglomerular staining was found in the renal medulla and was architecturally
distinct (Fig.3.5). No medullary P2X1 expression was observed. P2X7 expression
was found in the renal outer-medullary vasa recta of F344 (Fig.3.5B). P2X4 ex-
pression localised to the collecting ducts in F344 (Fig.3.5D). In the Lewis strain
P2X7 and P2X4 medullary staining was typically indistinguishable from back-
ground (Fig.3.5A and C).
3.3.2 Renal function
3.3.2.1 F344 and Lewis Strains
Compared to Lewis rats, F344 rats had a higher baseline blood pressure (Fig-
ure 3.6A) and a lower renal blood flow (Figure 3.6B): renal vascular resistance
was significantly higher in F344 rats than in Lewis (31.2±6.1 versus 11.2±2.2
mmHg/ml.min−1; P<0.05).
The imposition of a pressure ramp evoked an increase in urine flow rate in both
strains of rats (Fig. 3.7A). The slope of the relationship was significantly different
from zero in both groups (P<0.001) and the gradient was significantly blunted
in the F344 strain compared to the Lewis (P<0.01). There was no significant
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Figure 3.2: Renal P2X7 Localisation - Exemplar images of P2X7 positive
staining in large (A, B), intermediate (C, D) and small (E, F) renal arteries. Arrows
indicate endothelial staining. Glomerular staining indicated by (+). Images were
taken at 400x magnification.
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Figure 3.3: Renal P2X4 Localisation - Exemplar images of P2X4 positive
staining in large (A, B), intermediate (C, D) and small (E, F) renal arteries. Arrows




Figure 3.4: Renal P2X1 Localisation - Exemplar images of P2X1 positive
staining in large (A, B), intermediate (C, D) and small (E, F) renal arteries. Images
were taken at 400x magnification.
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Figure 3.5: Renal Medullary P2X Localisation - P2X7 receptor expression in
the renal outermedullary vasa recta in Lewis (A) and F344 (B). Vasa recta staining
was almost below detection in Lewis. P2X4 collecting duct expression was compara-




Figure 3.6: Blood Pressure and Renal Haemodynamics in F344 and Lewis
strains - A) Mean arterial blood pressure; (B) left renal artery blood flow in Lewis
(n = 8; open bars) and F344 (n = 7; black bars) rats. Data are mean ± SEM.
Statistical comparisons were made with unpaired t-test. ***P<0.001; **P<0.01.
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Figure 3.7: Blood Pressure and Flow Relationships in F344 and Lewis
strains - (A) Pressure diuresis and (B) pressure flow relationship in Lewis (n =
8; open squares) and F344 (n = 7; black squares) rats. Data are mean±SEM.
Statistical test was performed by linear regression analysis
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relationship between blood flow and blood pressure in either strain of animals,
indicative of intact auto-regulation (Figure 3.7B).
3.3.2.2 Strain dependent responses to BBG
Under baseline (non-ligated) conditions, acute infusion of BBG caused a significant
reduction of mean arterial blood pressure in F344 rats but not in Lewis animals
(Fig.3.8A). Blood flow through the left renal artery was not significantly affected
by BBG in either group (Fig.3.8B). However, BBG caused a significant decrease
in renal vascular resistance in F344 rats (Fig.3.8C).
Acute infusion of BBG did not affect the pressure-diuresis relationship in Lewis
rats (Figure 3.9A). In F344 rats, BBG caused a significant leftward shift of the
pressure-diuresis intercept (Figure 3.9B), reducing the threshold of this response,
but did not alter the gradient of the slope. Renal blood flow remained flat over
the physiological pressure range studied, indicative of intact autoregulation.
41
3.3 Results
Figure 3.8: Effect of BBG on Blood Pressure, Flow and Renal Vascular
Resistance - (A)Mean arterial blood pressure; (B) left renal artery blood flow and
(C) renal vascular resistance in the left renal artery measured in Lewis and F344
rats receiving either saline or BBG by intravenous infusion. Data are mean±SEM.
Statistical comparisons were made within strain by unpaired t-test. ***P<0.001;




Figure 3.9: Effect of BBG on F344 and Lewis pressure diuresis - The
Pressure diuresis relationship measured in (A) Lewis and (B) F344 rats receiving
either saline (Lewis: open squares; F344: closed squares) or BBG (Lewis + BBG:
grey filled black squares; F344 + BBG: grey squares) by intravenous infusion. Data




This study is largely consistent with the published distribution of P2X receptors.
mRNA encoding P2Y1, P2Y2, P2X4 and P2X7 receptors have all been identified
in human vascular smooth muscle and endothelial cells (416, 522, 544).
P2X1 receptor expression was limited to the vascular smooth muscle of the
renal arteries and afferent arteriole. Renal autoregulation is severely attenuated
in P2X1 null mice, (166, 212, 215), illustrating the importance of this receptor for
renal vascular function. In the present study, renal autoregulation was intact in
both strains of rats and there was no evidence linking differential expression of the
P2X1 receptor, or indeed P2X4 or P2X7 receptors to the impaired renal vascular
function observed in F344 rats.
P2X4 and P2X7 receptors were localised to the endothelium of the pre-glomerular
vasculature. Bioinformatic ranking analysis associated increased expression with
vascular dysfunction and loss of blood pressure control. Both P2X4 (545) and
P2X7 receptors (294) can modulate blood vessel contractility by promoting the
release of vasodilators from the endothelium. One interpretation of the present
study is that the up-regulation of receptors in F344 rats is a compensatory re-
sponse to improve poor renal blood flow. Thus acute receptor antagonism in vivo
should inhibit this tonic vasodilation. There was a trend for this in the Lewis rats
but the reduction in blood flow induced by BBG was not statistically different.
BBG did induce a significant haemodynamic effect in F344 rats but this was to
increase blood flow, rather than to reduce it. One interpretation of this outcome
is that in F344 rats P2X4/P2X7 receptor activation induces a tonic vasoconstric-
tion. It is difficult to reconcile such an effect with the predominantly endothelial
location of these receptors. However, the endothelium also releases potent vaso-
constrictive mediators, including mono- or di-nucleoside polyphosphates such as
adenosine 5
′
tetraphosphate (495) and uridine adenosine tetraphosphate is a par-
tial agonist at the rat P2X4 receptor (536) causing profound vasoconstriction when
perfused via the intravascular route into the isolated rat kidney (495). Further-
more, although it is not presently known if there is strain specific (F344 or Lewis)
regulation of these receptors nor whether there are any sequence differences which
would account for differing responses to antagonism.
P2X4 and P2X7 receptors were also identified in the renal tubule in both
strains of rats. Tubular expression of P2X4 receptor is consistent with several
previous studies (18). There was some evidence of intracellular, punctate staining,
particularly in the Lewis rats. It is possible that this represents expression of P2X4
receptors in intracellular vesicles, which might act as a reservoir for trafficking of
receptors to the apical or basolateral membrane or serve as mediators of vacuolar
calcium release (464). P2X receptors, including P2X4 have an emerging role in
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regulating tubular sodium reabsorption processes (18) but in our studies BBG did
not affect urine flow rate.
Pericytes expressing P2X7 receptors have previously been described in the vasa
recta (84, 252). Contraction of the vasa recta was attributed to P2X7 receptor
expression on these vessels. In the present study however P2X7 expression was
found in the vasa recta vessels themselves; although distinction between pericyte
and vascular staining in the present study could not be delineated. Functionaly,
expression of P2X7 on the vasa recta itself could facilitate constriction (as seen in
sephenous vein (57)) ultimately increasing intraluminal vasa recta pressure, and
RIHP with consequently reduced solute and sodium excretion as described by the
pressure-natriuresis mechanism (see section 1.2.2).
The relationship between P2X7 and P2X4 receptor activation and sodium/wa-
ter reabsorption is complex, however, and may depend on the local sodium con-
centration. P2X7 and P2X4 are activated under different conditions, for example
P2X7 appears insensitve to ATP concentrations <100µM (371). Consequently
cation currents through P2X7 or P2X4 receptors vary significantly under local
ATP concentrations - examples of which have been modelled in Appendix A7 us-
ing a model of ligand gated activation of Goldman-Hodgkin-Katz currents fitted
to experimental data (Fig.7.2 and 7.1). Simulating activation of these receptors
in response to a local ATP concentrations (0.001-0.01 M) , it is clear that the
instantaneous calcium influx is higher through P2X4 receptors (Fig,7.3). However
sustained activation ultimately leads to longer-term Ca++ influx mediated through
P2X7 (Fig.7.4). Thus the calcium dynamics mediated by P2X4 and P2X7 receptor
activation are distinct and could well indicate distinct roles in vascular contractility
not resolved by the present study (371, 414).
An obvious concern in interpreting these results is the selectivity of the antago-
nist, BBG. This compound is a potent inhibitor of rat P2X7 receptors (IC50=10nM)
and although it can also block the P2X4 receptor, its selectivity for P2X7 receptor
is 1000-fold greater. BBG has been used previously in vivo to elucidate P2X7
receptor functionality (227, 401). Indeed, chronic administration of BBG reduces
renal injury and lowers blood pressure in the Dahl salt sensitive rat (225); P2X7
null mice are similarly protected from the renal injury associated with salt-induced
hypertension (226). Nevertheless, BBG may also antagonize rat P2X4 receptors
and our infusion protocol could inhibit both P2X receptor subtypes. Further-
more, a number of off-target effects of BBG have been reported (246), which
cannot exclude the possibility that P2X7-independent effects also contribute to
the haemodynamic actions of BBG observed in the F344 rats.
Altered sodium homoeostasis identified by the pressure-diuresis relationship
is a hallmark of hypertension and kidney disease. The work presented in this
chapter has focused on strain differences in identifying the cause(s) of impaired
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renal function, now the question to be answered is whether the renal vascular
expression of P2X7 and P2X4 in the F344 strain pertains impaired renal function
during over-activation of the RAS.
Data presented in this chapter have been published (323). A reprint of this
paper is included in Appendix B, section 8.2.
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In the previous chapter P2X7 and P2X4 receptor localisation and function was
determined in physiologically normal renal function. The present chapter will
now investigate the function of these receptors following chronic over-activation
of the RAS. An ANG II infusion model was selected for two reasons; (1) the rise
in blood pressure in Ren2 and Cyp1a1-Ren2 transgenic rat models is ANG II
dependent (279, 331) and (2) ANG II infusion models are well characterised (258).
ANG II infusion typically causes injury to the kidney, particularly in vascular
smooth muscle cells (258, 496). Injury occurs through mechanical transmission
of pressures (2, 229) and indirect activation of paracrine signalling networks (326,
339, 408, 432). The extent, and strain specificity, of renal injury following ANG II
infusion was determined by histological scoring as well as qualitative histological
analysis.
Distinct renal medullary immunolocalisation of P2X7 (vasa recta) and P2X4
(collecting duct) was identified in the previous chapter. These were quite distinct
in F344 but almost undetectable in Lewis rats. The vasa recta is considered the
critical site for mediating changes in RIHP resulting in the pressure-natriuresis
mechanism (see section 1.2.2 & 1.2.3). However P2X7 is most highly expressed on
macrophages (249, 533) and therefore increased renal expression following signifi-
cant injury may relate to the high expression of the P2X7 receptor on infiltrating
macrophages. To investigate the vascular and tubular roles of P2X7 and P2X4, a
low dose ANG II infusion was used to blunt the pressure-natriuresis mechanism
without confounding factors of significant renal injury. Thus in a separate cohort of
F344 rats in vivo measurements of both pressure-diuresis and pressure-natriuresis
were performed to investigate whether 1) inappropriately activated RAS caused a
change in the renal function curve and 2) whether acute infusion of BBG improved





4.2.1.1 Angiotensin II infusion model
This study investigated the histological consequences of chronic ANG II infusion in
Lewis and F344 rats. Osmotic minipumps (model 2002; Alzet, UK) were surgically
implanted under isofluorane anaesthetic. Pumps contained ANG II (A9525, Sigma,
UK) continuously infusing at 30ng/min for 14 days (Lewis + ANG II, n =6) and
(F344 + ANG II, n=6). On the 14th day tissues were harvested for analysis. The
right kidney was removed first and snap frozen on dry ice then stored at -80C prior
to Western analysis. The left kidney was immersion fixed in formalin for 48 hours
then placed in 70% ethanol for longer term storage.
4.2.1.2 Protein quantification
Kidneys stored at -80C were used for protein quantification: performed by Western
analysis as described in chapter 2, section 2.2.3. Control samples (Fig.2.1) were
used for comparison with rats receiving 14 day ANG II infusion.
4.2.1.3 Renal injury
Renal injury scoring was performed on hematoxylin and eosin (H&E) stained sec-
tions. Injury was determined by severity of sites of vacuolation which were distin-
guished from sectioning and staining artefact as having well defined edges close to
circular, displaced nuclei (these were often close to the vacuole edge and those not
obviously micro-capillaries containing red blood cells). Total number of vacuoles
counted was normalised to vessel thickness (number of smooth muscle cell nuclei
thick) to remove bias from over-selection of any renal arterial bed.
Macrophage staining was performed in collaboration with Dr. Frederick Tam
(Imperial College, London). Paraffin embedded kidney sections were dewaxed and
boiled for 15 mins in 0.01 M sodium citrate buffer. Peroxidases were blocked with
H2O2 (0.3% in 50% methanol), washed with phosphate buffered saline (PBS) and
incubated with goat serum (20%). Slides were incubated with CD68 antibody
(1:500; Serotec, UK) overnight followed by 45 mins incubation with goat anti-
mouse secondary antibody (Dako, UK). Finally slides were exposed to biotinylated
HRP (Vector Labs, UK) for 30 mins. CD68 positive staining was visualised with
DAB and counterstaining with haematoxylin. MΦ positive staining was quanti-
fied using the automated detection tool ImmunoRatio (500) and normalised to
haematoxylin positive staining within a manually selected region containing indi-
vidual glomeruli. At least 30 glomeruli were analysed per group. Sections stained
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with sirius red and periodic acid-Schiff (PAS) were also included to investigate the
extent of glomerular injury.
4.2.1.4 Renal immunolocalisation
Formalin fixed kidneys were used for renal immuolocalisation of P2X7, P2X4 and
P2X1: performed as described in chapter 3, section 3.2.1.
4.2.2 Statistical analysis
Data are presented as mean ± SEM. Statistical analysis was performed by ANOVA
with Bonferroni post-hoc correction unless otherwise stated.
4.2.3 Study 2
4.2.3.1 Angiotensin II infusion model
This study investigated the effect of ANG II on renal pressure-diuresis and pressure-
natriuresis via osmotic minipumps (model 2002; Alzet) implanted under isoflurane
anaesthetic. Minipumps infused ANGII (A9525, Sigma) at 30ng/min in F344 rats
(n=6) for 13-15 days.
4.2.3.2 Renal functional studies
Renal functional studies were performed as described previously in chapter 3, sec-
tion 3.2.2. Diuresis (gravimetric) and natriuressis (SmartLyte, Diamond Diagnos-
tics) measurements were made. Data are presented as scatter plots matching blood
pressure to either urine flow (pressure-diuresis) or sodium excretion (pressure-
natriuresis). Where both measurements could not be made the point does not
appear on the scatter plots but was included in statistical analysis as exact co-
ordinate matching was not required1. Renal functional studies were performed
after 13-15 days of ANG II infusion (F344 + ANG II; n=6). A second group re-
ceiving chronic ANG II infusion was treated acutely with constant BBG infusion
(50µg/min/100g) included in the saline infusate (F344 + ANG II + BBG; n=5).
1Several urine samples were over-sampled to the point where urine could not be pipetted
without mineral oil contamination and some samples even ran out completely following multiple
removals from cold storage (-80C) to measure electrolytes. This was unavoidable due to failure of
the original electrolyte machine and multiple replacement parts, then ultimately a replacement
machine. As a consequence, although both pressure-diuresis and pressure-natriuresis measure-
ments were performed on the same total animal number, it is clear that the pressure-natriuresis
scatter plot has fewer data points.
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Control F344 rats from chapter 3 were included where necessary for statistical
comparisons.
4.2.4 Statistical analysis
Data are presented as mean±SEM. Statistical analysis was performed by ANOVA
with Bonferroni post-hoc correction unless otherwise stated. Comparisons between




Western analysis of homogenates indicated that whole kidney P2X4 and P2X7






















































































































































































































































































4.3.1.2 Renal immunolocalisation of P2X7, P2X4 & P2X1 following
angiotensin II infusion
Renal P2X7 positive staining remained distinct in the endothelium of the entire
preglomerular vascular tree (Fig.4.2A-F) and was comparable to the distribution
seen in normotension (Fig.3.2A-F). Occasional myocyte staining was evident in the
larger renal segmental arteries in the F344 + ANG II group (Fig.4.2B). Glomerular
atrophy associated with apparent arteriolopathy was occasionally observed in the
F344 +ANG II group (Fig.4.2F).
Preglomerular P2X4 staining remained observable in vascular endothelial cells
during hypertension (Fig.4.3A-F). Renal medullary tubule staining was most ap-
parent in the F344 + ANG II group (Fig.4.3D,F) particularly adjacent to the
interlobar arteries indicated by (∗).
P2X1 positive staining in hypertension was distinct to the preglomerular arter-
ies (Fig.4.4A-F) as was seen in nornotension (Fig.3.4A-F). No staining was found
in the renal tubules.
4.3.1.3 Renal injury
Lewis rats remained protected from renal injury (Fig.4.5A,B). Conversely, ANG
II infusion caused a significant increase in myocyte vacuolation in the F344 strain
(Fig.4.5A). The extent of renal preglomerular vascular myocyte vacuolation was
most prominent in the intermediate arteries of the kidneys in F344 rats (Fig.4.5C).
Renal macrophage staining appeared qualitatively more intense in the F344 +
ANG II group (Fig4.6A, indicated with black arrow) however this did not with-
stand robust statistical testing (Fig4.6D) in part because of the variability ob-
served. Sirius red (Fig.4.6B) and PAS (Fig.4.6C) stained sections indicated that
neither fibrosis nor obvious changes to the basement membrane had occurred by




Figure 4.2: Renal P2X7 Localisation Following Chronic ANG II Infusion
- Exemplar images of P2X7 positive staining in large (A, B), intermediate (C, D) and
small (E, F) renal arteries of hypertensive rats. Black arrows indicate endothelial
staining, white arrows indicate smooth muscle cells staining. Glomerular staining
indicated by (+). Images were taken at 400x magnification.
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Figure 4.3: Renal P2X4 Localisation Following Chronic ANG II Infusion
- Exemplar images of P2X4 positive staining in large (A, B), intermediate (C, D) and
small (E, F) renal arteries of hypertensive rats. Arrows indicate endothelial staining.
Tubule staining indicated by (∗). Images were taken at 400x magnification.
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Figure 4.4: Renal P2X1 Localisation Following Chronic ANG II Infusion
- Exemplar images of P2X1 positive staining in large (A, B), intermediate (C, D)




Figure 4.5: Renal Vascular Injury Following Chronic ANG II Infusion
- Quantification of renal vascular injury (A). Exemplar renal segmental arteries
hypertensive strains are given in the lower panel for Lewis + ANG II (B) and F344
+ ANG II (C) respectively. Images were taken at 200x magnification. Arrows
indicate distinct sites of vacuolation. Statistical comparisons were made using by




Figure 4.6: Glomerular Injury Following Chronic ANG II Infusion -
Glomeruli showing immunopositive staining for MΦ with CD68 antibody (A). Sirius
red (B) and periodic acid-Schiff (PAS) (C) stained sections. D) Quantification of
glomerular ED-1 positive staining. Images were taken at 400x magnification. Statis-




4.3.3 Renal functional studies
ANG II infusion over 13-15 days resulted in a significant increase in blood pressure
in F344 rats (Fig.4.7A). Acute infusion of BBG lowered blood pressure to a level
comparable with controls. Renal blood flow was unchanged by both chronic ANG
II infusion or acute BBG (Fig.4.7B).
Acute infusion of BBG caused a significant shift in the ANG II infused pressure-
diuresis relationship (Fig.4.8). BBG caused a leftward shift in the curve (apparent
in the mean blood pressure drop shown in Fig4.7). Furthermore BBG infusion
increased the gradient of slope of the hypertensive pressure-diuresis relationship
significantly (linear regression, P<0.0001). BBG infusion induced a similarly sig-
nificant shift in the pressure-natriuresis relationship (Fig.4.9). The gradient of
slopes were significantly different between groups (linear regression, P<0.0001).
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Figure 4.7: Effect of BBG on Blood Pressure and Renal Blood Flow
Following Chronic ANG II Infusion - (A) blood pressure and (B) renal blood
flow data in F344 (n=7), F344 + ANG II (n=6) and F344 + ANG II + BBG (n=5)




Figure 4.8: Effect of BBG on Pressure-Diuresis Following Chronic ANG
II Infusion - Data are presented as scatter plots for the groups; ANG II () and
ANG II + BBG (). Solid lines are linear regression best-fits and broken lines




Figure 4.9: Effect of BBG on Pressure-Natriuresis Following Chronic
ANG II Infusion - Data are presented as scatter plots for the groups; ANG II ()
and ANG II + BBG (). Solid lines are linear regression best-fits and broken lines
are 95% confidence intervals. Statistical testing was performed by linear regression
analysis. Note some data points were omited where both pressure and sodium




4.4.1 Pathogenesis of kidney disease
Kidney injury and declining renal function are diagnostic indicators of kidney dis-
ease and present a global health burden with high population prevalence (109, 136,
147, 156, 436). Hypertension is a major risk factor for CKD (348) and progression
can be slowed if blood pressure is controlled (185).
Progression of renal injury is characterised by increasing albuminuria (202)
which typically precedes the development of hypertension(42, 253, 520). Drugs
that reduce albuminuria are considered important treatments for CKD as well as
cardiovascular disease in general (98, 514). However, blood pressure transmission
to the glomeruli can also initiate renal injury in hypertension (34, 262).
Failure of the myogenic response in the renal afferent arteriole is implicated
in the transmission of pressures required for glomerular injury (299, 465). The
larger renal arteries also contribute to total resistance (193, 236, 509) hence net
loss of renal vascular integrity is causative in the pathophysiology of hypertensive
renal injury (260, 285, 374, 466). Preglomerular vascular injury, especially in
the renal interlobar artery segments, typically precedes total renal damage and
dysfunction, see section 4.4.1 and (11, 374, 509). These studies are consistent with
the preglomerular vacuolation seen in the F344 strain following ANG II infusion.
However, renal injury and fibrosis can also develop independently of barotrauma
and the local actions of agents such as aldosterone (11, 248) and ANG II (339, 408)
have been implicated.
Nevertheless, causation between hypertension and CKD is unclear (135) and
several other key mechanisms worthy of note have not been studied here. The
severity of high blood pressure is moderated by 24 hour variability (393) such that
accurate measurement of blood pressure assists risk prediction (139, 184, 452).
Temporal measurements of blood pressure can identify individuals with a non
dipping night-time blood pressure phenotype, thought to be indicative of im-
paired renal sodium handling (21, 138), reversible by hydrochlorothiazide diuretics
(417, 505). Other likely important mechanisms such as the regulation of salt re-
abpsorption in a 24 hour period, remain to be uncovered (97, 283, 407).
Low birth weight is also associated with adulthood CKD and more generally
cardiovascular disease and morbidity (22, 22, 95, 424). Brenner originally hypothe-
sised that reduced nephron number is a key factor initiating primary hypertension
(43) due to hypertrophic compensatory mechanisms following reductions in renal
mass either by whole kidney removal or partial ablation (188). This hypothesis
is supported by micropuncture studies in 5/6 renal ablated rats which have com-
pensatory and deleterious single nephron hyperfiltration (9, 201). Observations
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in patients with primary hypertension found apparent compensation of reduced
glomerular number with hypertrophy or oligomeganephronia (251).
The complex pathologies of CKD eventually converge upon a significant inflam-
matory component (54, 126, 372) characterised by the infiltration, and activation,
of inflammatory mediators (37, 499) and immune cells (195, 448, 523). T-cell acti-
vation following minor injury can occur by a number of stimuli including oxidative
stress, salt imbalances and ANG II (37, 54, 174, 261, 411) promoting macrophage
infiltration. Macrophages can themselves cause vasoconstriction and drive blood
pressure higher still (302). Multiple P2 receptors are implicated in both pro - as
well as anti- inflammatory modulation (116, 219). Thus the kidney is likely the
cause of the hypertension that can ultimately deteriorate it (263).
4.4.2 Renal P2X7 and P2X4 receptors in a pre-fibrotic set-
ting
In the kidney P2X7 expression has been best described in the glomeruli and specif-
ically the messangial cell of the Ren2 transgenic rat (515). Uretral obstruction in
the mouse causes significant renal macrophage infiltration and collagen deposition
mediated by the P2X7 receptor (158). Loss of P2X7 receptor activity has been
associated with reduced cyst development in a Danio rerio model of polcystic kid-
ney disease (67) and reduced renal injury in glomerulosclerosis (488). Interactions
between P2X7 and P2X4 receptors occur in multiple tissues (83). P2X4 receptors
expressed on macrophages might enhance the P2X7 mediated response (247).
Whole protein Western analysis indicated that P2X7 and P2X4 were not reg-
ulated by the dose of ANG II infused. This is not surprising because together
the renal injury data did not indicate significant fibrosis. Renal injury scored sig-
nificantly higher in the F344 strain following ANG II infusion and was limited
to myocyte vacuoloation and occasional glomerular atrophy. This is consistent
with the earliest stages of renal injury in the Cyp1a1-Ren2.F rat (11). However,
macrophage infiltration into the preglomerular vascular wall was not observed fol-
lowing ANG II infusion in either strain suggesting the vascular injury was minimal.
Renal injury scoring also verified that ANG II infusion did not cause renal vascular
injury in Lewis rats. Unfortunately the quality of MΦ immunolocalisation was not
sufficiently clear to permit individual macrophage counting. Nonetheless it was
clear that total CD68 positive staining within the glomerulus did not increase.
It remains unclear whether (subject to the large variability) the CD68 positive
staining in F344 + ANG II group glomeruli (Fig.4.6A, black arrow) can explain
the P2X7 positive staining in glomeruli of this group (Fig.4.2F). Alternatively the




Acute P2X7 and P2X4 antagonism significantly ameliorated the blood pressure
rise caused by ANG II infusion. Increases in blood pressure are associated with
increases in renal interstitial ATP concentrations (365, 366) which enhances the
TGF mechanism (216, 367). Furthermore chronically elevated extracellular ATP
is associated with smooth muscle cell hypertrophy and hyperplasia (49, 120, 205,
469, 519). A role for renal purines in regulating renal vascular resistance in ANG
II dependent hypertension is well established (131, 132, 177, 178, 183, 527). P2
receptors are implicated in glomerular and vascular injury in ANG II hypertension
(161). ANG II infusion markedly decreases renal afferent arteriole calcium influx
and vasoconstriction via P2X, but not P2Y, receptors (549).
Pressure-natriuresis in the F344 rat was blunted by ANG II infusion. Ac-
tivation of the RAS sufficiently alters the renal functional curve inducing salt
sensitivity of blood pressure in several animal models (230). Furthermore the
pressure-natriuresis mechanism is hypothesised to shift prior to onset of hyperten-
sion (80, 180) such that even subpressor infusion of ANG II is sufficient to blunt
pressure-natriuresis (398, 462, 508). Thus the dominant functional consequence
of P2X7 and P2X4 expression following ANG II infusion in the F344 rat was a
blunting of the pressure-natriuresis mechanism.
In conclusion, low dose ANG II infusion in the F344 rat can model the earliest
stages of renal dysfunction and injury prior to significant macrophage infiltration
and fibrosis. Renal tissue hypoxia is implicated in the earliest stages of CKD pro-
gression, with low partial pressure of oxygen (pO2) eventually causing activation of
a pro-fibrotic cascade (128, 390, 535). The next chapter will therefore investigate




P2X7 AND P2X4 RECEPTORS IMPAIR RENAL
OXYGENATION AND PERFUSION FOLLOWING
CHRONIC ANGIOTENSIN II INFUSION
5.1 Introduction
Under physiological conditions renal pO2 is thought to have a marked cortico-
medullary gradient, with the medulla being poorly oxygenated compared to the
cortex (121). Cells of the medulla have a higher anaerobic capacity than those of
the cortex and paracrine signalling pathways also provide some resistance against
hypoxia (362). Nevertheless, the medulla is susceptible to hypoxic injury and
abnormal vascular reactivity can cause hypoperfusion initiating a vicious cycle of
microvasculature injury, inflammation and fibrosis (315). Hypertension imposes
increased metabolic demand on the kidney which may drive the medulla towards a
hypoxic state (44, 108, 127, 128, 129). As such, it has been proposed that hypoxia
is a common pathway in the genesis of CKD (375, 390).
Causation relating defects in renal oxygenation to renal disease is implied
by immunohistochemical detection of pimonidazole adducts (349), formed when
pO2 is <10 mmHg. This method is, however, insensitive and non-quantitative
(430). Oxygen sensitive microelectrodes offer a quantitative and sensitive ap-
proach, (121), but measurements made at the electrode tip cannot give insights
into the wider distribution of tissue oxygen. Moreover, being invasive, microelec-
trodes are not usually amenable to longitudinal studies of renal function and local
tissue damage (causing release of ATP) can make interpretation difficult.
Blood oxygenation-level dependent (BOLD) magnetic resonance imaging (MRI)
is emerging as a technique through which to assess renal oxygen bioavailability
(312). The BOLD signal (T2*) is a combination of the spin-spin relaxation rate
between local protons (T2) and local field inhomogeneities produced by the para-










The relaxation rate (R2*=1/T2*) is thus proportional to the level of deoxy-
hemoglobin and R2* reflects the oxygenation status of red blood cells (377, 409).
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R2* can be associated with tissue pO2 and indeed much of the physiological utility
of BOLD MRI rests on the assumption that tissue pO2 is in responsive equilibrium
with red blood cell pO2. In pigs the spatial gradients of oxygenation observed by
BOLD MRI are consistent with those measured in the contralateral kidney by O2
microelectrodes (397).
BOLD MRI thus provides a unique tool to investigate the regulation of re-
nal oxygenation during the progression of hypertension. In this chapter, Study 1
presents the development of a BOLD MRI acquisition and analysis protocol show-
ing that ANG II infusion caused a transient disturbance in renal oxygenation in
F344 rats. Study 2 investigated the effect of P2X7 and P2X4 receptor antagonism
on renal oxygenation.
5.2 Methods
5.2.1 MRI scanning protocol
BOLD MRI measurements were performed using a 7 Tesla preclinical MRI scan-
ner (Agilent Technologies, UK). Rats (n=6) were anesthetised with 1.5 - 2 %
isoflurane in oxygen-enriched air (0.5 l/min air, 0.5 l/min oxygen). Rectal temper-
ature was maintained at (37oC). Respiration and ECG were monitored for stability
throughout the scanning protocol. A birdcage volume coil (72 mm diameter) and
a 4-channel phased array surface coil (Rapid Biomedical GmbH, Germany) were
used for radio frequency transmission and signal reception, respectively.
Image acquisition used a multiple echo gradient-recalled BOLD MRI pulse
sequence of ten T2*-weighted echoes; TE = 4, 8, 12, 16, 20, 24, 28, 32, 36, 40
ms, TR=100 ms and flip angle of 30o at an 83 kHz bandwidth. An axial slice
through the centre of the right kidney was selected with 50 x 40 mm field of view
containing a 192 x 128 acquisition matrix (in-plane resolution = 0.26 x 0.31 mm).
A single axial slice, aligned parallel with the renal artery identified by rapid scout
scanning (fast gradient echo, 3 slices in coronal orientation), ensured slice position
encompassed the most representative section of the kidney regions. Slice thickness
was 2 mm with 14 signal averages. Temporal resolution was 3 minutes for each
BOLD scan.
5.2.2 Image analysis pipeline
Image analysis procedures were developed and coded in collaboration with Andrew





























































































































































































































































































Although the use of BOLD MRI to rapidly and non-invasively define renal
hypoxia is clinically attractive (152), interpretation of images is often challeng-
ing. Most post-acquisition analyses rely on manual selection of small regions of
interest (ROI) to generate anatomically informative R2* maps. However, kidneys
are subject to respiratory and cardiovascular motions that might be difficult to
gate against, particularly in experimental models. Unless image registration is
employed, time-series data within an individual ROI are unlikely to be acquired
from exactly corresponding anatomical regions. The selection of small segments
that are well delineated within the cortex and medulla has been advocated (153)
but this approach will discard from the analysis biological information contained
within the data set. Moreover, this approach is subjective and risks a selection
bias towards areas at the extremes of signal intensity (152).
In biomedical research, the use of algorithms that cluster individual data points
based on concepts of quantitative “nearness” or “similarity” are more commonly
associated with analysis of gene expression data sets (105) but is broadly ap-
plicable to large data sets, such as those generated through BOLD MRI. The
present method applied k-means clustering as an anatomically unbiased approach
to BOLD MRI analysis. The central tenet of this approach is that voxels clus-
tered on quantitative nearness of the R2* signal share a commonality of biological
process. Importantly, quantitative similarity does not necessarily equate to close
anatomical proximity of voxels or compartmentalization within a given region of
the kidney.
5.2.2.1 Image selection and registration
Motion correction was performed by complimentary measures to ensure voxels
in different frames overlapped; global registration (consistent over entire image),
intensity based registration (using grey-level image values) and rigid registration
(only allowing translation and rotation) were used on each rat and on each day
separately.
Initial outlier detection was assessed by a Hampel identifier, used to detect
scans having an intensity profile significantly different from the median (X0.5) or
outside the 90th percentile (X0.9): scan imprecision largely reflected significant






















































































































































































































Rigid registration was performed on the remaining images using an exhaustive
search. The third baseline scan was selected and all other scans in the sequence
were translated and rotated until the mutual information (gradient2) was max-
imised. This improved stability across sequences: 96% of scans required less than
one voxel translational correlation or less than 1o rotation, indicating that rigid
registration was sufficient for the present dataset.
5.2.2.2 K-means clustering analysis
Automated image segmentation was performed using a k-means clustering algo-
rithm (with k, the number of clusters). K-means clustering identifies k-clusters
within a multi-dimensional space using Euclidean distance (for details, see chapter
9.1 of (36)). Given a set of points, the target of the algorithm is to find k cluster-
centres such that the sum of square distances of each point to its closest cluster
centre is a minimum. The (local) minimum is searched for in an iterative manner,
the two steps of which are i) the association of the points with their closest cluster
centres and ii) the updating of the cluster centres such that the sum of square dis-
tances to the associated points is minimized. The final cluster configuration can
be dependent on the initial cluster configuration. To validate our approach the
appropriate number of initial conditions was therefore determined to establish the
lowest number insensitive to the starting conditions. The present dataset found
10 random initial conditions to fit this condition, thus the algorithm was run for
each scan set and saved the final configuration as that with the lowest sum of
intra-cluster distances.
To select the number of clusters (K) a pilot analysis was performed using
k=1,2,3,...13 to identify the value of k such that the increase in explained variance
of k+1 clusters was 50% of the additional variance explained by the kth cluster.
With the use of this approach k=2 was chosen, as the addition of a third cluster
did not contribute sufficiently to an increase in explained variance.
5.2.3 Study 1: Validation of renal BOLD MRI clustering
analysis
The effect of acetlycholine (5µg/kg, Sigma-Aldrich) on the R2* signal was deter-
mined prior to, and following administration of N-Nitro-L-arginine methyl ester
hydrochloride (L-NAME; 10mg/kg Sigma-Aldrich). Both compounds were admin-
istered via the tail vein in a volume of ∼0.15ml. Immediately following injection
the catheter was flushed through with a volume of saline equal to the catheter
volume. Scans obtained under control conditions (days -6 and -4) were com-
pared statistically and then (consequentally) combined into one control group. On
day 0, osmotic minipumps (Model 2002, Alzet, Charles River, UK), adapted for
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MRI by replacement of the stainless steel flow moderator with a polyetherether-
ketone equivalent (part #2496, PEEK, Charles River, UK), containing ANG II
(60ng/min) were surgically implanted under isofluorane anesthetic. Rats were
scanned again after 3 & 6 days of ANG II infusion (n=6 in each group).
The effect of acetylcholine and L-NAME on blood pressure and renal blood
flow were measured in a parallel study using the protocol described above for
control rats (n=4) and rats receiving ANG II (60ng/min; ANG II; n=5). Rats
were anesthetized (Thiobutabarbital 120 mg/kg IP). The right jugular vein was
cannulated for infusion of 0.9% NaCl containing 1% bovine serum albumin. Rats
were infused at 100µl/min until a total volume of 1.25ml/100g bwt was reached,
then 30µl/min maintenance rate. The left femoral artery was cannulated for blood
pressure measurement (MLT844, AD Instruments); a tracheotomy performed to
maintain a clear airway. A midline laparotomy was performed and a Doppler
transit time probe (MA1PRB; Transonic, USA) placed around the left renal artery.
Core body temperature was servo-maintained at 37oC.
5.2.4 Study 2: Effect of P2X7 and P2X4 antagonism on
renal BOLD signal
The effect of BBG (40mg/kg, Sigma-Aldrich) on the R2* signal was determined
by administered via the tail vein injections. Rats were scanned on day 0 and
following the final MRI scan, osmotic minipumps (Model 2002, Alzet, Charles
River, UK), adapted for MRI by replacement of the stainless steel flow moderator
with a polyetheretherketone equivalent (part #2496, PEEK, Charles River, UK),
were implanted subcutaneously containing ANG II (30ng/min; n=6). Rats were
scanned again after 14 days of ANG II infusion.
5.2.5 Statistical analysis
Data are presented as mean ± standard error of the mean (SEM). Statistical
analysis was performed by ANOVA with Bonferroni post-hoc correction unless
otherwise stated. Comparisons between groups of the pressure-diuresis relation-
ship were made by linear regression. Histograms were used to compare signal




5.3.1 Study 1: Validation of renal BOLD MRI clustering
analysis
The clustering approach was used to generate R2* maps within a kidney quadrant
in each of six control rats, using the postacquisition pipeline (Fig.5.1). Two com-
partments of distinct mean R2* intensities were created (cluster 1 = 70.96±1.48;
cluster 2 = 79.00±1.50; means±SE; n = 18 scans in 6 rats; P<0.01). Each rat
underwent three consecutive baseline scans on control days 6 and 4 and following
3 days of ANG II infusion. In control rats, baseline scans repeated sequentially
on separate days or on different rats did not vary significantly for either cluster 1
(Fig.5.3A) or cluster 2 (Fig.5.3B). ANG II infusion did not effect the consistency
of consecutive baselines found verifying scan reproducibility. Baseline scans were
therefore combined for both groups.
Systemic injection of acetylcholine significantly attenuated the R2* signal (P<0.01,
ANOVA) in both clustered compartments (Fig.5.4A), suggesting an increase in
pO2 throughout the kidney. This effect was transient; reaching its nadir in the
scan performed 6 min post-injection. In a parallel study, acetylcholine initially
caused a rapid fall in mean blood pressure and renal blood flow ((Fig.5.4B & bi).
This effect was short lived (<1 min), and during the BOLD MRI scan protocol,
renal blood flow was ∼30% higher than at baseline. Importantly, the average re-
nal blood flow remained stable suggesting intact autoregulation. Administration
of L-NAME caused a slowly progressive increase in signal intensity in the high
R2* compartment (P<0.01, ANOVA) but was without effect in the low R2* com-
partment (Fig.5.4A). L-NAME also caused a reduction in renal blood flow over
this time course (Fig.5.4B & bii). Acetylcholine was again injected. The effect on
blood pressure and renal blood flow persisted, but the attenuation of R2* signal
by acetylcholine was no longer observed.
Blood pressure and renal blood flow were not significantly affected by 3 day
infusion of ANG II. Following 3 days of ANG II infusion, the R2* signal was no
longer significantly affected by administration of either acetylcholine or L-NAME
(Fig.5.5A). Nevertheless, acetylcholine still induced a transient reduction in renal
blood flow and blood pressure (Fig.5.5B) and L-NAME increased renal vascular
resistance.
The k-means clustering approach resolved the data into distinct compartments;
indeed, convergence is assured by this algorithm, but the magnitude of the differ-
ence in intensity between the two compartments was much reduced (cluster 1 =
71.30±2.00; cluster 2 = 72.48±1.27; mean±SE; NS). Critically, baseline means of
the two clustered compartments were less distinct during baseline and no longer
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Figure 5.3: Reproducibility of Baseline BOLD MRI Data. - Rats were
scanned in triplet (baseline 1, 2, and 3) and in 2 cohorts on day 6 (solid grey
lines) or day 4 (broken grey lines). No significant difference between any of these




Figure 5.4: Control BOLD MRI and Renal Haemodynamic Data. -
Acetylcholine exerts a non-heamodynamic NO-dependent R2* effect in the nor-
motensive kidney. (A) R2* trace measured over scanning protocol. (B) Renal
vascular resistance (RVR) haemodynamic study following protocol time course and
zoomed in regions around first ACh dose (bi) and ACh following LNAME (bii)




Figure 5.5: Renal BOLD MRI and Haemodynamic Analysis After 3 Day
ANG II infusion. - A: R2* trace measured by k-means clustering, red line(cluster
1) and blue line (cluster 2) signal. B: renal vascular resistance (RVR) haemodynamic
study following protocol time course and insert showing ACh (bi) or L-NAME (bii)
trace with blood pressure (black line) and RBF (red line).
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mapped to discrete anatomical regions of the kidney (see Fig.5.6 for example im-
ages). This suggests that a short exposure to ANG II disrupts the oxygenation
gradient through the kidney, creating areas of high and low pO2 in both cortex
and medulla. As stated previously, the R2* signal actually reflects oxygenation of
red blood cells and thus altered patterns of renal perfusion may also account for
the disrupted gradient. However this effect appeared transient since rats scanned
following 6 days of ANG II infusion, the baseline scan regions became once again
more distinct (suggesting a re-establishment of pO2 gradient in the kidney) whilst
the effects of ACh and L-NAME on the R2* signal remained impaired (Fig 5.7).
5.3.2 Study 2: Effect of P2X7 and P2X4 antagonism on
renal BOLD signal
In control animals two compartments of distinct mean R2* intensities were created
(cluster 1 = 60.21±1.38; cluster 2 = 67.61±1.68; means±SE; n = 18 scans in 6 rats;
P<0.05). Acute injection of BBG produced no observable effect in normotensive
animals (Fig.5.8A). Following 2 week ANG II infusion clustering analysis found
distinct clusters (cluster 1 = 65.75±3.20; cluster 2 = 75.56±4.89; means±SE; n =
18 scans in 6 rats; P<0.01). Following 2 week ANG II infusion, injection of BBG
produced an observable decrease in renal R2*(Fig.5.8B).
The variance of Study 2 was a factor of ∼1x106 lower than that observed in
Study 1 (2.44x106 v.s. 0.04; Study 1 v.s. Study 2 respectively). To clarify whether
this reduced variability was weighted towards the ‘high’ or ‘low’ T2* values it was
necessary to construct histograms of both studies. For clarity these hitograms have
been overlapped to demonstrate that the reduced variability in fact translated into
a reduced number of observed intensities over most of the distribution (Fig.5.9).
This might be interpreted as reduced overall T2* signal within Study 2 (compared




Figure 5.6: Anatomical Heterogeneity of Renal BOLD Signal After 3
Day ANG II Infusion. - Exemplar clustering analysis in manually delineated
renal quadrants of rat kidney under control conditions (A) and following ANG II
infusion (B). The k-means clustering was used to segment data on a quantitative
basis into low (dark grey) and high (light grey) R2* clusters. In control conditions,
these clusters mapped to anatomical regions; following ANG II infusion, the spatial
relationship between similar R2* values was less well defined
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Figure 5.7: Renal BOLD MRI After 6 Day ANG II infusion. - R2* trace
measured by k-means clustering, red line(cluster 1) and blue line (cluster 2) signal.




Figure 5.8: R2* Effect of P2X7 and P2X4 Antagonism - (A) Control (B)
ANG II infusion. Arrow indicates time point of BBG injection. Data are presented
as mean±SE; cluster 1 data (open squares); cluster 2 data (closed circles). Statistical












































































































































































































































































































BOLD MRI is an attractive tool for clinical research since it does not require
exogenous contrast agents which can be nephrotoxic and has a rapid acquisition
time (154). BOLD MRI is increasingly used to quantify renal oxygenation in
a variety of disease settings and studies typically focus on the medulla, which
is vulnerable to hypoxic insult. Hypoxia of the cortex is also evident in severe
renovascular disease (155) and in diabetic and non-diabetic CKD (309) . A global
map of renal R2* could therefore be a valuable diagnostic/prognostic tool for
ischemic renal disease. However, the relationship between R2* and tissue hypoxia
is complex (312). R2* reports oxygenation of the red blood cells and the signal
reflecting local perfusion, is also influenced by pH and hydration status. In CKD,
BOLD MRI studies have produced conflicting data (328, 541). This partially
reflects the complexity of CKD; the future diagnostic utility of renal BOLD MRI
is nevertheless contentious (210).
One major challenge for the field is standardization of protocols, particularly
for post-processing, that would facilitate meaningful cross-comparison of data sets.
Most studies quantify renal oxygenation by measuring R2* signal intensity in small
manually selected ROI. A strength of this approach is that the generation of time-
series data is based firmly on anatomical knowledge of renal structure. Reliable
placement can be difficult, however, and averaging across several ROI can mask the
heterogeneity of oxygenation. Importantly, the ROI approach discards from analy-
sis much of the biological information contained within an image and the power of
BOLD MRI to assess renal oxygenation on a global scale is often underexploited.
5.4.1 Clustering analysis of renal BOLD MRI data
Data-led segmentation of datasets has previously been used for analysis of brain
(55) and kidney (107, 551) MRI. The proposed method here offers two differences.
First, each cluster is defined from time series since voxel variation in time is in-
formative and more easily controlled than maps defined in a separate computed
tomography scanner where renal orientation might be difficult to replicate. Second,
distinct and separate cortical and medullary R2* distributions are not necessary
to define by different distribution functions or otherwise. Semi-automated post-
acquisition pipeline for analysis of BOLD MRI images using k-means (where k=2)
clustering assigned individual voxels into one of two statistically distinct compart-
ments. The advantages of the method are that it: i) does not require user-led
selection of small anatomical ROI but rather a gross quadrant of the whole kidney
to be segregated into two compartments in a user-independent manner; ii) obvi-
ates the need for voxel-tracking through a time-series stack; iii) is anatomically
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unbiased, identifying on a global scale clusters of pO2 homogeneity for each patient
or experimental subject.
This study has clinical relevance: a recent study, averaging R2* across multi-
ple ROI, demonstrated cortical hypoxia in a small number of CKD patients (309).
The effect size was small and the variation large, suggesting that constraints of
statistical power will make comparisons of absolute R2* across patients and be-
tween studies difficult (328, 541). Qualitatively, Manotham and colleagues noted
that the R2* signal was more heterogeneous and liable to rapid decay in CKD
patients than in controls (309). This suggests that global disruption of a spatially
constrained pO2 gradient may be a hallmark of the defects in oxygenation associ-
ated with renal injury. The present study partially supports this notion. However
the disruption of pO2 gradient (3 day ANG II) was transient and not observed 3
days later (6 day ANG II). This limits the utility of pO2 gradient mapping as a
diagnostic tool.
Acutely, NO bioavailability was manipulated pharmacologically. The manoeu-
vres were designed to change whole kidney blood flow, either rapidly and reversibly
with acetylcholine, or with sustained effect through nitric oxide synthesis inhibi-
tion, without altering autoregulatory capacity (28). Chronically ANG II was in-
fused to cause a change in R2*: over this time frame there would be no major
change in renal vascular resistance but an increase in renal tubular sodium reab-
sorption (11, 508, 548). These complimentary experiments provided the means
to dissect the physiologically complex R2* signal, resolving the influence of nitric
oxide bioavailability and renal blood flow.
Acute administration of ANG II causes a rapid increase in R2* in healthy
subjects, attributed to a fall in renal perfusion (439). Conversely, acute blockade of
AT1 receptors increases pO2 in the renal cortex of CKD patients (309). An increase
in cortical oxygenation following AT1 receptor blockade has also been observed in
normal (370) and hypertensive rats (531), effects attributed to improved blood
flow and efficiency of O2 usage respectively. In Study 1, a 3-day infusion of ANG
II did not increase blood pressure, consistent with previous data (70) and gross
renal blood flow was unchanged. Tubular sodium reabsorption is increased within
this time-frame (11, 548), and there was evidence for disruption of the regional
homogeneity of pO2. This may reflect a local mismatch of delivery/consumption or
a reduction in the efficiency of O2 utilization, as reported in the ANG II-dependent
Goldblatt model (531).
Most MRI scanners are not calibrated directly for pO2. The absolute R2*
value is often therefore less informative for cross-comparison than is the dynamic
response to manoeuvres affecting perfusion or sodium transport. In this study,
injection of acetylcholine suppressed the R2* signal throughout the kidney. This
was probably not dependent on whole kidney perfusion, there being temporal
82
5.4 Discussion
separation between the reduction in blood flow and the reduction in R2*. The
attenuation of R2* was dependent on NO generation, being inhibited by L-NAME,
and had a delayed onset, being evident only in the second scan post injection. A
previous study also reported no immediate effect of NO on R2* intensity (439).
NO reacts irreversibly with both oxy- and deoxyhaem moieties (113). These
reactions are rapid and hemoglobin and deoxyhemoglobin levels should be equiva-
lently affected over each three minute BOLD scan. Reduced R2* therefore might
indicate an NO-dependent increase in pO2 throughout the kidney, most probably
reflecting inhibition of tubular sodium transport (145). The effect of acetylcholine
was lost following 3 day ANG II infusion. Prolonged exposure to ANG II causes
oxidative stress in rats (281) and these data plausibly reflect accumulation of su-
peroxide anion leading to NO deficiency and defects in renal oxygenation (530).
There are two important limitations. First, it was not possible to measure re-
nal blood flow and BOLD signal simultaneously. The invasive surgery required for
Doppler measurements of renal arterial blood flow also mean that measurements
were not made in the same animals: repeated R2* measurements were instead ob-
tained in a longitudinal study. Second, the BOLD MRI and renal blood flow data
were obtained under differing anaesthetic regimens. Maintenance of anaesthesia
within the MRI scanner required ECG monitoring under gas anaesthesia (Isoflu-
rane) while stability of renal perfusion following the invasive abdominal surgery is
best obtained with a long-lasting barbiturate (517). Renal haemodynamics may
be differentially affected by the anaesthetics but it unlikely that this accounts for
the temporally distinct dynamic response to acetylcholine of the R2* signal and
blood flow.
This study presents the development of an anatomically unbiased method for
the assessment of renal function by BOLD MRI, employing signal analysis to re-
move errors inherent in manual ROI selection. These data indicate that protocols
assessing the dynamic response of R2* to acetylcholine can provide information re-
lating to renal NO bioavailability and offer temporal insight into renal oxygenation
homeostasis. Data presented in this study have been published (324). A reprint
is included in Appendix B, section 8.2.
5.4.2 The effect of P2X7 and P2X4 antagonism on renal
oxygenation
Under control conditions acute injection of BBG had no effect on renal R2* signal.
This result was surprising because during constant acute infusion BBG caused a
significant decrease in blood pressure (Figs.3.8 & 3.9). There are several possible
explanations for this; 1) this was a consequence of the lower total dose of BBG
injected in the present study, 2) there was activation of an unknown compensatory
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mechanism maintaining constant oxygenation while perfusion is significantly re-
duced or 3) the loss of BOLD MRI signal in the second study reduced the sensitivity
of the BOLD signal. Signal intensity was indeed weaker in Study 2 and the distri-
bution of intensities (indicated by the histrogram) was also reduced. Loss of signal
might have limited the sensitivity of Study 2 to both the clustering approach and
acute pharmacological manoeuvres.
Following ANG II infusion BBG induced a transient decrease in renal R2*
signal. This result suggests that P2X7 and P2X4 receptors mediate renal perfu-
sion/oxygenation following over activation of the RAS. Furthermore these data are
consistent with the renal functional studies which demonstrated improved pressure-
natriuresis following acute BBG infusion in chronically ANG II infused F344 rats
(chapter 4, section 4.3.3).
ATP activated P2X receptors are indeed implicated in disease progression
(35, 255). Local hypoxia can induce cellular ATP release from several cell types
including erythrocytes (31) and endothelial cells (48) where P2X7 and P2X4 re-
ceptors are expressed. The present study has demonstrated that P2X7 and P2X4
receptor activation is associated with hypoxia. Eventually this will lead to inflam-





The starting point of this research was to mine a renal microarray in order to
identify genes contributing to differential susceptibility to hypertensive vascular
injury. This result, although limited to protein encoding genes, used an unbiased
comparative approach. Ace was the top ranked gene by this approach, consistent
with previous research published from this laboratory using alternative strategies
where both the validity of the microarray and expression of Ace was validated
(295). The injury susceptible F344 background had higher renal ACE concen-
tration, lower concentration of the anti-inflammatory tetrapeptide N-acetyl-Ser-
Asp-Lys-Pro (Ac-SDKP) and showed a greater blood pressure increase following
exposure to I3C. All of these differences likely contributed to the modifying effect
of Ace and this was not investigated further here.
P2x7 and P2x4 genes were identified as the next top ranking hits for injury
susceptibility (Fig.6.1). The molecular physiological approaches described in this
thesis provide compelling data for functional expression of these receptors in the
renal vasculature. F344 rats had higher expression of P2X7 and P2X4 receptors
at the genetic and protein levels. P2X7 and P2X4 receptors were identified on the
vascular endothelium. In smooth muscle cells the vascular contractile responses
to ATP have been largely attributed to P2X1 receptors (216). In the endothelium
P2X4 receptors are the most abundantly expressed, followed by P2X7 (∼50%) and
then by P2Y1 and P2Y2 (∼20%) receptors (544). A similar profile is observed in
endothelial cells cultured from the mouse pulmonary artery (545) and P2X4 and
P2X7 receptors have also been immunolocalised to the endothelium of the larger





























































   










   



























































































































However, the P2X7 receptor is most highly expressed on macrophages (533).
Chronic activation results in the release of interleukin 1 beta (IL-1β) amongst
other cytokines (116, 292) and eventually causes cell death. P2X7 facilitates these
processes through association of its long c-terminal tail with membrane pores, such
as pannexin-1 (399), making it unique amongst the P2X receptor family. P2X4
receptors can also activate pro-inflammatory cascades (247, 502). Acute infusion
of BBG, under surgical conditions, was selected over chronic treatment to cause
a functional response attributable to the receptors expressed in the vasculature.
Using this approach it was identified that P2X7 and P2X4 may contribute to the
normal control of renal arterial resistance of the F344 strain. BBG is 1000 times
more selective for the P2X7 receptor then P2X4 (227). These receptors therefore
cannot be separated pharmacologically with BBG, however, their expression was
distinct and appeared on separate cell types of the renal medulla. P2X7 staining
was observed in the vasa recta of F344, but not Lewis, rats. One explanation of the
renal functional response of F344 to BBG infusion could be a direct consequence of
this since the vasa recta plays a key role in the pressure-natriuresis mechanism (80).
P2X7-mediated contractions have been also demonstrated in human saphenous
veins (57) and indeed the renal vasa recta (84), although contraction of the renal
vasa recta was entirely attributed to pericytes. P2X4 was not expressed on the
vasa recta. Together these data implicate P2X7 receptors expressed on the vasa
recta in mediating the pressure-natriuresis seen in F344 rats.
To investigate the role of blood pressure per se, antagonism of P2X7 and P2X4
in the F344 strain was investigated following ANG II infusion. ANG II has been
shown to increase expression of P2 receptors (132, 549) however this was not
observed here likely because the dose of ANG II selected did not cause overt
hypertension or injury. Acute BBG infusion did however significantly improved
the pressure-natriuresis relationship of chronically ANG II infused F344 rats.
Further evidence supporting the role of the P2X7 receptor in the functional data
described here is found in gene deleted mice: P2X4 deficiency is not protective
whilst P2X7 deficiency is. P2x4−/− mice have impaired endothelial-dependent
vascular function (545). P2x7−/− mice infused with deoxycorticosterone acetate
(DOCA) salt develop more profound hypertension and renal injury compared to
DOCA salt infused controls (226) and are partially protected from experimental
glomerulonephritis (488). BBG has also been used to ameliorate renal injury and
hypertension in Dahl salt sensitive rats (225). Together these studies implicate
P2X7 in the initiation of a cascade of profibrotic events (Fig.6.1).
The encoding gene for P2X7 transcribes a large number of splice variants with
reportedly different functionality (467, 542) which may also contribute to con-
trasting vasoactive effects in different strains of rat as observed here. The P2X7
antibody used in the present study binds to the c-terminal region (epitope: 576-
87
595) which would exclude the detection of truncated forms of the receptor (311).
In humans P2X4 and P2X7 are located within 130kb of each other on chromo-
some 12. These genes can be regulated independently: the endothelial expression
of P2X4 receptors in the human aorta is increased following injury; P2X7 receptor
expression is not affected (410). It is possible, however, that these receptors have
common promotor elements. Physiological interactions between the receptors are
postulated (83) and the locus is associated with human disease. For example, a
SNP in the first intron of P2x7 is strongly associated with elevated blood pres-
sure (392) and a loss-of-function SNP in the P2x7 coding region associates with
protection against ischemic stroke (150). Similarly, a loss of function SNP in the
P2X4 receptor has been associated with increased pulse pressure (478).
Two separate clinical trials have targeted P2X7 in rheumatoid arthritis (254,
394) and were unsuccessful in ameliorating the symptoms of this disease compared
with current treatment (methotrexate). Loss of function receptor variants might
explain these observations since stratification was not performed. However, this
thesis has also identified a novel vascular role of P2X7. This suggests that targeting
P2X7 before the onset of overt inflammation and fibrosis might improve clinical
outcomes of CKD (Fig.6.1).
There are at least two broadly important avenues for future research. Firstly
refinement of the physiological methods discussed here by both improved phar-
macology (using pharmaceutical industry prepared compounds) as well as in vitro
studies on isolated vascular beds (for example using wire myography for the pre-
glomerular endothelial P2X receptor function) will further refine the molecular
mechanism(s) of independent P2X7 and/or P2X4 receptor activation. Secondly,
investigating whether P2X receptor sequence differences between the rat strains
studied here exist and might account for loss/gain of receptor function will further
explain the renal functional data. Furthermore the availability of P2X7 antagonists
for human studies presents a strong translational potential for this research.
In conclusion this thesis indicates that P2X7 activation impairs renal perfusion,
the pressure-natriuresis response and reduced oxygenation. In combination with
the well defined roles of P2X7 on macrophages these data indicate that P2X7 is
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E. H. Birth weight relates to
salt sensitivity of blood pres-
sure in healthy adults. Hyperten-
sion, 51(4):928–32, 2008. (page 62).
[96] De Gasparo, M., Catt, K. J.,
Inagami, T., and Wright, J. W.
International Union of Phar-
macology . XXIII . The An-
giotensin II Receptors. Phar-
macological reviews, 52(3):415–472,
2000. (page 16).
[97] de Leeuw, P. W. Nyc-
themeral relationship between
renal function and sodium
homeostasis. Current hyperten-
sion reports, 13(2):136–41, 2011.
(page 62).
[98] de Zeeuw, D. Albuminuria,
not only a cardiovascular/renal
risk marker, but also a target
for treatment? Kidney inter-
national. Supplement, 66(92):S2–6,
2004. (page 62).
[99] Deen, P. M., Verdijk, M. A. J.,
Knoers, N. V. A. M., Wieringa,
B., Monnens, L. A. H., van Os,
C. H., and van Oost, B. A.
Requirement of human renal
water channel aquaporin-2 for
vasopressin-dependent concen-
tration of urine. Science, 264:92–
95, 1994. (page 9).
[100] Deng, A. Y. Genetic basis of
polygenic hypertension. Hu-
man molecular genetics, 16 Spec
No(2):R195–202, 2007. (page 3).
[101] Denton, D. A., McKinley,
M. J., and Weisinger, R. S. Hy-
pothalamic integration of body
fluid regulation. Proceedings of
the National Academy of Sciences
of the United States of America,
93(14):7397–404, 1996. (page 4).
[102] Di, A. and Malik, A. B. TRP
channels and the control of vas-
cular function. Current opinion in
pharmacology, 10(2):127–32, 2010.
(page 6).
[103] Dickinson, D. P., Gross, K. W.,
Piccini, N., and Wilson, C. M.
Evolution and variation of
renin genes in mice. Genetics,
108(3):651–67, 1984. (page 15).
[104] Donoghue, M., Hsieh, F.,
Baronas, E., Godbout, K.,
Gosselin, M., Stagliano, N.,
Donovan, M., Woolf, B.,
et al. A Novel Angiotensin-
Converting Enzyme-Related
Carboxypeptidase (ACE2)




[105] Dougherty, E. R., Barrera,
J., Brun, M., Kim, S., Ce-
sar, R. M., Chen, Y., Bit-
tner, M., and Trent, J. M.
Inference from clustering with
Application to gene-expression
microarrays. Journal of Compu-
tational biology, 9(1):105–126, 2002.
(page 68).
[106] Dzau, V. J. and Herrmann,
H. C. Hormonal control
of angiotensinogen production.




[107] Ebrahimi, B., Gloviczki, M.,
Woollard, J. R., Crane, J. A.,
Textor, S. C., and Lerman,
L. O. Compartmental Analysis
of Renal BOLD MRI Data: In-
troduction and Validation. In-
vest Radiol, 47(3):175–182, 2012.
(page 81).
[108] Eckardt, K.-U., Bernhardt,
W. M., Weidemann, A., War-
necke, C., Rosenberger, C.,
Wiesener, M. S., and Willam,
C. Role of hypoxia in the
pathogenesis of renal disease.
Kidney international. Supplement,
68(99):S46–51, 2005. (page 65).
[109] Eckardt, K.-U., Coresh, J.,
Devuyst, O., Johnson, R. J.,
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[150] Gidlöf, O., Smith, J. G., Me-
lander, O., Lövkvist, H. k.,
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Pflügers Archiv : European journal
of physiology, 425(3-4):208–12,
1993. (page 13).
[191] Hernández, D., Muriel, A.,
Abraira, V., Pérez, G., Por-
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Appendix A: Computational Models of P2X4 and P2X7
During my PhD I spent several months working at the NIH Systems Biology Cen-
tre Virtual Physiological Rat Project (VPR; http://virtualrat.org/) within
the Medical College of Wisconsin under the supervision of the VPR investigators
Drs. Dan Beard, Brian Carlson and Allen Cowley Jr. The intention of this work
was to develop a quantitative understanding of the electrophysiological events me-
diated by P2X7 and P2X4 receptor activation that might delineate their function.
This was deemed necessary because the alternative experimental approaches such
as high affinity pharmacology and/or gene deletion in the F344 rat were financially
impractical. Thus computational modelling (using literature mined experimental
data to guide model parameters) was used to investigate demonstrates the similar-
ities (and distinctions) between P2X7 and P2X4 activation by ATP which could
be functionally important in terms of their vascular expression. These data are
discussed in the context of the renal functional data (chapter 3, section 3.4).
7.1 Modelling P2X Receptor Electrophysiology
P2X4 and P2X7 channels are ATP gated ion channels. A computational model
utilising channel activation by ligand binding affinities was designed using a lig-
and binding affinity framework (91). The Goldman-Hodgkin-Katz flux equation
provide the means to model Na+, Ca2+ and K+ currents through P2X receptors
(157, 199). Model fitness was tested against experimentally determined single
channel patch-clamp voltage-current relationships of P2X7 (425) and P2X4 (361)
receptors respectively.
Two dimensionless values of ATP-dependent activity inside, αin , or outside,
αout, the membrane are determined from the Hill equation for a given ATP concen-
tration, [ATP]. This relationship is described in Eqn.7.1 where K is the dissociation
constant and n is the Hill coefficient. The dimensionless value α0out/0in represents








7.1 Modelling P2X Receptor Electrophysiology
The open probability for each ion , equates to a factor of the ion specific ac-
tivity, the relative permeability for each cation and maximal permeabilities for
each receptor shown in Eqn.7.2, where subscript S indicates one of the three ions
Na+, Ca2+ or K+. The cation permeability of P2X7 and P2X2 do not differ sig-
nificantly (481). Permeability ratios established in experiments of P2X2 receptors
were therefore used to parameterise the P2X7 model. Relative permeabilities for
P2X4 were taken from (471). It is worthy of note that sustained receptor activation
changes these permeabilities (see Fig. 1D of (110)). This is not addressed since
the present model was focused on identifying cation permeabilities pertaining to
altered contractile function, not the permeability of large molecules. Nonetheless
this is a limiting factor of these P2X7 and P2X4 models.
PSout/in = PSP2Xφ.αout/in.P0P2Xφ (7.2)
P2X channel fluxes were constructed from the Goldman HodgkinKatz flux
equation as shown in Eqn.7.3. Symbols are given for membrane potential (Vm),












Total current for the individual channels was then calculated by Na+, Ca2+
influx and K+ efflux.The resulting, P2X4 channel current is given in Eqn.7.4.
For time-dependent simulations the exponential factor e−0.009359.t for time, t =
0 − 300 seconds, was included. The factor 0.009359 was established by curve
fitting experimental data from Fig. 6 of (544). The importance of this decay can
be seen by blocking the P2X7 receptor which causes no sustained calcium influx
over time (see Fig.1 in (433)).
IP2X4 = Am(Fzs)JP2X4S .e
−0.009359.t (7.4)
P2X7 current, Eqn. 7.5, specifically calcium influx, is highly sustained following
activation by ATP, (110, 371), this is reflected in the exponential decay factor for
time-dependent simulations.
IP2X7 = Am(Fzs)JP2X7S .e
−0.0009359.t (7.5)
The solutions to Eqns.7.4 and 7.5 provided the final P2X individual channel
current models for total current as well as Na+, Ca2+ and K+ individually for
simulations.
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Figure 7.1: Human P2X7 Receptor Voltage-Current Relationship - Exper-
imental and simulation data of voltage current relationships of the P2X7 receptor.
Experimental data for long openings (black circles) and short openings (red open
circles); silumation results for short openings (red broken line) or long openings
(black broken line). Experimental data from (425).
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Figure 7.2: Human P2X4 Receptor Voltage-Current Relationship - Exper-
imental and simulation data of voltage current relationships of the P2X4 receptor.
Experimental data (open black circles); silumation result (broken black line). Ex-
perimental data from (361).
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Figure 7.3: Calcium Currents Mediated by P2X7 and P2X4 Receptors
- Simulation of endothelial P2X4 and P2X7 currents under a range of local ATP
concentrations (0.001-0.01M). Simulation for P2X4 (black broken line) and P2X7
(red broken line).
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Figure 7.4: Time Dependent Calcium Currents Mediated by P2X7 and
P2X4 Receptors - Simulation of endothelial P2X4 and P2X7 currents in response
to a local ATP concentration of 200µM. Simulation for P2X4 (black broken line) and
P2X7 (red broken line). Arrow indicates simulated application of ATP, activating








5 % voltage−current experimental patch−clamp data
6 % −−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
7 % P2X7 which has two open states long/short
8 [Header, P2X7] = Irreg HD Load('VI P2X7 fig4c.txt');
9 Vh short= P2X7(:,1);
10 I short = P2X7(:,2);
11 Vh long= P2X7(:,3);
12 I long = P2X7(:,4);
13
14 %P2X4
15 [Header Data] = Irreg HD Load('VI P2X4 fig1c.txt');
16 Vp2x4 = Data(:,1);





22 % Universal constants
23 F = 96485.3399; % Faraday constant (C/mole)
24 R = 8314.472; % Gas constant ...
((C*mV)/(K*mole))
25 T = 293; % Temperature (K)
26 RT = R*T; % RT term ...
((C*mV)/mole)
27 FRT = F/RT; % F/RT term (1/mV)
28
29 % Membrane properties
30 C m = 25; % Total membrane ...
capacitance (pF)
31 A m = C m/1e6; % Area scaled by ...
capacitance (cmˆ2)
32 % Ionic valences
33 z K = 1; % Potassium valence ...
(unitless)
34 z Na = 1; % Sodium valence ...
(unitless)
35 z Ca = 2; % Calcium valence ...
(unitless)
36




39 %P2X4 and P2X7 channel permeabilities
40 % −−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
41 % P2X7 channel
42
43 PNa P2X = 4.2e−4;
44 PK P2X = 1.05*PNa P2X;
45 PCa P2X = 2.7*PNa P2X;
46
47 PNa P2X4 = 4.2e−4;
48 PK P2X4 = .99*PNa P2X4;
49 PCa P2X4 =4.2*PNa P2X4;
50
51
52 %% P2X4 (SINGLE CHANNEL) model
53 % I−V data from Negulyaev and Markwardt Neurosc. Lett. 279 ...
2000 165−168
54 %% P2X4
55 for i = 1:length(V m);
56 ATP = 0.1e−3;
57 alpha out 0 = .001; % External cation activity coefficient ...
(unitless)
58 alpha in 0 = 40; % Internal cation activity coefficient ...
(unitless)
59 n =1.4; % Hill coefficient (cooperativity) for ...
ligand binding
60
61 % Incorporate ligand binding to the channel
62 % The flux/current through the ion channel obeyes the ...
Goldman−Hodzkin−Katz
63 % equation.
64 pK = 5; K = 10ˆ−pK;
65 Po P2X4 = .26;
66
67 % Compute calcium uniporter fluxes from the calcium uniporter ...
model
68 alpha out4 = alpha out 0*(ATPˆn/(Kˆn + ATPˆn));
69 alpha in4 = alpha in 0*(ATPˆn/(ATPˆn + ATPˆn));
70
71 %openings
72 Po Na out4 = PNa P2X4*alpha out4*Po P2X4;
73 Po Na in4 = PNa P2X4*alpha in4*Po P2X4;
74
75 Po K out4 = PK P2X4*alpha out4*Po P2X4;
76 Po K in4 = PK P2X4*alpha in4*Po P2X4;
77
78 Po Ca out4 = PCa P2X4*alpha out4*Po P2X4;





82 dPhi Na4 = z Na*FRT*V m(i);
83 dPhi K4 = z K*FRT*V m(i) ;
84 dPhi Ca4 = z Ca*FRT*V m(i);
85
86 if (V m(i) == 0)
87 fluxNa4 = −(Po Na in4*ATP − Po Na out4*ATP);
88 fluxK4 = −(Po K in4*ATP − Po K out4*ATP);
89 fluxCa4 = −(Po Ca in4*ATP − Po Ca out4*ATP);
90 else
91
92 fluxNa4 = ...
dPhi Na4*(Po Na in4*ATP*exp(−dPhi Na4)−Po Na out4*ATP)...
93 /(exp(−dPhi Na4)−1);
94 fluxK4 = dPhi K4*(Po K in4*ATP*exp(−dPhi K4)−Po K out4*ATP)...
95 /(exp(−dPhi K4)−1);
96 fluxCa4 = ...
dPhi Ca4*(Po Ca in4*ATP*exp(−dPhi Ca4)−Po Ca out4*ATP)...
97 /(exp(−dPhi Ca4)−1);
98
99 INa P2X4 = z Na*F*fluxNa4;
100 IK P2X4 = z K*F*fluxK4 ;
101 ICa P2X4 = z Ca*F*fluxCa4 ;
102
103 IP2X4(i) = (INa P2X4 − IK P2X4+ ICa P2X4);
104
105 %Calcium current equation for time−dependent model for t = 0:300
106 % exponential decay curve modeled on experimental data from:
107 % Yamamoto et al. AJP Heart Circ 279: H285−H292, 2000










118 plot(V m, IP2X4, '−−k','LineWidth',1.5)





124 legend('IP2X {4} data','IP2X {4} simulation', ...
'Location','SouthEast')





128 %% P2X7 (SINGLE CHANNEL)
129 % I−V data from Riedel et. al Biophys J 92 2007 2377−2391
130
131 for i = 1:length(V m);
132 ATP1 = .57e−3; %(M)
133
134 %approx alpha (cation activity) by the concentration − OK for ...
small concs.
135 alpha out 0 = 4.5; % External cation activity coefficient ...
(unitless)
136 alpha in 0 = 11.5; % Internal cation activity coefficient ...
(unitless)
137 ns =1.4; % Hill coefficients (cooperativity) for ...
ligand binding
138 nl = 1.1;
139
140 pK s = 5; K s = 10ˆ−pK s;
141 pK l = 3.93; K l = 10ˆ−pK l;
142
143 Po P2Xs = 0.28;
144 Po P2Xl = .18;
145
146
147 Salpha out = alpha out 0*(ATP1ˆns/(K sˆns + ATP1ˆns));
148 Salpha in = alpha in 0*(ATP1ˆns/(ATP1ˆns + ATP1ˆns ));
149
150 Lalpha out = alpha out 0*(ATP1ˆnl/(K lˆnl + ATP1ˆnl));
151 Lalpha in = alpha in 0*(ATP1ˆnl/(ATP1ˆnl + ATP1ˆnl ));
152
153 %Short openings
154 sPo Na out = PNa P2X *Salpha out*Po P2Xs;
155 sPo Na in = PNa P2X*Salpha in*Po P2Xs;
156
157 sPo K out = PK P2X *Salpha out*Po P2Xs;
158 sPo K in = PK P2X*Salpha in*Po P2Xs;
159
160 sPo Ca out = PCa P2X *Salpha out*Po P2Xs;
161 sPo Ca in = PCa P2X*Salpha in*Po P2Xs;
162
163 %Long openings
164 lPo Na out = PNa P2X *Lalpha out*Po P2Xl;
165 lPo Na in = PNa P2X*Lalpha in*Po P2Xl;
166
167 lPo K out = PK P2X *Lalpha out*Po P2Xl;
168 lPo K in = PK P2X*Lalpha in*Po P2Xl;
169
170 lPo Ca out = PCa P2X *Lalpha out*Po P2Xl;





174 dPhi Na = z Na*FRT*V m(i);
175 dPhi K = z K*FRT*V m(i) ;
176 dPhi Ca = z Ca*FRT*V m(i);
177
178 if (V m(i) == 0)
179 sfluxNa = −(sPo Na in*ATP1 − sPo Na out*ATP1);
180 sfluxK = −(sPo K in*ATP1 − sPo K out*ATP1);
181 sfluxCa = −(sPo Ca in*ATP1 − sPo Ca out*ATP1);
182
183 lfluxNa = −(lPo Na in*ATP1 − lPo Na out*ATP1);
184 lfluxK = −(lPo K in*ATP1 − lPo K out*ATP1);
185 lfluxCa = −(lPo Ca in*ATP1 − lPo Ca out*ATP1);
186 else
187
188 sfluxNa = ...
dPhi Na*(sPo Na in*ATP1*exp(−dPhi Na)−sPo Na out*ATP1)...
189 /(exp(−dPhi Na)−1);
190 sfluxK = dPhi K*(sPo K in*ATP1*exp(−dPhi K)−sPo K out*ATP1)...
191 /(exp(−dPhi K)−1);
192 sfluxCa = ...
dPhi Ca*(sPo Ca in*ATP1*exp(−dPhi Ca)−sPo Ca out*ATP1)...
193 /(exp(−dPhi Ca)−1);
194
195 lfluxNa = ...
dPhi Na*(lPo Na in*ATP1*exp(−dPhi Na)−lPo Na out*ATP1)...
196 /(exp(−dPhi Na)−1);
197 lfluxK = dPhi K*(lPo K in*ATP1*exp(−dPhi K)−lPo K out*ATP1)...
198 /(exp(−dPhi K)−1);
199 lfluxCa = ...




203 INa P2Xs = z Na*F*sfluxNa;
204 IK P2Xs = z K*F*sfluxK ;
205 ICa P2Xs = z Ca*F*sfluxCa ;
206
207 INa P2Xl = z Na*F*lfluxNa;
208 IK P2Xl = z K*F*lfluxK ;
209 ICa P2Xl = z Ca*F*lfluxCa ;
210
211 IP2X long(i) = INa P2Xs − IK P2Xs + ICa P2Xs;
212 IP2X short(i) = INa P2Xl − IK P2Xl + ICa P2Xl;
213
214 %Calcium current equation for time−dependent model for t = 0:300
215 % P2X7 mediated Ca−influx is highly sustained following ATP






220 p2x7 = figure(1);
221 plot(Vh short,I short,'o','MarkerEdgeColor','r',...




225 plot(V m, IP2X short, '−−r','LineWidth',1.5)




230 plot(V m, IP2X long , '−−k','LineWidth',1.5)
231 ylabel('i (pA)','FontSize',18)
232 xlabel('V {h} (mV)','FontSize',18)
233 % plot a cross−hair to indicate zero−zero crossing
234 x = [0 0 0 0 0 0 0 0];
235 y = [0 0 0 0 0 0 0 0];
236 plot(x,I long, 'k')
237 plot(Vh long, y, 'k')
238 xlim([−150 50])
239 legend('IP2X {7s} data','IP2X {7s} simulation','IP2X {7l} ...
data',...
240 'IP2X {7l} simulation', 'Location','SouthEast')
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Introduction
Hypertension is a major world health problem associated with a
substantial cost, in terms of patient mortality/morbidity and
economic burden. Tremendous strides have been made in this
field and there are several treatments for reducing blood pressure
in most patients. Nevertheless, basic research to establish causal
pathways may lead to more effective management of existing
hypertension or importantly provide a foundation for life-style
advice in the pre-hypertensive phase. This endeavor is facilitated
by the use of appropriate animal models. One such model is the
cyp1a1-Ren2 transgenic rat (TGR) in which hypertension can be
reversibly induced, without surgical intervention, by dietary
administration of the non-toxic, naturally occurring (for example
in brassicas) aryl hydrocarbon, indole-3-carbinol (I3C) [1]. An
advantage of this model is that changing the dose of I3C
administered can alter the severity of hypertension. This allows,
for instance, the generation of a slowly-developing hypertension,
analogous to chronic infusion of subpressor doses of angiotensin II
[2,3] or malignant hypertension (MH), characterized by rapidly
accelerating blood pressure and injury to target organs [4].
In the cyp1a1-Ren2 rat, a transgene has been integrated into the Y
chromosome. This transgene places mouse Ren2 cDNA expression
under the control of an inducible cytochrome p450-1a1 promotor
[1]. Expression of Ren2, primarily in the liver, leads to increased
circulating renin levels, activation of the renin-angiotensin-aldoste-
rone system and a rise in blood pressure. This rise in pressure is
accompanied by a sustained elevation of circulating renin.
Intrarenal synthesis of angiotensin II [5,6], promoted by elevated
renin and pro-renin receptor expression [7], contributes to the
pathology of hypertension in the cyp1a1-Ren2 rat, and the model is
therefore complementary to approaches using chronic infusion of
angiotensin II, in which renin activity is suppressed.
The current study was designed to resolve key mechanisms
leading to hypertension in the cyp1a1-Ren2 TGR and focuses on
sodium transport in the distal convoluted tubule. Several lines of
evidence led us to hypothesize that hypertension in the TGR
model originates in the kidney and reflects an impaired ability to
excrete sodium. First, dietary sodium loading exacerbates
hypertension [5]. Second, renal blood flow is attenuated [4],
pressure natriuresis is impaired [8] and tubuloglomerular feedback
is activated [9], whilst third, the systemic hormonal profile of
elevated angiotensin II and aldosterone would reduce natriuretic
capacity by effects on the tubule epithelium [10,11,12,13] and
medullary vasa recta [14]. Our hypothesis is further supported by
the observation that manoeuvers improving renal blood flow and/
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or sodium excretion blunt the hypertensive response to Ren2
activation [15,16].
We find that induction of hypertension in the cyp1a1-Ren2 TGR
causes sustained activation of the thiazide-sensitive co-transporter
by angiotensin II in the distal tubule. Renal injury is predom-
inantly vascular, precedes the development of hypertension and
may involve mineralocorticoid-dependent pathways.
Results
Systolic blood pressure and diastolic blood pressure increased
significantly during the 24 hours following the second dose of I3C
(Figure 1). Over the experimental time-course, systolic increased
proportionally more than diastolic blood pressure and pulse
pressure was therefore increased. Heart rate fell significantly
during the period of transgene induction, consistent with an intact
baroreceptor reflex. The day-night cycle of locomotor activity was
unaffected by RAAS activation. The statistically significant
periodicity of blood pressures, heart rate and activity was
approximately circadian during the baseline period. Analysis was
performed on de-trended data from the hypertensive period and
persistency of circadian rhythmicity was observed.
Activation of the cyp1a1-Ren2 transgene promotes anti-
natriuresis
Under anaesthesia, we observed a progressive increase in mean
arterial blood pressure (Figure 2A, ANOVA P,0.001) with
Figure 1. Telemetry data from Cyp1a1-Ren2 transgenic rats. Recordings were made in rats (n = 5) over a baseline period and following 7
consecutive days of indole-3-carbinol administration (I3C; Shaded area). A) locomotor activity; B) Blood pressure (BP), with systolic as a solid line and
diastolic as a dashed line and C) HR. Data are hourly means, smoothed with a 5-point rolling average and shown without error bars for clarity. The
vertical lines represent the midnight time point. I3C was administered at 10am.
doi:10.1371/journal.pone.0036311.g001
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repeated doses of I3C, with a small but significant rise being
observed on day 2 of Ren2 induction. Glomerular filtration rate
rose significantly, at least until day 4 (Figure 2B; ANOVA P,0.01)
but then fell back to control levels. Effective renal plasma flow
(Table 1) was stable. In consequence, filtration fraction was
elevated only on day 4 and renal vascular resistance only on day
8(Table 1). Transgene induction reduced natriuretic capacity
(Figure 2C; ANOVA P,0.001), with sodium excretion falling to
,50% of control values by day 2. There was a significant linear
trend toward hypokalaemia (P,0.05), despite which fractional
potassium excretion remained robust (Table 1).
Fractional sodium excretion fell (Table 1) with transgene
induction, indicating a tubular origin for the antinatriuresis. We
attempted to localize this effect by measuring the fractional
excretion of lithium excretion (Figure 2D). This was initially
elevated (ANOVA P,0.01), indicating diminution of proximal
tubular reabsorption and localizing the antinatriuretic effect to
more distal nephron segments.
In conscious rats, sodium intake (initially 2.3860.11 mmol/
24 h), declined over the induction period but this was not
statistically significant until the final day (1.3860.17 mmol/24 h;
P,0.01). Body weight was found not to change significantly, with
end-weight being 96.561.2% of start weight. 24 h urinary
aldosterone excretion was increased ,20 fold over the induction
period (Figure 3 ANOVA P,0.001) and we therefore focused our
experiments on the aldosterone-sensitive distal nephron (ASDN).
Sodium-chloride co-transport (NCC, Slc12a3) and the epithelial
sodium channel (ENaC, Scnn1) account for the majority of sodium
transport in the ASDN and the contribution of each was assessed
pharmacologically. At baseline, thiazide-sensitive transport was
responsible for the reabsorption of ,5% of the filtered sodium
load. This increased progressively during Ren2-transgene induction
(Figure 4A; ANOVA P,0.01), as did abundance of total NCC
protein relative to GAPDH (Figure 4B; ANOVA P,0.001). A
positive correlation (Pearson r = 0.60; P,0.01) was observed
between NCC protein abundance and thiazide-sensitive sodium
reabsorption. An amiloride-sensitive pathway reabsorbed ,2% of
the filtered sodium in non-induced rats. There was a slight initial
increase in both amiloride-sensitive sodium reabsorption
(Figure 4C) and in the abundance of aENaC relative to GAPDH
(Figure 4D). Although neither reached statistical significance, both
sets of data suggest a similar trend- a transient rise, with both back
to baseline by day 8.
The role of NCC-mediated sodium reabsorption was assessed
by chronically administering thiazide during transgene induction.
The blood pressure increase was significantly attenuated
(Figure 4E), but still remained significantly higher than control
animals. The partial rescue of the hypertensive phenotype was
associated with a large increase in fractional sodium excretion
(Figure 4F). An acute bolus of hydrochlorothiazide produced no
Figure 2. Renal function in anaethetized rats. A) mean arterial blood pressure (MABP); B) glomerular filtration rate (GFR); C) urinary sodium
excretion and D) the fractional excretion of lithium. Measurements were made in cyp1a1-Ren2 transgenic rats, on either day 2 (n = 9), 4 (n = 9) or 8
(n = 9) in the induction regimen. Non-induced rats (n = 8) served as control. Data are mean 6 SE. Statistical comparisons were made using ANOVA
with Bonferroni post-test. ***P,0.001, **P,0.01, *P,0.05 versus the control group.
doi:10.1371/journal.pone.0036311.g002
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further natriuretic effect (data not shown), confirming that NCC
blockade was complete at the chronic infusion level.
Activation of the cyp1a1-Ren2 transgene causes
microvascular injury
Modest albuminuria developed over the experimental time-
course (Figure 5; ANOVA P,0.001) and kidneys were therefore
examined for microvascular injury. An ordered categorical scoring
of microvascular injury indicated a significant (X2 analysis;
P = 0.028) contingency between the duration of transgene
induction and microvascular injury. After 1 day of treatment,
medial myocyte vacuolation was evident in arcuate and the larger
interlobular arteries, indicative of vasospasm (Figure 6A). There
was also rare focal medial myocyte cell death (Figure 6B). No such
injury was observed in the control group. In rats studied at day 4,
vascular damage was both more prevalent and severe, with foci of
confluent medial myocyte death, apoptotic nuclear fragments and
hemorrhage into the necrotic foci (Figure 6C). There was low-
grade mononuclear cell infiltration into the perivascular adventi-
tia. By day 8, the destructive vascular injury was more extensive
still (Figure 6D), and fibroid necrosis was also evident in smaller
interlobular arteries and afferent arterioles, consistent with our
previous data [4]. Areas of tubuloinsterstitial injury were also
observed, which were small and localized mainly in the cortex.
There was no histological evidence of malignant phase hyperten-
sion, such as ‘‘onion-skinning’’ of the renal arterioles.
Effect of spironolactone or losartan on blood pressure,
renal function an microvascular injury
Chronic administration of losartan blunted the hypertensive
response to transgene induction (Figure 7A), increased fractional
sodium excretion (Ren2 induction alone = 0.1560.03% versus co-
administration of losartan = 0.4060.04; P,0.01) and normalized
thiazide-sensitive sodium reabsorption (Figure 7B). Kidneys from
three of these rats were examined histologically and there was no
evidence of hypertensive vascular injury. Spironolactone had no
antihypertensive effect (Figure 7A) and nor did it have any effect
on thiazide-sensitive sodium reabsorption (Figure 7B). Mineralo-
corticoid receptor blockade did, however, prevent the develop-
ment of albuminuria during transgene induction (albumin
excretion in mg/24 h) Ren2 induction alone = 1.1660.12; Ren2
induction with co-administration of spironolactone = 0.1860.07;
P,0.01). Kidneys from five spironolactone treated rats were
examined histologically: in two cases there was no evidence of
vascular injury; in the other three, variable fibroid necrosis was
observed.
Discussion
In this study we investigated the early renal adaptation to RAAS
activation in the cyp1a1-Ren2 TGR. We show that the early phase
of hypertension, characterized in this model by circulating
angiotensin II in the high physiological range [5], is associated
with impaired natriuresis due to activation of the thiazide-sensitive
sodium-chloride cotransporter, with little contribution from
amiloride-sensitive sodium transport.
Hypertension, sodium reabsorption and thiazide-
sensitive co-transport
The synergistic effect of angiotensin II and sodium intake on
blood pressure has long been known but underlying mechanisms
are not fully understood. Angiotensin II promotes sodium
retention and volume expansion, particularly if sodium intake is
high [17,18,19]. However, a strong correlation between sodium
balance and blood pressure is not a consistent feature [19,20],
perhaps because increased renal arterial pressure can stimulate
natriuresis [21]. Sustained hypertension may also reflect salt-
induced sensitization of the sympathetic nervous system [22] and
vascular smooth muscle [23] to angiotensin II.
Previous studies in cyp1a1-Ren2 TGR have demonstrated that
hypertension is associated with enhanced sodium reabsorption [6]
and the rise in blood pressure is aggravated by dietary sodium-
loading [5]. In the current study, sodium intake was lower by
,10% over days 1–4 of transgene induction and reduced by 40%
by the final day. This might contribute to a reduced sodium
excretion, particularly in rats studied after 8 days of hypertension.
Table 1. Renal data and plasma electrolytes in cyp1a1-Ren2
transgenic rats before and after the induction of
hypertension.
Control Day 2 Day 4 Day 8 ANOVA
n 8 9 9 8
Body weight (g) 324614 318616 343613 305613 NS
FENa (%) 0.3960.06 0.1660.03
** 0.1560.03** 0.0960.02** ,0.001
FEK (%) 38.064.5 30.362.9 31.762.2 30.069.4 NS
V (ml/min) 9.860.7 13.663.5 13.261.0 9.362.0 NS
PNa (mmol/l) 135.960.4 134.360.7 134.060.6 132.6.361.7 = 0.059
PK (mmol/l) 4.2360.06 4.1060.12 4.0360.11 3.8760.09 NS
Hct (%) 46.561.0 48.360.5 48.761.0 52.061.1** ,0.01
eRPF (ml/min) 6.7 6 0.6 8.360.8 7.260.4 7.661.0 NS
RBF (ml/min) 12.760.7 16.061.3 14.060.7 16.162.1 NS
FF (%) 28.461.6 29.862.2 37.062.0** 20.061.5* ,0.01
RVR
(mmHg.ml.min21)
10.560.6 9.760.8 12.460.6 14.461.3* ,0.01
Data are mean6 SE. Comparisons were made using one-way ANOVA (P value
shown in column), with Bonferroni post-hoc test: * = P,0.05, ** = P,0.01. FENa
and FEK indicates the fractional excretion of sodium and potassium; V is urine
flow rate; PNa and PK are the plasma concentration of sodium and potassium;
Hct is hematocrit; eRPF and RBF are effective renal plasma and blood flow,
respectively; FF is filtration fraction and RVR is renal vascular resistance.
doi:10.1371/journal.pone.0036311.t001
Figure 3. 24-hour urinary excretion of aldosterone. Urine was
collected from conscious cyp1a1-Ren2 transgenic rats (n = 8) maintained
in individual metabolism cages, over consecutive days of transgene
induction. Data are mean 6 SE. Statistical comparisons were made
using ANOVA with Bonferroni post-test. ***P,0.001, **P,0.01 versus
the control day.
doi:10.1371/journal.pone.0036311.g003
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Figure 4. Sodium transport pathways in the aldosterone-sensitive distal nephron. A) hydrochlorthiazide-sensitive sodium reabsorption
(DthiazideNa); B) the expression of the thiazide-sensitive co-transporter protein (NCC) in whole kidney extracts, normalized to that of GAPDH; C)
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Nevertheless, body weight was stable and in the cross-sectional
studies plasma sodium was not changed. In this setting we
observed an impaired capacity to excrete an intravenous saline
load. In the proximal tubule, angiotensin II exerts a biphasic effect
on sodium transport, becoming inhibitory at high concentrations
[24,25]. In our study, the increase in fractional lithium excretion
observed at days 2 and 4 indicates a reduction in proximal tubule
sodium reabsorption [26] and localizes the antinatriuresis to more
distal nephron segments. Since mice infused chronically with
angiotensin II display increased sodium reabsorption in the ASDN
[27], we probed the function of this region with inhibitors of the
major pathways for sodium transport, ENaC and NCC. Both
angiotensin II and aldosterone can stimulate ENaC activity
[13,28] but we found the amiloride-sensitive pathway small and
not greatly influenced by transgene induction. There was perhaps
a trend towards an increase in both amiloride-sensitive transport
and aENaC protein abundance but this normalized by day 8. Our
protocol ultimately causes malignant hypertension after ,14 days
[4]. In contrast, when induction is aimed at producing a non-
malignant stable hypertension, chronic amiloride treatment causes
a transiently negative sodium balance and abolishes hypertension
in cyp1a1-Ren2 TGR [3], even though ENaC mRNA levels do not
change. It is plausible that that modest increases in angiotensin II
activate existing pools of ENaC and the resulting increase in blood
pressure is amiloride-sensitive. However, when angiotensin II
levels are increased further, a sustained increase in NCC activity is
observed. The increased sodium reabsorption in the DCT would
reduce sodium delivery to the collecting duct and thereby limit
amiloride-sensitive sodium transport. Under such circumstances,
hypertension would be expected to be mainly thiazide-sensitive
(Figure 4E). The thiazide-resistant component in the present study
was small (Figure 4E) and may be due to the transiently increased
ENaC activity, uncovered when NCC is inhibited.
Thiazides are considered to be selective inhibitors of transport
by NCC, but recently it has been shown that they also inhibit
sodium reabsorption through Slc4A8 in the collecting duct [29].
However, the strong positive correlation between NCC abun-
dance and thiazide-sensitive sodium reabsorption suggests that
transport through Slc4A8 plays only a minor role in our studies.
In order to be physiologically active, NCC must be phosphor-
ylated on threonine and serine residues in a regulatory domain in
the N-terminus [30,31], and it must be correctly trafficked to the
apical membrane of the DCT. In our study, we did not measure
NCC phosphorylation or define localization to a specific sub-
cellular compartment. Measurements of NCC phosphorylation
are increasingly used as a surrogates for those of transport, yet
evidence suggests that although phosphorylation is necessary, it is
not sufficient, to explain transport activation in cation-chloride co-
transporters [32]. Thus, we consider that the increase in total
NCC expression, which paralleled the blood pressure rise, was
more than sufficient to account for the increased thiazide-sensitive
sodium reabsorption observed.
Previous studies have shown that both angiotensin II and
aldosterone can independently increase NCC-mediated sodium
transport in the DCT [12,33,34,35,36]. Our data show that the
activation of NCC occurs via AT1R as losartan caused a
natriuresis and fully normalized NCC activity. In contrast,
spironolactone, at levels sufficient to achieve complete mineralo-
corticoid receptor blockade [37], had no effect on thiazide-
sensitive sodium reabsorption or blood pressure. MR activation
does not therefore appear to be major factor in our model,
consistent with some previous studies [3,6,27], but contrasting with
others [38]. It is also reported that hypertension per se reduces
NCC expression in the apical membrane of the DCT [39]. We
cannot discount a countervailing influence of hypertension on
NCC activity, but our data indicate that the overall outcome was
an angiotensin II-mediated increase in thiazide-sensitive sodium
transport.
Chronic infusion of either hydrochlorothiazide or losartan was
an effective antihypertensive measure. Both treatments also
increased fractional sodium excretion, implying that renal sodium
retention is a key hypertensive mechanism in this model. In
support of this hypothesis, reciprocal transplantation studies in
AT1AR null and wild-type mice show that renal AT1R mediate
the chronic hypertensive effects of angiotensin II infusion by
promoting renal sodium reabsorption [40]. However, in our study
there was a trend towards volume contraction as blood pressure
rose, suggesting that the effects of angiotensin II and dietary salt on
blood pressure do not necessarily reflect volume expansion here
[19,20]. Indeed, other studies indicate that the antihypertensive
effect of thiazide diuretics in angiotensin II-dependent hyperten-
sion is not exclusively related to depletion of plasma volume [19]
and thiazides might have beneficial effects on vascular resistance
[41].
Renal microvascular injury
The afferent arteriole, glomerulus and post-glomerular struc-
tures were relatively protected from injury throughout the
experiment: mild albuminuria developed by day 4 and was
further increased coincident with raised renal vascular resistance.
Our data suggest that protection from barotrauma reflects
maintenance of efficient autoregulation [42]. In contrast, injury
to the larger pre-glomerular resistance arteries was evident on the
amiloride-sensitive sodium reabsorption (DamilorideNa); D) the expression of the a subunit of the epithelial sodium channel (aENaC) normalized to
that of GAPDH. Measurements were made in cyp1a1-Ren2 transgenic rats, on either day 2 (n = 9), 4 (n = 9) or 8 (n = 9) in the induction regimen. Non-
induced rats (n = 8) served as control. E) mean arterial blood pressure (MABP) and F) fractional sodium excretion. Measurements were made in
cyp1a1-Ren2 transgenic rats receiving either vehicle (grey bar) or hydrochrorothaizide (hatched bar) by minipump. Data are mean 6 SE. Statistical
comparisons were made using ANOVA with Bonferroni post-test. P,0.001, **P,0.01, *P,0.05 versus the control group.
doi:10.1371/journal.pone.0036311.g004
Figure 5. 24-hour urinary excretion of albumin. Urine was
collected from conscious cyp1a1-Ren2 transgenic rats (n = 8) maintained
in individual metabolism cages, over consecutive days of transgene
induction. Data are mean 6 SE. Statistical comparisons were made
using ANOVA with Bonferroni post-test. **P,0.01, *P,0.05 versus the
control day.
doi:10.1371/journal.pone.0036311.g005
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second day, before elevation of blood pressure into the
hypertensive range. Renal injury was consistent with vasospasm,
and might reflect damaging intermittent surges in systolic blood
pressure [43]. These were not visualized in our telemetry analysis
but data were only acquired hourly for short periods.
Pressure-independent renal injury, involving both angiotensin II
and aldosterone [44,45,46] is also possible. The extent of pressure-
independent renoprotection following RAAS inhibition is conten-
tious [47] as AT1R blockade has exacerbated organ damage in
some clinical trials [48]. Animal models suggest that transmission
of high pressure to the kidney drives vascular remodeling and
injury in angiotensin II-dependent hypertension [49,50]. Our data
show a protective effect of AT1R blockade, perhaps partially due
to losartan’s antihypertensive effect. However, chronic thiazide
therapy, which caused a similar fall in blood pressure, did not
abolish vascular injury, supporting a direct role for angiotensin II
in end-organ injury. The beneficial effects of spironolactone were
more clearly independent of blood pressure. Experimental and
clinical data suggest that aldosterone, some of which may be
synthesized in the kidney itself [51], is directly fibrogenic [52] and
can damage renal structures [53]. Aldosterone-induced podocyte
injury [54], for example, may explain the beneficial effect of
spironolactone on the albuminuria seen here.
Concluding Remarks
Renal, vascular and endocrine measurements have established
distinctive aetiologies of hypertensive and renovascular disease
following the conditional over-expression of renin in cyp1a1-Ren2
TGR. Our data show that angiotensin II, aldosterone and sodium
status act in concert to cause hypertension and renal impairment
and underscore the key role of thiazide-sensitive sodium transport
in the long-term regulation of blood pressure. Approximately 1/
3rd of the blood pressure rise was resistant to thiazide or losartan
treatment. A similar proportion of hypertension persists in AT1R
null mice infused with angiotensin II [46], pointing to non-renal,
non-AT1R-mediated mechanisms. These may involve direct,
detrimental actions of renin on vascular function [55], sensitization
of the vasculature to vasoactive agents [23] and activation of the
sympathetic nervous system [56].
Materials and Methods
Ethics Approval
Experiments were performed under a UK Home Office Project
License and protocols were approved by The University of
Edinburgh. All surgery was performed under anaesthesia (details
are given under relevant sections, below) and all efforts were made
to minimize suffering.
Experiments were performed on male cyp1a1-Ren2 TGR on a
Fischer (F344) background, from a colony maintained in the
university’s animal house. Rats, aged 12–14 weeks, were given free
access to water and commercial rat chow, containing 0.3% sodium
by weight (Special Diet Services, UK) and were maintained under
controlled conditions of temperature (2161uC), humidity
(50610%) and light/dark (light 7am–7pm).
Blood pressure measurement in conscious rats
Radiotelemetry devices (Model TA 11PAC20, Data Sciences,
UK) were implanted into the thoracic aorta of Cyp1a1-Ren2 TGR
(n = 5) under ketamine/medetomidine anaesthetic, with bupre-
norphine used as a reversal agent and analgesic. After recovery,
one-week equilibration was given during which restoration of the
circadian rhythms for blood pressures, activity and heart rate was
confirmed. Experimental data were then recorded and decoded
using Art 4.0 software (Data Sciences, UK).
Baseline readings were taken over four consecutive days and, on
day 5, the cyp1a1-Ren2 transgene was induced by administering the
naturally occurring xenobiotic, indole-3-carbinol (I3C; 100 mg/
kg/day in vegetable oil), by gastric gavage at 10am; this was
repeated on the following 6 days. Data were obtained on the hour,
processed to means, smoothed using a 5-point rolling average and
Figure 6. Temporal progression of microvascular injury in kidneys from cyp1a1-Ren2 transgenic rats. (A) After 1 day of transgene
activation myocycte vacuolation was observed in the media of the larger arteries (indicated by arrow). (B) After 3 days apoptotic nuclear fragments
were observed (arrow) and (C) there were areas of hemorrhage into necrotic foci. (D) After 7 days, vasculopathy was more extensive still and there
were foci of tubulointerstitial injury.
doi:10.1371/journal.pone.0036311.g006
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used to observe circadian patterns in blood pressure, activity and
heart rate (for Figure 1). To analyze statistically periodicity, hourly
means were smoothed by 3rd order local polynomial regression,
de-trended and analyzed using the x2-periodogram algorithm
[57].
Renal function in anaesthetized rats
Separate cohorts of cyp1a1-Ren2 TGRs received I3C for either
1, 3 or 7 days; the control group (n = 8) received an equivalent
volume of vegetable oil over a 7-day period. Time-points are
designated as control (n = 8), day 2 (n = 9); day 4 ( = 9) and day 8
(n = 9). In each group, mean arterial blood pressure and renal
function were measured twenty-four hours after the final gavage
treatment, as follows. Following thiobutabarbital anaesthesia
(Inactin, 120 mg/kg IP; Sigma Aldrich UK), a cannula was
inserted into the right jugular vein through which a solution,
containing (in mmol/l): 120 NaCl, 10 LiCl, 15 NaHCO3 and 5
KCl, was infused (1 ml/h/100 g IV). The infusate also contained
0.5% p-amino hippuric acid (PAH) and 0.5% FITC-inulin. A
cannula, containing heparin-saline, was placed in the right carotid
artery for collection of blood and measurement of mean arterial
blood pressure. The bladder was catheterized for collection of
urine and a tracheostomy was performed to maintain a clear
airway.
One hour after the completion of surgery, rats underwent the
following protocol: three consecutive collections of urine were
made, each of 60 minutes. A sample (75 ml) of arterial blood was
drawn at the start and then after each urine collection period for
the measurement of haematocrit, FITC-inulin and PAH.
After the first urine collection, amiloride was administered
(2 mg/kg bolus; 2 mg/kg/h infusion). After the second urine
collection, hydrochlorothiazide was administered (2 mg/kg bolus;
2 mg/kg/h infusion) alongside the amiloride. The drugs were
delivered in a DMSO vehicle (2% v:v), which, in a separate group
of rats (n = 7), had no effect on renal function or blood pressure
(data not shown). Finally, a 1 ml sample of arterial blood was
taken for measurement of plasma electrolytes and the kidneys
frozen at 280uC and used for Western blot. Animals were then
killed by an overdose of anaesthetic.
Analysis & calculations
The concentration of Na, K and Li in plasma and urine was
measured using ion-selective electrodes (Roche ISE, model 9180).
The effect of amiloride on sodium excretion was taken as the
difference between excretion rates in the first and second urine
collections; that of hydrochlorothiazide was taken as the difference
between excretion rates in the second and third urine collections.
FITC-inulin and PAH concentrations were measured as
described [4]. The clearance of PAH was taken as effective renal
plasma flow and used to calculate renal blood flow. Renal vascular
resistance was taken as the quotient of arterial blood pressure and
renal blood flow. Lithium clearance was used as an index of fluid
delivery to the end of the proximal tubule [26].
Urine collection in conscious rats
Cyp1a1-Ren2 transgenic rats (n = 8) were housed individually in
metabolism cages with free access to powdered rat chow and
water. Rats were acclimatized and after a 4-day control period,
I3C was administered on each of 7 consecutive days, as described
above. Urine was collected every 24-hours. Albumin was
measured using commercial assays (Alpha Laboratories Ltd.,
UK), aldosterone by ELISA [58].
Interventional studies
Hydrochlorothiazide (4 mg/kg/d; n = 6), spironolactone
(20 mg/kg/d; n = 6) or losartan (10 mg/kg/d, n = 6) were
administered by osmotic minipump (Alzet, Model 2ML1, Charles
River UK), implanted on day 0 under isofluorane anaesthesia. A
control group of rats (n = 6) received vehicle (50% DMSO, 50%
saline) alone. After implant, the Ren2 transgene was induced over a
period of three days before being anesthetized for renal function
studies, as described. A three-day induction was selected as a time-
point at which significant changes to tubular function were not
associated with a decline in renal haemodynamics or major
destructive vascular lesions.
Western blot analysis
Total protein was extracted from one kidney by homogeniza-
tion and differential centrifugation in ice-cold buffer, containing
250 mM sucrose, 10 mM triethanolamine and 2% protease
inhibitor cocktail, pH 7.6 (Pierce Protein Research, Thermo-
scientific, UK). Protein solubilized in sample buffer (50 mg of total
protein per lane) was separated by SDS-PAGE and blotted to
PVDF membrane by semi-dry transfer. Immunoblotting was
Figure 7. Contributions to hypertension of AT1 and mineral-
ocorticoid receptors. A) Mean arterial blood pressure (MABP) and B)
hydrochlorthiazide-sensitive sodium reabsorption (DthiazideNa) in
cyp1a1-Ren2 transgenic rats. Measurements were made in cyp1a1-
Ren2 transgenic rats, anaesthetized on day 4 of the experimental
regimen. The first control group (n = 6; open bars) received vehicle, the
second control group (n = 8; grey bars) received I3C to induce the Ren2
transgene. Experimental groups received I3C and either losartan (n = 6;
grey hatched bars) or spironolactone (n = 6; open hatched bars). Data
are means 6 SE and statistical comparisons were made using ANOVA
with Bonferroni post-test. ***P,0.001, **P,0.01, *P,0.05 versus the
non-induced control group and other comparisons as stated.
doi:10.1371/journal.pone.0036311.g007
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performed using polyclonal antibodies against NCC (Chemicon,
UK; 1:2500) and aENaC (Upstate, NY, USA; 1:2000) and
horseradish peroxide-conjugated secondary antibodies. Immuno-
detection was quantified by densitometry using ImageJ after
treatment of the blots with ECL reagents. Equal loading of total
protein was confirmed in the GAPDH (R&D Systems, UK;
1:5000) immunoblot.
Histopathologic analysis
Kidneys were immersion-fixed in 10% neutral buffered
formalin for 48 h followed by paraffin embedding. Four-micron
sections were examined blind by a Consultant Pathologist
(C.O.B.). Kidneys from at least three rats per experimental group
were examined. For each, 2 complete hemisections of the left
kidney were blocked and all vascular profiles in each hemisection
examined at 4 different levels in the block. Two were stained with
hematoxylin and eosin and two with Periodic Acid Schiff, giving 8
levels per case. Analysis of microvascular injury was performed
using an ordered categorical scale according the presence of
destructive microvascular arterial or arteriolar lesions character-
ized by intramural necrosis and/or fibrinoid change. A score of
‘‘one’’ indicates non-confluent necrosis and isolated myocyte
death; ‘‘two’’ indicates a single foci of necrosis per section; ‘‘three’’
indicates 2–3 foci; and ‘‘four’’ indicates .3 foci of destructive
vascular lesions. Undamaged sections were scored zero.
Statistics
Data are presented as mean 6 SE. Comparisons were made
using either one- or two-way analysis of variance, as appropriate:
post-hoc comparisons were made using the Holm-Sidak test. For
scoring of microvascular injury, contingency tables were generated
for X2 analysis.
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Reduced glomerular filtration, hypertension and renal microvascular injury are hallmarks
of chronic kidney disease, which has a global prevalence of ∼10%. We have shown
previously that the Fischer (F344) rat has lower GFR than the Lewis rat, and is more
susceptible to renal injury induced by hypertension. In the early stages this injury is
limited to the pre-glomerular vasculature. We hypothesized that poor renal hemodynamic
function and vulnerability to vascular injury are causally linked and genetically determined.
In the present study, normotensive F344 rats had a blunted pressure diuresis relationship,
compared with Lewis rats. A kidney microarray was then interrogated using the Endeavour
enrichment tool to rank candidate genes for impaired blood pressure control. Two
novel candidate genes, P2rx7 and P2rx4, were identified, having a 7- and 3- fold
increased expression in F344 rats. Immunohistochemistry localized P2X4 and P2X7
receptor expression to the endothelium of the pre-glomerular vasculature. Expression
of both receptors was also found in the renal tubule; however there was no difference
in expression profile between strains. Brilliant Blue G (BBG), a relatively selective P2X7
antagonist suitable for use in vivo, was administered to both rat strains. In Lewis rats,
BBG had no effect on blood pressure, but increased renal vascular resistance, consistent
with inhibition of some basal vasodilatory tone. In F344 rats BBG caused a significant
reduction in blood pressure and a decrease in renal vascular resistance, suggesting
that P2X7 receptor activation may enhance vasoconstrictor tone in this rat strain. BBG
also reduced the pressure diuresis threshold in F344 rats, but did not alter its slope.
These preliminary findings suggest a physiological and potential pathophysiological role
for P2X7 in controlling renal and/or systemic vascular function, which could in turn affect
susceptibility to hypertension-related kidney damage.
Keywords: purinergic, ATP, kidney disease, renal injury, renal vascular resistance
INTRODUCTION
Kidney injury and declining renal function are diagnostic indi-
cators of kidney disease and present a global health burden with
high population prevalence (Eckardt et al., 2013). Genetic, epi-
genetic and environmental factors determine susceptibility to
renal injury and the development of chronic kidney disease.
Hypertension is a major risk factor for kidney disease (Nakayama
et al., 2011) and progression can be slowed if blood pres-
sure is controlled (Hart and Bakris, 2010). Nevertheless, renal
injury and fibrosis develop independently of barotrauma and the
local actions of agents such as aldosterone (Ashek et al., 2012;
Kawarazaki et al., 2012) and angiotensin II (Mori and Cowley,
2004; Polichnowski et al., 2011) have been implicated.
We have previously used the Cyp1a1-Ren2 transgenic rat to
investigate pathways leading to renal injury. In these rats, blood
pressure is increased by dietary administration of the non-toxic
aryl hydrocarbon, indole-3-carbinol (Kantachuvesiri et al., 2001).
The rise in blood pressure can be titrated to study the organ
injury associated with slowly developing (Conway et al., 2012)
or malignant hypertension (Kantachuvesiri et al., 2001). In the
malignant setting, vascular injury predominates, with myocycte
vacuolation preceding confluent myocyte cell death and microal-
buminuria (Ashek et al., 2012).
Genetic background influences susceptibility to renal injury
in several rat models (Churchill et al., 1997; Schulz and Kreutz,
2012), the Cyp1a1-Ren2 transgenic rat being no exception
(Kantachuvesiri et al., 2001). Here, the Fischer (F344) strain is
susceptible while Cyp1a1-Ren2 transgenic rats on the Lewis back-
ground are protected from renal injury. We have used these
informative strains to identify Quantitative Trait Loci for organ
injury (Kantachuvesiri et al., 1999) and the development of recip-
rocal congenic lines enabled us to validate Ace, the gene encoding
Angiotensin Converting Enzyme, as a plausible modifier of renal
injury (Liu et al., 2009). Although the angiotensin receptor antag-
onist losartan prevents the blood pressure rise in this model, it
is only partially protective against renal vascular injury (Ashek
et al., 2012). This suggests that susceptibility to renal injury
in this model is governed by the interplay between multiple
www.frontiersin.org October 2013 | Volume 4 | Article 305 | 1
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pathways. We hypothesized that genes differentially expressed
in the Cyp1a1-Ren2 transgenic rat in the normotensive state
would contain candidates contributing to poor renal function
and susceptibility to renal injury in the F344 strain or the relative
renoprotection observed on the Lewis background.
In the present study we compared the pressure diuresis rela-
tionship between the differentially susceptible F344 and Lewis
rats. This response being blunted in F344 animals, we re-mined
a renal exon-microarray (Liu et al., 2009) identifying the genes
encoding the P2X4 receptor and P2X7 receptor as candidates for
altered vascular function in F344 rats.
MATERIALS AND METHODS
MICROARRAY ANALYSIS
A previously published Affymetrix microarray (Liu et al., 2009)
was re-mined to identify differentially expressed probe-sets in
the kidney of normotensive Cyp1a1-Ren2 transgenic rats, i.e.,
rats in which the Ren2 transgene was silent. The array was
performed on four groups of rats (n = 4 per group): the two
consomic parental strains (F344, Lewis) and the two recip-
rocal congenic strains (F344-MOD-Lewis, Lewis-MOD-F344)
containing a 14 Mb region of chromosome 10. This con-
genic region contained the Ace locus and the congenics were
included in the present analysis to determine whether cis (or
trans) regulation occurred. The 16 CEL intensity files were
imported into Bioconductor and arrays normalized by the
Robust Multi-array Average (RMA) method. The Linear Models
for Microarray Data (LIMMA) algorithm was used to calcu-
late fold-change and p-value statistics from the normalized
intensities.
Differentially expressed genes were imported into the web
client online version of the multi-database enrichment tool
Endeavour (Aerts et al., 2006, 2009). A list of 157 “training”
genes isolated from the rat genome database (Laulederkind
et al., 2002) was also imported. The “training” genes used
in this study were selected for their association with blood
pressure regulation in the rat. They were not tissue specific
and assumed no mutual exclusivity with inflammatory, or
other disease, processes. The Endeavour method then employed
multiple database mining using parallel approaches to enrich
the list of differentially regulated genes. These approaches
were: (i) published literature text mining; (ii) protein-protein
interactions in the STRING database; (iii) transcriptome anal-
ysis from the WalkerEtAl database; (iv) sequence compari-
son with BLAST; and (v) annotations within Gene Ontology,
InterPro, KEGG, and Swiss-Prot. Finally, global ranking by
Q-statistic generated a list of genes in order of prioritiza-
tion for the observed phenotype, known as “genomic data
fusion.”
ANIMALS
Experiments were performed on male F344 and Lewis rats
(Charles River, UK). All rats had access to food and water (Special
Diet Services, Witham, Essex, UK) ad libitum. Procedures were
performed in accordance with the UK Home Office Animals
(Scientific Procedures) Act of 1986 after ethical review by The
University of Edinburgh.
For Western analysis and immunohistochemistry, F344 and
Lewis rats (n = 3 per genotype) were killed by decapitation. The
kidneys were rapidly excised and the left kidney was snap frozen
and stored at −80C for subsequent extraction of total protein.
The right kidney was immersion fixed in 10% buffered formalin,
transferring to 70% ethanol after 48 h. These kidneys were then
paraffin embedded and transverse sections taken for IHC.
IMMUNOHISTOCHEMISTRY
Primary rabbit polyclonal antibodies against the P2X1 (APR-
001, Alomone Labs), P2X4 (APR-002, Alomone Labs), and
P2X7 (APR-004, Alomone Labs) receptors were selected based
on published validation for use in the rat. Each antibody
was then optimized in a dilution series (1:250, 500, 1000,
2000, 4000, 5000, and 7500) using control rat kidney, fol-
lowing heat-induced epitope recovery (HIER) with citrate
buffer. The final titers were selected to give minimal back-
ground: P2X1 (1:5000), P2X4 (1:7500), and P2X7 (1:2000).
All staining was performed on a Leica Bond × immunos-
taining robot using a refined HRP polymer detection system.
Briefly, after HIER and blocking in Peroxidase, the section was
incubated in primary antibody for 2 h at room temperature.
Following two 5 min washes, sections were exposed to anti-rabbit
HRP polymer before being washed. Immunopositive staining
was visualized with 3,3′-diaminobenzidine and counterstaining
with hematoxylin.
WESTERN BLOT
Whole kidneys were homogenized in ice-cold buffer con-
taining 250 mmol/l sucrose and 10 mmol/l triethanolamine.
Protease inhibitors (Cocktail set III, Calbiochem) and phos-
phatase/kinase inhibitors (2 mmol/l EDTA, 50 mmol/l NaF,
25 mmol/l sodium glycerophosphate, 5 mmol/l pyrophosphate,
and 1 mmol/l sodium orthovanadate) were added and the pH
adjusted to 7.6. Following quantification by Bradford assay, pro-
tein samples were added to Laemlli buffer and resolved by SDS-
PAGE, on a NuPAGE Tris-Acetate gel (8% NovexTM) using a
Tris-acetate running buffer (50 mmol/l tricine, 50 mmol/l Tris
base, 0.1% SDS, pH 8.24) NuPAGE antioxidant was added to the
upper chamber. For the P2X4 studies, 12 µg of total protein was
loaded; 20 µg for P2X7 receptor experiments. Following semi-
dry transfer the membrane was incubated overnight at 4C with
the primary antibody (P2X4 1:2000; P2X7 1:1000; Alomone as
described above). A goat-antirabbit HRP secondary antibody was
then added and the bands visualized by ECL. The P2X4 anti-
body detected a band of ∼60 kDa; the P2X7 antibody detect a
band at ∼75 kDa. The autoradiogram was scanned and band
intensity (corrected for background) was quantified by den-
sitometry using ImageJ. Values were normalized to the total
protein intensity (Coomasie-Blue) at the appropriate molecular
weight.
RENAL FUNCTIONAL STUDIES
Rats were anaesthetized (Thiobutabarbital 120 mg/kg IP) and
prepared surgically for measurement of the pressure-diuresis rela-
tionship. The right jugular vein was cannulated and 0.9% NaCl
was infused at a rate of 50 µl/min/100 g during abdominal surgery
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(to replace surgical losses) and then at 33 µl/min/100 g during the
post-surgical equilibration (60 min) and throughout the exper-
imental protocol. The left femoral artery was cannulated and
connected to brass transducer (MLT844; Capto) connected to a
Powerlab (AD Instruments, UK). Blood pressure was recorded
continuously at 1 kHz. A midline laparotomy was performed and
a Doppler transit time probe (MA1PRB; Transonic, USA) placed
around the left renal artery. Acoustic gel was used to ensure good
sonic coupling. Loose silk ties were placed around the superior
mesenteric and coeliac arteries: these ligatures were tightened
during the experimental procedure to create an acute pressure
ramp of two stages above baseline blood pressure. The bladder
was catheterized for urine collection under mineral oil with flow
rate being determined gravimetrically. The entire procedure was
performed under homeostatic temperature control at 37◦C.
Pressure-diuresis experiments were performed first on a con-
trol group of F344 (n = 7) and Lewis (n = 5) rats and then on
a second cohort of F344 (n = 5) and Lewis (n = 6) rats receiv-
ing an IV infusion (50 µg/min/100 g) of Brilliant Blue G (BBG,
Sigma, UK).
STATISTICAL ANALYSIS
Data are presented as mean ± s.e.m. or as individual data with
median. Statistical analysis was performed by Mann-Whitney
U-test (for Western analysis) or by unpaired t-test (physiologi-
cal data). Comparisons between groups of the pressure-diuresis
relationship were made by linear regression.
RESULTS
PRESSURE DIURESIS RELATIONSHIP
Compared to Lewis rats, F344 rats had a higher baseline blood
pressure (Figure 1A) and a lower renal blood flow (Figure 1B):
renal vascular resistance was significantly higher in F344 rats
than in Lewis (Figure 1C). The imposition of a pressure ramp
evoked an increase in urine flow rate in both strains of rats
(Figure 2A). The slope of the relationship was significantly dif-
ferent from zero in both groups (P < 0.001) but was blunted in
the F344 strain compared to the Lewis (P < 0.01). There was no
significant relationship between blood flow and blood pressure
in either strain of animals, indicative of intact auto-regulation
(Figure 2B).
RENAL MICROARRAY ANALYSIS
After normalization, 67 probe-sets were differentially regulated
on the basis of genetic background: 23 over-expressed and 44
under-expressed (Table 1). Endeavour analysis was used to rank
the differentially expressed genes enriched against the training
genes of blood pressure regulation. The ten highest globally
ranked genes are given in Table 2. Ace was the highest ranked
gene, consistent with our previous QTL and congenic studies
(Liu et al., 2009), and was not studied further. The 2nd and 3rd
ranked genes were P2rx7 and P2rx4, respectively. The expres-
sion of both was higher in the F344 rats than in the Lewis
rats. This was confirmed by Western analysis: there was a 7-fold
increase in total P2X7 receptor protein (P < 0.05; Figure 3A)
and a 3-fold increase in P2X4 receptor abundance (P < 0.05;
Figure 3B).
FIGURE 1 | (A) Mean arterial blood pressure; (B) left renal artery blood flow
and (C) renal vascular resistance in the left renal artery measured in Lewis
(n = 8; open bars) and F344 (n = 7; black bars) rats. Data are mean ± SE.
Statistical comparisons were made with unpaired t-test. ∗∗∗P < 0.001;
∗∗P < 0.01.
FIGURE 2 | (A) Pressure diuresis and (B) pressure flow relationship in
Lewis (n = 8; open squares) and F344 (n = 7; black squares) rats. Data are
mean ± SE. Statistical test was performed by linear regression analysis.
RENAL LOCALIZATION OF P2X1,4, and 7 RECEPTORS
We observed no differences between strains in the distribu-
tion of immunostaining for the P2X receptors. Renal vascular
P2X4 immuno-positive staining was restricted to the endothelium
throughout the preglomerular vasculature (Figure 4A). P2X4
receptor staining was observed in the renal tubules of both strains.
In some places this staining was punctate and localized to both the
nucleus and cytoplasm (Figure 4B).
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Table 1 | Genome wide comparison of gene expression between F344
and Lewis inbred strains listed in order of magnitude of fold change
(F344 vs. Lewis, fold > ± 1.2, p < 0.05).
Over expressed genes (+) Under expressed genes (−)
Symbol Fold p-value Symbol Fold p-value
Rpl30 +7.6798 0.0226 Olr1668 −27.2451 0.0123
Akr1c2 +7.3466 0.0241 Olr1680 −24.6268 0.0162
Spta1 +5.6906 0.0090 RGD1309362 −13.1217 0.0162
Akr1b8 +4.6613 0.0178 Pigzl1 −6.7012 0.007
LOC361914 +3.6785 0.0094 Kif5c −6.6248 0.009
Ace +3.5400 0.0178 Ces1e −5.7903 0.0094
LOC100359585 +3.3860 0.0250 Cyp4v3 −5.2337 0.0166
Guca2b +2.7994 0.0479 Olr1326 −5.1722 0.0336
Ypel4 +2.7596 0.0253 Acsm5 −4.7035 0.0178
Rtp4 +2.6916 0.0241 Hhip −4.6118 0.0166
Clstn2 +2.5879 0.0253 Hmgcs2 −4.2039 0.0336
P2rx4 +2.5327 0.0162 Cyp2d5 −3.8624 0.0289
Klkb1 +2.4303 0.0090 Rdh2 −3.4214 0.0162
Exnef +2.4073 0.0090 LOC302192 −3.3622 0.0256
Pigr +2.3473 0.0336 Lcn2 −3.097 0.0253
P2rx7 +2.1586 0.0336 Csmd1 −3.019 0.0336
Akr1b7 +2.1071 0.0336 Slc10a2 −2.7769 0.0226
Cd59 +1.8540 0.0256 Rxrg −2.6987 0.0336
Fam149a +1.7008 0.0336 Cntnap4 −2.6686 0.0192
P4ha2 +1.6668 0.0336 RT1-CE5 −2.6679 0.0336
Arl4d +1.5187 0.0336 Erc2 −2.5297 0.0253
Igfbp4 +1.4873 0.0336 Ptprq −2.4522 0.0182






















Genes identified by enrichment analysis (Table 2) shown in bold font.
Vascular P2X7 receptor staining was observed in the endothe-
lium of the pre-glomerular arteries, including the afferent arteri-
oles of both rat strains (Figures 4B,C). Staining was also observed
in the glomerulus (Figure 4C). In the larger arteries, occasional
expression in the vascular smooth muscle was observed but in
a given vessel this was limited to a small number of myocytes
(Figure 4D).
As shown by the low magnification image, P2X1 receptor
expression was limited to the vascular network and not expressed
in the renal tubules (Figure 4E). P2X1 receptor immuno-
positive staining was observed in the smooth muscle layer of
all artery types from lobar to afferent arteriole in both rat
strains.
EFFECT OF INFUSION OF BRILLIANT BLUE G
Under baseline (non-ligated) conditions, acute infusion of BBG
caused a significant reduction of mean arterial blood pressure
in F344 rats but not in Lewis animals (Figure 5A). Blood flow
through the left renal artery was not significantly affected by BBG
in either group (Figure 5B). However, BBG caused a significant
decrease in renal vascular resistance in F344 rats (Figures 5C, 6B).
Acute infusion of BBG did not affect the pressure-diuresis rela-
tionship in Lewis rats (Figure 6A). In F344 rats, BBG caused
a significant leftward shift of the pressure-diuresis intercept
(Figure 6B), reducing the threshold of this response, but did not
alter the gradient of the slope. There was no significant relation-
ship between blood flow and blood pressure in either strain (data
not shown).
DISCUSSION
F344 rats are susceptible to renal vascular injury whereas Lewis
rats are relatively protected (Liu et al., 2009). We find that
normotensive F344 rats have a blunted pressure diuresis rela-
tionship, which would impair blood pressure control and may
underpin the susceptibility to vascular injury observed in this
strain. At a genetic level, we identified increased renal expres-
sion of P2X4 and P2X7 receptors, which may contribute to
impaired vascular function in F344 rats, compared to the Lewis
strain.
Multiple subtypes of P2X and P2Y receptors are expressed
throughout the kidney and extracellular nucleotides regulate
renal tubular, endocrine, and vascular functions (Bailey and
Shirley, 2009; Bailey et al., 2012; Shirley et al., 2013). Purinergic
control of renal vascular tone is complex and the net vasoactive
effect depends upon the route of administration/physiological
source of the extracellular nucleotide. Thus, ATP applied in vitro
to the adventitial surface of the renal microvasculature causes
contraction (Inscho et al., 1992) mediated by P2X1 receptors
(Inscho et al., 2003) in the vascular smooth muscle (Chan
et al., 1998). In contrast, infusion of ATP into the renal artery
increases blood flow (Tagawa and Vander, 1970) and the vasodi-
latation is dependent on production of nitric oxide/prostacyclin
by the endothelium (Eltze and Ullrich, 1996). The P2 recep-
tor subtype(s) that mediate the vasodilatory response to ATP
is not resolved and may vary in different vascular beds. mRNA
encoding P2Y1, P2Y2, P2X4, and P2X7 receptors have all been
identified in human arterial endothelial cells (Yamamoto et al.,
2000; Ray et al., 2002). P2X4 receptors are the most abun-
dantly expressed, followed by P2X7 (∼50%) and then by P2Y1
and P2Y2 (∼20%) receptors (Yamamoto et al., 2000). A sim-
ilar profile is observed in endothelial cells cultured from the
mouse pulmonary artery (Yamamoto et al., 2006) and P2X4 and
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Table 2 | Global prioritization by the Endeavour enrichment method.
Gene Known biological function(s) Global prioritization
Rank Score Rank ratio
Ace (ENSRNOG00000007467) BP regulation 1 0.0187 0.0909
P2rx7 (ENSRNOG00000001296) Ion transport, cell volume, apoptosis 2 0.0624 0.182
P2rx4 (ENSRNOG00000001300) Ion transport, BP regulation, NOS 3 0.118 0.273
Rgs7 (ENSRNOG00000021984) G-protein signaling 4 0.583 0.364
Erc2 (ENSRNOG00000015148) Nerve terminal assembly 5 0.674 0.455
Klkb1 (ENSRNOG00000014118) Proteolysis, coagulation, inflammation 6 0.787 0.545
Kif5c (ENSRNOG00000004680) Motor axon guidance 7 0.796 0.636
Dpp6 (ENSRNOG00000030547) Proteolysis 8 0.933 0.727
Pigr (ENSRNOG00000004405) Antibody receptor 9 0.936 0.818
Rdh2 (ENSRNOG00000029651) Retinoid metabolism, oxidation reduction 10 0.988 0.909
FIGURE 3 | Western blot analysis of (A) P2X7 receptor and (B) P2X4 receptor expression in whole kidney homogenates. The top panels show the blot
performed in Lewis and F344 rats (n = 3 in each). The bottom panels show the blot intensity (normalized to protein loading) quantified by densitometry.
P2X7 receptors have also been immunolocalized to the endothe-
lium of the larger renal arteries of the rat (Lewis and Evans,
2001).
Our studies are largely consistent with this distribution of
P2X receptors. P2X1 receptor expression was limited to the vas-
cular smooth muscle of the renal arteries and afferent arteriole.
Renal autoregulation is severely attenuated in P2X1 null mice,
(Inscho et al., 2004; Guan et al., 2007; Inscho, 2009), illus-
trating the importance of this receptor for renal vascular func-
tion. In the present study, renal autoregulation was intact in
both strain of rats and we find no evidence linking differen-
tial expression of the P2X1 receptor, or indeed P2X4 or P2X7
receptors to the impaired renal vascular function observed in
F344 rats.
We did find increased abundance of P2X4 and P2X7 recep-
tor, both in the microarray analysis and at the protein level.
In humans the encoding genes, P2RX4 and P2RX7, are located
within 130 kb of each other on chromosome 12. These genes
can be regulated independently: the endothelial expression of
P2X4 receptors in the human aorta is increased following injury;
P2X7 receptor expression is not affected (Pulvirenti et al., 2000).
It is possible, however, that these receptors have common pro-
motor elements. Physiological interactions between the receptors
are postulated (Craigie et al., 2013) and the locus is associated
with human disease. For example, a single nucleotide polymor-
phism (SNP) in the first intron of P2RX7 is strongly associ-
ated with elevated blood pressure (Palomino-Doza et al., 2008)
and a loss-of-function SNP in the P2RX7 coding region asso-
ciates with protection against ischemic stroke (Gidlöf et al.,
2012). Similarly, a loss of function SNP in the P2X4 receptor
has been associated with increased pulse pressure (Stokes et al.,
2011).
Consistent with the previous studies described, we localized
P2X4 and P2X7 receptors to the endothelium of the pre-
glomerular vasculature. Our bioinformatic ranking analysis asso-
ciated increased expression with vascular dysfunction and loss
of blood pressure control. Both P2X4 (Yamamoto et al., 2006)
and P2X7 receptors (Liu et al., 2004) can modulate blood
vessel contractility by promoting the release of vasodilators
from the endothelium. One interpretation of our data is that
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FIGURE 4 | (A) Vascular P2X4 receptors were expressed in the
endothelium (Image from F344 rat ×400) and (B) the afferent arteriole
(Image Lewis rat ×500). (C) P2X7 receptors were stained in the
endothelium of the preglomerular vasculature, including the afferent
arteriole (arrow) and cells of the glomerulus (Image F344 rat, ×400). (D)
Occasional smooth muscle staining of P2X7 was observed (arrow; Lewis
rat, ×400). (E) P2X1 immunopositive staining was only observed in the
vasculature and was limited to the smooth muscle layer of large and small
diameter vessels (F344 rat, ×50).
the up-regulation of receptors in F344 rats is a compensatory
response to improve poor renal blood flow. Thus, acute recep-
tor antagonism in vivo should inhibit this tonic vasodilation.
There was a trend for this in the Lewis rats but the reduction in
blood flow induced by BBG was not statistically different. BBG
did induce a significant hemodynamic effect in F344 rats but
this was to increase blood flow, rather than to reduce it. One
interpretation of this outcome is that in F344 rats P2X4/P2X7
receptor activation induces a tonic vasoconstriction. It is difficult
to reconcile such an effect with the predominantly endothe-
lial location of these receptors. However, the endothelium also
releases potent vasoconstrictive mediators, including mono- or
di-nucleoside polyphosphates such as adenosine 5′ tetraphos-
phate (Tolle et al., 2008) and uridine adenosine tetraphosphate
is a partial agonist at the rat P2X4 receptor (Wildman et al.,
1999) and causes a profound vasoconstriction when perfused via
the intravascular route into the isolated rat kidney (Tolle et al.,
2008).
An obvious concern in interpreting these results is the selectiv-
ity of the antagonist, BBG. This compound is a potent inhibitor
of rat P2X7 receptors (IC50 = 10 nM) and although it can also
block the P2X4 receptor, its selectivity for P2X7 receptor is
FIGURE 5 | (A) Mean arterial blood pressure; (B) left renal artery blood flow
and (C) renal vascular resistance in the left renal artery measured in Lewis and
F344 rats receiving either saline or Brilliant Blue G by intravenous infusion.
Data are mean ± SE. Statistical comparisons were made within strain by
unpaired t-test. ∗∗∗P < 0.001; ∗P < 0.05. Statistical comparisons were made
using one way ANOVA with Bonferroni post-test.
FIGURE 6 | The Pressure diuresis relationship measured in (A) Lewis
and (B) F344 rats receiving either saline (closed symbols) or Brilliant
Blue G (open symbols) by intravenous infusion. Data are mean ± SE.
Statistical test was performed by linear regression analysis.
1000-fold greater. BBG has been used previously in vivo to elu-
cidate P2X7 receptor functionality (Jiang et al., 2000; Peng et al.,
2009). Indeed, chronic administration of BBG reduces renal
injury and lowers blood pressure in the Dahl salt sensitive rat
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(Ji et al., 2012a); P2X7 null mice are similarly protected from
the renal injury associated with salt-induced hypertension (Ji
et al., 2012b). Nevertheless, BBG may also antagonize rat P2X4
receptors and our infusion protocol could inhibit both P2X
receptor subtypes. Furthermore, a number of off-target effects
of BBG have been reported (Katrahalli et al., 2010), so we can-
not exclude the possibility that P2X7-independent effects also
contribute to the hemodynamic actions of BBG observed in the
F344 rats.
P2X4 and P2X7 receptors were also identified in the renal
tubule in both strains of rats. Tubular expression of P2X4 recep-
tor is consistent with several previous studies (Bailey et al.,
2012). We found some evidence of intracellular, punctate stain-
ing, particularly in the Lewis rats. It is possible that this rep-
resents expression of P2X4 receptors in intracellular vesicles,
which might act as a reservoir for trafficking of receptors to the
apical or basolateral membrane or serve as mediators of vac-
uolar calcium release (Sivaramakrishnan and Fountain, 2012).
P2X receptors, including P2X4 can regulate tubular sodium
reabsorption processes (Bailey et al., 2012) but in our studies
BBG did not affect urine flow rate. The relationship between
P2X4 receptor activation and sodium/water reabsorption is com-
plex, however, and may depend on the local sodium concentra-
tion.
In summary, P2X7 and P2X4 receptors are expressed in the
vascular endothelium and may contribute to the normal control
of renal arterial resistance. Both receptors are attractive candi-
date genes for impaired renal vascular function and susceptibility
to kidney injury. However, their respective roles are not easy to
define: the present findings are consistent with a predominant
vasoconstrictor effect of P2X7 and vasodilator effect of P2X4,
but the relationship is likely to be more complex than this sim-
ple dichotomy suggests. For example, endothelial P2X7 receptors
can mediate the release of factors that modulate the inflamma-
tory state of the vessel wall (Wilson et al., 2007). Moreover, the
encoding gene for P2X7 transcribes a large number of splice vari-
ants with reportedly different functionality (Sluyter and Stokes,
2011; Xu et al., 2012), which may also contribute to contrast-
ing vasoactive effects in different strains of rat as observed
here.
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Menzies RI, Zammit-Mangion A, Hollis LM, Lennen RJ, Jansen
MA, Webb DJ, Mullins JJ, Dear JW, Sanguinetti G, Bailey MA. An
anatomically unbiased approach for analysis of renal BOLD magnetic reso-
nance images. Am J Physiol Renal Physiol 305: F845–F852, 2013. First
published July 17, 2013; doi:10.1152/ajprenal.00113.2013.—Oxygenation
defects may contribute to renal disease progression, but the chronol-
ogy of events is difficult to define in vivo without recourse to invasive
methodologies. Blood oxygen level-dependent magnetic resonance
imaging (BOLD MRI) provides an attractive alternative, but the R2*
signal is physiologically complex. Postacquisition data analysis often
relies on manual selection of region(s) of interest. This approach
excludes from analysis significant quantities of biological information
and is subject to selection bias. We present a semiautomated, anatom-
ically unbiased approach to compartmentalize voxels into two quan-
titatively related clusters. In control F344 rats, low R2* clustering was
located predominantly within the cortex and higher R2* clustering
within the medulla (70.96  1.48 vs. 79.00  1.50; 3 scans per rat;
n  6; P  0.01) consistent anatomically with a cortico-medullary
oxygen gradient. An intravenous bolus of acetylcholine caused a
transient reduction of the R2* signal in both clustered segments (P 
0.01). This was nitric oxide dependent and temporally distinct from
the hemodynamic effects of acetylcholine. Rats were then chronically
infused with angiotensin II (60 ng/min) and rescanned 3 days later.
Clustering demonstrated a disruption of the cortico-medullary gradi-
ent, producing less distinctly segmented mean R2* clusters (71.30 
2.00 vs. 72.48  1.27; n  6; NS). The acetylcholine-induced
attenuation of the R2* signal was abolished by chronic angiotensin II
infusion, consistent with reduced nitric oxide bioavailability. This
global map of oxygenation, defined by clustering individual voxels on
the basis of quantitative nearness, might be more robust in defining
deficits in renal oxygenation than the absolute magnitude of R2* in
small, manually selected regions of interest defined exclusively by
anatomical nearness.
k-means; acetylcholine; angiotensin II; nitric oxide; hypoxia
RENAL TISSUE HYPOXIA IS IMPLICATED in the pathogenesis of
chronic kidney disease (CKD), with low partial pressure of
oxygen (PO2) causing activation of a profibrotic cascade (27).
Even under physiological conditions, the PO2 within the kidney
is thought to have a marked cortico-medullary gradient, with
the medulla being poorly oxygenated (9). Cells of the medulla
have a higher anaerobic capacity than those of the cortex and
paracrine signaling pathways also provide some resistance
against hypoxia (25). Nevertheless, the medulla is susceptible
to hypoxic injury and chronic hypoperfusion, which can initi-
ate a vicious cycle of microvasculature injury, inflammation,
and fibrosis (21).
A causal link between defects in renal oxygenation and renal
disease is supported by immunohistochemical detection of
pimonidazole adducts (24), formed when PO2 is 10 mmHg.
This method is, however, insensitive and nonquantitative (30).
O2-sensitive microelectrodes offer a quantitative and sensitive
approach (10), but measurements made at the electrode tip
cannot give global insights into the distribution of oxygen.
Moreover, being invasive, microelectrodes are not usually
amenable to longitudinal studies of renal function.
Blood oxygen level-dependent magnetic resonance imaging
(BOLD MRI) is emerging as a technique through which to
assess renal oxygen bioavailability (20). BOLD imaging ex-
ploits the paramagnetic properties of deoxyhemoglobin, gen-
erating images based on the dephasing of spin relaxation rate
from an applied electromagnetic field pulse. This relaxation
rate (R2*  1/T2*) is proportional to the level of deoxyhemo-
globin, and the R2* reflects the oxygenation status of red blood
cells. This can be associated with tissue PO2 and indeed much
of the physiological utility of BOLD MRI rests on the assump-
tion that tissue PO2 is in responsive equilibrium with red blood
cell PO2. In pigs the spatial gradients of oxygenation observed
by BOLD MRI are consistent with those measured in the
contralateral kidney by O2 microelectrodes (28).
Although the use of BOLD MRI to rapidly and noninva-
sively define renal hypoxia is clinically attractive (14), inter-
pretation of images is often challenging. Most postacquisition
analyses rely on manual selection of small regions of interest
(ROI) to generate anatomically informative R2* maps. How-
ever, kidneys are subject to respiratory and cardiovascular
motions that might be difficult to gate against, particularly in
experimental models. Unless image registration is employed,
time-series data within an individual ROI are unlikely to be
acquired from exactly corresponding anatomical regions. The
selection of small segments that are well delineated within the
cortex and medulla has been advocated (12), but this approach
will discard from the analysis biological information contained
within the data set. Moreover, this approach is subjective and
risks a selection bias towards areas at the extremes of signal
intensity (14).
In biomedical research, the use of algorithms that cluster
individual data points based on concepts of quantitative “near-
ness” or “similarity” are more commonly associated with
analysis of gene expression data sets (6) but are broadly
applicable to large data sets, such as those generated through
BOLD MRI. The present study applied k-means clustering as
an anatomically unbiased approach to BOLD MRI analysis.
The central tenet of this approach is that voxels clustered on
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quantitative nearness of the R2* signal share a commonality of
biological process. Importantly, quantitative similarity does
not necessarily equate to close anatomical proximity of voxels
or compartmentalization within a given region of the kidney.
We employed two complementary strategies to affect R2* in
an acute and chronic time frame. Acutely, we manipulated
pharmacologically nitric oxide bioavailability. The maneuvers
were designed to change whole kidney blood flow, either
rapidly and reversibly with acetylcholine, or with sustained
effect through nitric oxide synthesis inhibition, without altering
autoregulatory capacity (2). To cause a chronic change in R2*
we infused angiotensin II: over this time frame we anticipated
no major change in renal vascular resistance but an increase in
renal tubular sodium reabsorption (1, 32, 38). These compli-
mentary experiments provided the means to dissect the phys-
iologically complex R2* signal, resolving the influence of
nitric oxide bioavailability and renal blood flow.
METHODS
All experiments were performed under a UK Home Office license
following ethical approval by The University of Edinburgh. Male
F344/IcoCrl rats (Charles River), aged 12–16 wk, were given free
access to water and commercial rat chow (0.3% sodium by weight;
Special Diet Services) and housed under controlled conditions of
temperature (24  1°C), humidity (50  10%), and light/dark (light
7 AM-7 PM) during the experiments.
BOLD MRI. Measurements were performed using a 7 Tesla pre-
clinical MRI scanner (Agilent Technologies). Rats (n  6) were
anesthetized with 1.5 - 2% isoflurane in oxygen-enriched air (0.5
l/min air and 0.5 l/min oxygen). Rectal temperature was maintained at
(37°C). Respiration and ECG were monitored for stability throughout
the scanning protocol. A birdcage volume coil (72-mm diameter) and
a 4-channel phased array surface coil (Rapid Biomedical) were used
for radio frequency transmission and signal reception, respectively.
Image acquisition used a multiple echo gradient-recalled BOLD
MRI pulse sequence of ten images weighted in T2*; TE  4, 8, 12,
16, 20, 24, 28, 32, 36, and 40 ms; TR  100 ms and flip angle of 30°
at an 83 kHz bandwidth. An axial slice through the centre of the right
kidney was selected with 50  40 mm field of view containing a
192  128 acquisition matrix (in-plane resolution  0.26  0.31
mm). A single axial slice, aligned parallel with the renal artery
identified by rapid scout scanning (fast gradient echo, 3 slices in
coronal orientation), ensured slice position encompassed the most
representative section of the kidney regions. Slice thickness was 2 mm
with 14 signal averages. Temporal resolution was 3 min for each
BOLD scan.
Scans obtained under control conditions (days 6 and 4) were
compared statistically and then combined into one group. On day 0,
osmotic minipumps (model 2002; Alzet, Charles River, UK), adapted
for MRI by replacement of the stainless steel flow moderator with a
polyetheretherketone equivalent (part no. 2496, PEEK, Charles River,
UK), containing angiotensin II (60 ng/min) were surgically implanted
under isofluorane anesthetic. Rats were scanned again after 3 days of
angiotensin II infusion.
Image selection and registration. Motion correction was performed
by complimentary measures to ensure voxels in different frames
overlapped; global registration (consistent over entire image), inten-
sity-based registration (using grey-level image values), and rigid
registration (only allowing translation and rotation) were used on each
rat and on each day separately.
Initial outlier detection was assessed by a Hampel identifier, used
to detect scans having an intensity profile significantly different from
the median (X0.5) or outside the 90th percentile (X0.9): scan impreci-
sion largely reflected significant motion artefact and these outliers
were rejected.
Rigid registration was performed on the remaining images using an
exhaustive search. The third baseline scan was selected and all other
scans in the sequence were translated and rotated until the mutual
information (gradient2) was maximized. This improved stability
across sequences: 96% of scans required less than one voxel transla-
Fig. 1. Analysis pipeline of blood oxygen level-dependent magnetic resonance imaging (BOLD MRI) data. Following registration of the images, a kidney
quadrant was manually selected. The k-means clustering of the data for time series analysis was then performed automatically, using the MATLAB code provided
(https://github.com/andrewzm/BOLD_Kidney) and two compartments identified with statistically distinct mean R2* time series. For clarity blue arrows indicate
manual steps and red arrows automation. ROI, regions of interest; BL, baseline; L-NAME, N-nitro-L-arginine methyl ester hydrochloride.
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tional correlation or less than 1° rotation, indicating that rigid regis-
tration was sufficient for the present dataset.
k-Means clustering analysis. Automated image segmentation was
performed using a k-means clustering algorithm (with k, the number
of clusters). The k-means clustering identifies k-clusters within a
multi-dimensional space using Euclidean distance (for details, Ref. 3,
chapter 9.1). Given a set of points, the target of the algorithm is to find
k cluster-centers such that the sum of square distances of each point
to its closest cluster centre is a minimum. The (local) minimum is
searched for in an iterative manner, the two steps of which are 1) the
association of the points with their closest cluster centers, and 2) the
updating of the cluster centers such that the sum of square distances
to the associated points is minimized. The final cluster configuration
can be dependent on the initial cluster configuration. To validate our
approach, the appropriate number of initial conditions was therefore
determined to establish the lowest number insensitive to the starting
conditions. The present dataset found 10 random initial conditions to
fit this condition, thus for each scan set we ran the algorithm and saved
the final configuration as that with the lowest sum of intracluster
distances.
To select the number of clusters (k), we performed pilot analysis
using k  1, 2, 313 to identify the value of k such that the increase
in explained variance of k  1 clusters was 50% of the additional
variance explained by the kth cluster. With the use of this approach
k  2 was chosen, as the addition of a third cluster did not contribute
sufficiently to an increase in explained variance. Each time series
required 50 ms to converge run in MATLAB on a standard desktop
computer.
Pharmacological protocol. The effect of acetlycholine (5 g/kg;
Sigma-Aldrich) on the R2* signal was determined before and follow-
ing administration of N-nitro-L-arginine methyl ester hydrochloride
(L-NAME; 10 mg/kg; Sigma-Aldrich). Both compounds were admin-
istered via the tail vein in a volume of 0.15 ml. Immediately
following injection, the catheter was flushed through with a volume of
saline equal to the catheter volume. The potential effects of water
loading must be considered (15). However, in the present study, the
volume of saline injected for each animal over 1 h did not exceed
0.95 ml in total.
Measurement of blood pressure and renal blood flow. The effects
of acetylcholine and the nitric oxide synthase inhibitor L-NAME on
blood pressure and renal blood flow were measured in a parallel study
using the protocol described above. Renal blood flow data are nor-
malized to total kidney weight. Control rats (n  4) and rats receiving
angiotensin II (60 ng/min; n  5) were anesthetized (120 mg/kg ip
thiobutabarbital). The right jugular vein was cannulated for infusion
of 0.9% NaCl containing 1% bovine serum albumin. Rats were
infused at 100 l/min until a total volume of 1.25 ml/100 g body wt
was reached and then 30 l/min maintenance rate. The left femoral
artery was cannulated for blood pressure measurement (MLT844; AD
Instruments); a tracheotomy was performed to maintain a clear air-
way. A midline laparotomy was performed, and a Doppler transit time
probe (MA1PRB; Transonic) was placed around the left renal artery.
Core body temperature was servo-maintained at 37°C.
Statistics. Data are presented as means  SE. Statistical analysis
was performed by repeated-measures ANOVA, unless otherwise
stated. Post hoc significance testing was performed by the Bonferroni
method unless otherwise stated.
RESULTS
Postacquisition generation of R2* maps. The clustering
approach was used to generate R2* maps within a kidney
quadrant in each of six control rats, using the postacquisition
pipeline shown in Fig. 1. Two compartments of distinct mean
R2* intensities were created (cluster 1  70.96  1.48; cluster
2 79.00  1.50; means  SE; n  18 scans in 6 rats; P 
0.01). Each rat underwent three consecutive baseline scans on
control days 6 and 4 and following 3 days of angiotensin II
infusion. In control rats, baseline scans repeated sequentially
on separate days or on different rats did not vary significantly
for either cluster 1 (Fig. 2A) or cluster 2 (Fig. 2B). Consecutive
baseline scan reproducibility was also observed following
chronic angiotensin II infusion. Baseline scans were therefore
combined for both groups.
In control rats, the cluster having a low R2* mean (“higher”
oxygenation) had anatomical coordinates that largely overlaid
regions of the renal cortex and the higher R2* mean (“lower”
oxygenation) lay within regions of the renal medulla. Thus, in
the control setting, regions of quantitative oxygen homogeneity
were also spatially proximate, mapping to distinct anatomical
regions of the kidney. The spatial oxygenation gradient estab-
lished here is consistent with that reported using ROI selection
and with direct PO2 measurement by microelectrodes.
Nitric oxide bioavailability and renal R2*. Systemic injec-
tion of acetylcholine significantly attenuated the R2* signal
(P  0.01, ANOVA) in both clustered compartments (Fig. 3A),
suggesting an increase in PO2 throughout the kidney. This
effect was transient; reaching its nadir in the scan performed 6
min postinjection. In a parallel study, acetylcholine initially
caused a rapid fall in mean arterial pressure and renal blood
flow. This effect was short lived (1 min), and during the
BOLD MRI scan protocol, renal blood flow was 30% higher





























Fig. 2. Reproducibility of baseline BOLD MRI data. Rats were scanned in
triplet (baseline 1, 2, and 3) and in 2 cohorts on day 6 (solid grey lines) or day
4 (broken grey lines). No significant difference between any of these measure-
ments was observed (black line); thus baseline scans were assimilated into one
baseline value.
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flow for the entire period remained unchanged (Table 1)
suggesting intact autoregulation.
Administration of L-NAME caused a slowly progressive
increase in signal intensity in the high R2* compartment (P 
0.01, ANOVA) but was without effect in the low R2* com-
partment (Fig. 3C). This is consistent with previous observa-
tions showing no effect of nitric oxide synthesis inhibition on
R2* intensity in cortical ROI (29). L-NAME also caused a
reduction in renal blood flow over this time course (Fig. 3D).
The effects of L-NAME on both R2* and renal vascular
resistance reached steady state after 20 min in general agree-
ment with the reported inhibitory effect on nitric oxide bio-
availability (16). Acetylcholine was again injected. The effect
on blood pressure and renal blood flow persisted, but the
attenuation of R2* signal by acetylcholine was no longer
observed (data not shown).
Effect of chronic angiotensin II infusion. Angiotensin II was
infused by osmotic minipump over a 3-day period and BOLD-
Fig. 3. Renal BOLD-MRI and hemodynamic analysis in control rats. Effect of systemic acetylcholine on R2* signal (A) and renal blood flow (RBF; B) in the
left renal artery. Effect of L-NAME on R2* signal (C) and RBF (D). For renal BOLD data in A and C: , cluster 1 data; , cluster 2 values. **P  0.01 and
* P  0.05.
Table 1. Mean arterial blood pressure and left renal artery blood flow in control rats or rats receiving a chronic infusion of
angiotensin II
Baseline ACh1 L-NAME ACh2
BP, mmHg
Control 89  2 89  1 114  4* 113  4
Angiotensin II 90  3 91  3 110  2* 109  2
RBF, ml·min	1·g kidney wt	1
Control 2.70  0.3 3.04  0.4 1.73  0.2* 1.74  0.2
Angiotensin II 3.19  0.4 3.41  0.5 1.63  0.2* 1.60  0.2
Mean arterial blood pressure (BP) and left renal artery blood flow (RBF) in control rats (n  4) or rats receiving a chronic infusion of angiotensin II (60 ng/min)
for 3 days (n  5). Data are means  SE and taken during steady state at baseline and during injection of acetylcholine (ACh), either before or after administration
of N-nitro-L-arginine methyl ester hydrochloride (L-NAME). *P  0.05, baseline vs. L-NAME.
F848 CLUSTERING ANALYSIS OF RENAL BOLD MRI
AJP-Renal Physiol • doi:10.1152/ajprenal.00113.2013 • www.ajprenal.org
MRI scans were once again obtained. Blood pressure and renal
blood flow were not significantly affected by this infusion
(Table 1). The k-means clustering approach resolved the data
into distinct compartments; indeed, convergence is assured by
this algorithm, but the magnitude of the difference in intensity
between the two compartments was much reduced (cluster 1 
71.30  2.00; cluster 2  72.48  1.27; mean  SE; NS).
Critically, baseline means of the two clustered compartments
were less distinct during baseline and no longer mapped to
discrete anatomical regions of the kidney (see Fig. 5 for
example images). This suggests that a short exposure to an-
giotensin II disrupts the oxygenation gradient through the
kidney, creating areas of high and low PO2 in both cortex and
medulla. As stated previously, the R2* signal actually reflects
oxygenation of red blood cells and thus altered patterns of renal
perfusion may also account for the disrupted gradient. Follow-
ing angiotensin II infusion, the R2* was no longer significantly
affected by administration of either acetylcholine or L-NAME
(Fig. 4A). Nevertheless, acetylcholine still induced a transient
reduction in renal blood flow and blood pressure (Fig. 4, B and
C) and L-NAME significantly increased renal vascular resis-
tance.
DISCUSSION
BOLD MRI is an attractive tool for clinical research since it
does not require exogenous contrast agent and has a rapid
acquisition time (14). BOLD MRI is increasingly used to
quantify renal “oxygenation” in a variety of disease settings,
and studies typically focus on the medulla, which is vulnerable
to hypoxic insult. Hypoxia of the cortex is also evident in
severe renovascular disease (13) and in diabetic and nondia-
betic CKD (19). A global map of renal R2* could therefore be
a valuable diagnostic/prognostic tool for ischemic renal dis-
ease. However, the relationship between R2* and tissue hyp-
oxia is complex (20). R2* reports oxygenation of the red blood
Fig. 4. Renal BOLD-MRI and hemodynamic analysis in rats
after angiotensin II infusion. A: R2* trace measured by k-means
clustering, open squares (cluster 1) and circles (cluster 2)
signal. B: renal vascular resistance (RVR) hemodynamic study
following protocol time course and insert showing ACh trace
with BP (broken line) and RBF (solid line). Area under the
curve analysis for RBF following injection of ACh (C) OR
L-NAME (D).
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cells, and the signal reflecting local perfusion is also influenced
by pH and hydration status. In CKD, BOLD MRI studies have
produced conflicting data (22, 37). This partially reflects the
complexity of CKD; the future diagnostic utility of renal
BOLD MRI is nevertheless contentious (17).
One major challenge for the field is standardization of
protocols, particularly for postprocessing, that would facilitate
meaningful cross-comparison of data sets. Most studies quan-
tify renal oxygenation by measuring R2* signal intensity in
small manually selected ROI. A strength of this approach is
that the generation of time-series data are based firmly on
anatomical knowledge of renal structure. Reliable placement
can be difficult, however, and averaging across several ROI
can mask the heterogeneity of oxygenation. Importantly, the
ROI approach discards from analysis much of the biological
information contained within an image and the power of
BOLD MRI to assess renal oxygenation on a global scale is
often underexploited.
Data-led segmentation of datasets has previously been used
for analysis of brain (4) and kidney (7, 39). MRI and our work
complements the recent compartmentalization approach to
analysis of Ebrahimi et al. (7). Our method has two main
differences. First, our cluster is defined from time series since
voxel variation in time is informative and more easily con-
trolled than maps defined in a separate computed tomography
scanner where renal orientation might be difficult to replicate.
Second, we were not able to resolve distinct and separate
cortical and medullary R2* distributions and therefore assume
no anatomically defined distribution functions. We have incor-
porated this approach, developing a semi-automated postacqui-
sition pipeline for analysis of BOLD MRI images: k-means
(where k  2) clustering was used to assign individual voxels
into one of two statistically distinct compartments. The advan-
tages of the method are that it: 1) does not require user-led
selection of small anatomical ROI but rather a gross quadrant
of the whole kidney to be segregated into two compartments in
a user-independent manner; 2) obviates the need for voxel-
tracking through a time-series stack; and 3) is anatomically
unbiased, identifying on a global scale clusters of PO2 homo-
geneity for each patient or experimental subject. The analysis
pipeline is shown in Fig. 1 and our MATLAB code is available
freely (https://github.com/andrewzm/BOLD_Kidney).
In control rats, the clustering analysis delineated compart-
ments that largely mapped to discrete anatomical regions of the
kidney (Fig. 5). The low R2* cluster was located predomi-
nantly in the cortex, and the high R2* cluster localized primar-
ily to the outer medulla. Under control conditions the cluster-
ing approach supports the notion of a cortico-medullary PO2
gradient and perhaps offers little interpretive gain over ROI
selection. However, the clustering analysis indicated a dissipa-
tion of the cortex-to-medulla renal PO2 gradient following
angiotensin II infusion (Fig. 5). This global map of oxygen-
ation captures nuances of regional gradients.
This has clinical relevance: a recent study, averaging R2*
across multiple ROI, demonstrated cortical hypoxia in a small
number of CKD patients (19). The effect size was small and
the variation large, suggesting that constraints of statistical
power will make comparisons of absolute R2* across patients
and between studies difficult (22, 37). Qualitatively, Man-
otham et al. (19) noted that the R2* signal was more hetero-
geneous and liable to rapid decay in CKD patients than in
controls. We suggest that this global disruption of a spatially
constrained PO2 gradient may be a hallmark of the defects in
renal oxygenation associated with renal injury.
Acute administration of angiotensin II causes a rapid in-
crease in R2* in healthy subjects, attributed to a fall in renal
perfusion (31). Conversely, acute blockade of AT1 receptors
increases PO2 in the renal cortex of CKD patients (19). An
increase in cortical oxygenation following AT1 receptor block-
ade has also been observed in normal (26) and hypertensive
rats (34), effects attributed to improved blood flow and effi-
ciency of O2 usage respectively. In our study, a 3-day infusion
of angiotensin II did not increase blood pressure, consistent
with previous data (5), and gross renal blood flow was un-
changed. Tubular sodium reabsorption is increased within this
timeframe (1, 38), and we found evidence for disruption of the
regional homogeneity of PO2. This may reflect a local mis-
match of delivery/consumption or a reduction in the efficiency
of O2 utilization, as reported in the angiotensin II-dependent
Goldblatt model (36).
Most MRI scanners are not calibrated directly for PO2. The
absolute R2* value is often therefore less informative for
cross-comparison than is the dynamic response to maneuvers
affecting perfusion or sodium transport. In this study, injection
Fig. 5. Anatomical heterogeneity of renal R2* signal following
chronic angiotensin II infusion. Exemplar clustering analysis in
manually delineated renal quadrants of rat kidney under control
conditions (A) and following angiotensin II infusion (B). The
k-means clustering was used to segment data on a quantitative
basis into low (dark grey) and high (light grey) R2* clusters. In
control conditions, these clusters mapped to anatomically re-
gions; following angiotensin II infusion, the spatial relationship
between similar R2* values was less well defined.
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of acetylcholine suppressed the R2* signal throughout the
kidney. This was probably not dependent on whole kidney
perfusion, there being temporal separation between the reduc-
tion in blood flow and the reduction in R2*. The attenuation of
R2* was dependent on NO generation, being inhibited by
L-NAME, and had a delayed onset, being evident only in the
second scan postinjection. A previous study also reported no
immediate effect of NO on R2* intensity (31).
We recognize that NO reacts irreversibly with both oxy- and
deoxyhaem moieties (8). These reactions are rapid, and hemo-
globin and deoxyhemoglobin levels should be equivalently
affected over each 3-min BOLD scan. We therefore ascribe the
reduced R2* to an NO-dependent increase in PO2 throughout
the kidney, most probably reflecting inhibition of tubular
sodium transport (11). The effect of acetylcholine was lost
following chronic angiotensin II infusion. Prolonged exposure
to angiotensin II causes oxidative stress in rats (18), and our
data plausibly reflect accumulation of superoxide anion leading
to NO deficiency and defects in renal oxygenation (35).
There are two important limitations to our study. First, it was
not possible to measure renal blood flow and BOLD signal
simultaneously. The invasive surgery required for Doppler
measurements of renal arterial blood flow also mean that
measurements were not made in the same animals: we chose
instead to obtain repeated R2* measurements in a longitudinal
study. Second, the BOLD MRI and renal blood flow data were
obtained under differing anesthetic regimens. Maintenance of
anesthesia within the MRI scanner required ECG monitoring
under gas anesthesia (isoflurane) while stability of renal per-
fusion following the invasive abdominal surgery is best ob-
tained with a long-lasting barbiturate (33). Renal hemodynam-
ics may be differentially affected by the anesthetics, but it
unlikely that this accounts for the temporally distinct dynamic
response to acetylcholine of the R2* signal and blood flow.
In summary, we have developed an anatomically unbiased
method for the assessment of renal function by BOLD MRI,
employing signal analysis to remove errors inherent in manual
ROI selection. These data indicate that protocols assessing the
dynamic response of R2* to acetylcholine can provide infor-
mation relating to renal NO bioavailability and offer temporal
insight into renal oxygenation homeostasis.
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